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ABSTRACT 
It is well established that parathyroid hormone (PTH) plays an essential role in 
regulating calcium and bone homeostasis in the adult. The role, if any, ofPTH in fetal-
placental mineral homeostasis has been uncertain. Therefore, the purpose of the present 
doctoral research was to examine the role ofPTH in fetal-placental calcium homeostasis. 
It was hypothesized that: PTH, despite its low circulating levels during fetal life, plays an 
important role in regulating not only fetal blood calcium and skeletal development, but 
also placental calcium transfer. To address this, two different genetic mouse models of 
PTH deficiency were utilized. The Pthtm!Dgo knockout (i.e. Pth null) mice served as a 
model of complete absence ofPTH because they have enlarged parathyroids that are 
incapable of making PTH, while the Gcm21miKryknockout (i.e. Gcm2 null) mice served as 
a model of severe hypoparathyroidism because they lack parathyroids but have some 
PTH. 
Both nulls displayed a fetal hypoparathyroid phenotype, experiencing 
hypocalcemia, hypomagnesemia, hyperphosphatemia, low amniotic fluid mineral 
content, and reduced skeletal mineral content. When Pth null fetuses were treated in 
utero with PTH (1-84), placental calcium transfer increased, and placental gene 
expression was altered. It was also discovered that PTH is expressed in the placenta of 
wild-type and Gcm2 null fetuses. Thus, from the present study it is evident that PTH does 
indeed play an important role in fetal-placental mineral homeostasis. More specifically, 
PTH is important for fetal blood calcium, fetal skeletal development, is expressed locally 
in the placenta, regulates placental gene expression, and may directly regulate the transfer 
of calcium from mother to fetus. 
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I. Introduction 
A. Preamble 
By examining fetal mice deficient in parathyroid hormone (PTH) ( Gcm2 null 
mice) and completely lacking PTH (Pth null mice), the present work provides some 
clarity on the role ofPTH in fetal calcium and bone metabolism, and some very exciting 
new evidence to support a role for PTH in regulating the transfer of calcium across the 
placenta from mother-to-fetus. The role ofPTH in fetal life has been uncertain for quite 
some time, and it has not been thought to have a role in regulating placental calcium 
transfer. To gain a better understanding of our prior knowledge about the role ofPTH in 
regulating fetal-placental calcium and bone metabolism, this review will start by 
summarizing how calcium metabolism is regulated in the adult, and then how the fetal 
system differs. Next, the expression, signaling, and receptors for two very important 
calcitropic hormones, PTH and parathyroid hormone-related protein (PTHrP), will be 
reviewed. Finally, previous studies will be reviewed which examined the role ofPTH in 
regulating fetal blood calcium, fetal skeletal development and mineralization, and 
placental calcium transfer. 
B. Adult Calcium Homeostasis 
The adult skeleton has evolved to serve several functions including structural 
support, movement, protection of vital organs, and maintenance of calcium homeostasis 
(1). In the adult human, there is approximately 1000g of calcium and 99% of this is 
stored in the skeleton as hydroxyapatite crystals [Calcium (Ca)10 Phosphate (P04) 6 
1 
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hydroxide (OH)2]. The remaining 1% of calcium in the body can be found in the blood, 
extracellular fluid and soft tissues. In the blood, 50% of the calcium is ionized and can 
move into cells and activate cellular processes. Thus, this fraction is known as the 
biologically active portion of calcium and in humans it is typically maintained at a 
concentration of 1.15 - 1.30 mmol/L, while the total serum concentration is typically 
2.20 - 2.60 mmol/L. The remaining 50% of calcium has no function except to serve as a 
store of calcium, with 40% circulating bound in a pH-dependent manner to proteins 
(mainly albumin) and 10% circulating complexed to either phosphate or citrate. The 
concentration of ionized calcium in the blood is tightly regulated. It is required for 
numerous important biological processes including muscle contraction, neuronal 
excitability and plasma membrane integrity, just to name a few (2, 3). One of the central 
players in maintaining calcium homeostasis is PTH. Its actions on the skeleton, intestine, 
and kidneys serve to maintain the ionized calcium and the overall balance of calcium in 
the body (4). 
Calcium-sensing receptors (CaSR's) are G protein-coupled receptors that are 
located on the plasma membrane of parathyroid cells (5). They act as a calcium 
thermostat, or "calciostat", that detects fluctuations of calcium in the blood. Activation of 
the CaSR by calcium binding leads to inhibition ofPTH synthesis and release. When 
ionized calcium falls below the target level, the inhibitory signaling by the CaSR is 
removed, and PTH is released ( 4, 6). PTH works in several classical ways to return the 
ionized calcium level to normal. In bone, calcium is initially immediately released from a 
pool of calcium that is stored near the bone surface. If the blood calcium remains low for 
2 
several hours, calcium is also then released from an addition pool of calcium that has a 
slower turnover (4). However, with extended periods of hypocalcemia, PTH acts to 
increase osteoclastic bone resorption to liberate calcium (and phosphorous) from the 
skeletal reservoir ( 6). This is accomplished through the receptor activator of nuclear 
factor kappa B (RANK)IRANK ligand (RANKL)/osteoprotegerin (OPG) triad. In this 
system, when PTH binds to the type 1 PTH/PTHrP receptor (PTHlR) located on 
osteoblasts (bone forming cells), osteoblastic bone fonnation is initially stimulated. With 
prolonged stimulus by PTH, the expression ofRANKL (on the surface of osteoblasts) 
and macrophage-colony stimulating factor (M-CSF) is increased. As a result of these 
stimuli, osteoclast precursors differentiate into mature osteoclasts (bone resorbing cells), 
and the activity of existing mature osteoclasts is increased. The prolonged binding of 
PTH to the PTHlR on osteoblasts also results in a decrease in the expression ofOPG, 
which is a soluble receptor expressed by osteoblasts, that is often referred to as a "decoy" 
receptor because of it homology to RANK. The decrease in OPG and the increase in 
RANKL and M-CSF together stimulate the activity of mature osteoclasts and 
osteoclastogenesis, causing both calcium (and phosphorous) to be released into the blood 
to help retum the blood calcium level to normal (4) (Figure 1). 
In the kidney, PTH has little effect on the proximal tubule where 65% of filtered 
calcium is normally reabsorbed. However, in both the cortical thick ascending limb of the 
loop ofHenle (where 20% of filtered calcium is normally absorbed), and the distal 
convoluted tubule (where 15% of calcium is normally reabsorbed), PTH immediately 
stimulates calcium reabsorption and inhibits phosphate reabsorption. Thus, under the 
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influence ofPTH, less calcium but more phosphate is excreted in the urine; this helps 
increase the level of calcium in the blood (3, 4). With prolonged PTH binding to the 
PTHlR in the kidney, the activity of !-alpha-hydroxylase (la(OH)ase) is stimulated, 
which leads to an increase in the conversion of circulating 25-hydroxyvitamin D3 to the 
active 1,25-dihydroxyvitamin D3 (1 ,25(0H)2D3). This increase in 1,25(0H)2D3 in turn 
enhances intestinal calcium absorption which also helps to increases the blood calcium 
level (3, 4). 
In summary, when the blood calcium level decreases below normal, the CaSR's 
on parathyroid glands are not stimulated and PTH is released into the circulation. PTH 
then acts directly in bone to increase bone resorption, and in kidney to increase calcium 
reabsorption, and indirectly in the intestines to enhance calcium absorption. Overall, the 
net effect of these actions results in the blood calcium level being restored to normal (3, 
4) (Figure 2). The opposite is also true: when blood calcium rises above the normal 
range, activation ofthe CaSR' s on parathyroid cells inhibits PTH release and less 
1 ,25(0H)2D3 is produced by the kidneys. As a result, less calcium is released from the 
skeleton, less calcium is reabsorbed by the kidneys, and intestinal calcium absorption is 
decreased. Thus, the overall effect is that blood calcium level decreases back to the 
normal level (3, 4). 
C. Fetal Calcium Homeostasis 
Although it is known that calcium and bone metabolism is regulated differently in 
the fetus as compared to the adult, relatively little is known about how the fetus maintains 
4 
mineral homeostasis. This is largely in part due to the understandable limitations of 
studying human fetuses. Thus, much of what we do know regarding fetal regulation of 
calcium homeostasis has been inferred from animal studies. For numerous reasons 
however, including the fact that much of the data are consistent among mammalian 
studies and that placentation is very similar between humans and rodents, it is likely that 
such findings also apply to humans. The possibility exists that species differences occur 
between animals and humans, but the information gathered from animal research is 
extremely critical because equivalent human data will never be possible. 
The fetal period is unique. It is a time of rapid development and specific needs are 
placed upon the developing fetus. First, the fetus must meet the demand to provide the 
required amount of calcium and other minerals to fully mineralize the fetal skeleton 
before birth. One might anticipate that this process occurs slowly throughout gestation, 
however, mineralization of the fetal skeleton occurs quite rapidly in the latter part of 
pregnancy; in humans 80% ofthe 20-30g of mineral required to mineralize the fetal 
skeleton before birth is accreted in the third trimester (7), while rats accrete 95% of the 
required 12.5 mg during the last 5 days of a 3 week gestational period (8). Second, the 
fetus must maintain physiologically appropriate levels of calcium and other minerals that 
are needed for the fetal system to function normally. More specifically, in several species 
including humans (9, 10), sheep (11), cattle (12) and rodents (11), the fetal blood calcium 
is normally maintained at a higher level than that of the mother. This increase in blood 
calcium is mainly due to an increase in the ionized calcium level, although total calcium 
is also elevated (13). The physiological relevance of this fetal hypercalcemic state 
5 
remains unknown. However, it appears to exist independently of the maternal calcium 
level, because the fetal blood calcium level is usually unaltered in situations where the 
mother experiences either hypocalcemia (14) or hypercalcemia (15). 
Studies in humans (10, 16), rats (17, 18), and sheep (19), have shown that fetal 
serum phosphorous levels are also maintained at a higher level than that observed in the 
mother. Like calcium, it is likely that the high levels of phosphorous in the fetus facilitate 
normal bone formation. 
Studies comparing fetal serum magnesium levels to matemallevels have shown 
varying results between species and studies. However, the majority of studies conclude 
that fetal magnesium is approximately equal to the maternal level, or at most, modestly 
increased or decreased (20-23). 
In the fetal milieu, many calcitropic hom1ones including PTH, 1,25(0H)2D3, and 
PTHrP are also maintained at levels that differ from the adult. In many species, including 
humans (24), lambs (25), cattle (12), and rodents (unpublished data), fetal full length or 
intact PTH (i.e. PTH [1-84]) levels are significantly lower than maternal levels. This low 
level ofPTH in the fetus has been noted in late gestation, however it is still unclear 
whether this low level is maintained throughout gestation, after the parathyroids form and 
start to produce PTH on embryonic day 11.5 (26) , or if it is just suppressed late in the 
gestational period (20). Several studies in rats and non-human primates have shown that 
PTH does not cross the placenta (18, 27, 28). Consistent with this, fetal mice lacking 
parathyroids had undetectable levels ofPTH despite having mothers with near normal 
PTH levels (20). Thus, it is likely that the PTH detected in the fetal circulation derives 
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solely from fetal tissues. Although PTH levels are very low in the fetal circulation, it still 
appears to be biologically important because fetal mice that lack parathyroids are 
hypocalcemic and have undermineralized skeletons (29). 
Like PTH, 1 ,25(0H)2D3 also circulates at lower levels in the fetus as compared to 
the mother (20, 30). Furthermore, 1,25(0H)2D3 detected in the fetal circulation is also 
considered to be mainly, if not completely, derived from fetal tissue because it is also 
thought to not cross the placenta (20, 31 , 32). Unlike PTH however, 1 ,25(0H)zD3 may 
not play a critical role in fetal mineral homeostasis. This is because no impairments in 
skeletal mineralization or serum mineral concentrations were noted in vitamin D receptor 
(Vdr) null fetal mice as compared to their WT littermates (33). 
PTHrP is also maintained at a different level in the fetus as compared to the adult, 
with PTHrP circulating at higher levels in the fetus. It is nonnally not detected in the 
adult circulation, except during pregnancy and lactation (34). However, even at term, 
studies have reported that PTHrP levels in human umbilical cord blood are significantly 
higher than that of simultaneous maternal PTHrP levels (35, 36). Furthermore, when 
expressed in molar units and compared to simultaneous PTH levels in cord blood at term, 
levels ofPTHrP are approximately 15-fold higher than PTH (32). Given that the 
molecular weight of intact PTHrP is twice that ofPTH, and that PTH cannot cross the 
placenta, it is also unlikely that PTHrP would cross the placenta. Thus, similar to both 
PTH and 1 ,25(0H)zD3, whole length PTHrP circulating in the fetus is believed to be 
exclusively derived from fetal tissues. However, although it has not been studied, it 
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remains possible that smaller fragments ofPTHrP could cross the placenta, and that some 
might have biological activity (20, 31 ). 
Although the fetus differs from the adult with respect to the level of minerals and 
calcitropic hormones that it maintains in the blood, like the adult, it can also utilize the 
kidneys, intestine and bone to maintain the appropriate fetal blood calcium level. 
Calcium, phosphorous and magnesium that is filtered by the fetal kidneys can be partly 
reabsorbed into the circulation to maintain the blood calcium concentration. However, the 
precise handling of calcium, and other minerals by the kidneys may not be as important 
in the fetus as in the adult. This conclusion is based on several factors. First, it has been 
suggested that the response to PTH in the fetal kidneys is bhmted compared to the adult 
(37, 38). This blunted response has been associated with very low expression levels ofthe 
CaSR in the fetal kidneys, which increases substantially over the first postnatal week 
(39), along with the renal tubular response to PTH (37). Second, minerals wruch are 
excreted in the urine by the fetal kidneys are not permanently lost. Fetal urine, containing 
the non-reabsorbed minerals, is excreted into the amniotic fluid, which may then be 
swallowed by the fetus, allowing the minerals to be absorbed by the intestine. Similar to 
the adult, maintaining the appropriate level of calcium in the blood is of vital importance. 
Thus, as in the adult, calcium from the developing skeleton can be reabsorbed to supply 
calcium to the blood if necessary (20, 32, 34). 
In addition to the kidneys, intestine and bone, the fetus has another organ which 
plays a vital role in the overall regulation of calcium homeostasis. The placenta is of vital 
importance for the fetus because it is responsible for, among many other things, 
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transferring calcium (and other minerals) from the mother to the fetus (20, 32, 40). This 
transfer can occur via simple diffusion, paracellular transport, vesicular transport, or by 
active transport (20). One may think that the transfer of calcium from the mother to the 
fetus is a one-way process. However, several studies have shown that there is some 
degree ofbackflux. That is, some calcium from the fetal circulation returns to the 
maternal circulation. This fetal-to-maternal backflux is difficult to measure accurately. 
Some studies have reported that the backflux is less than 1% of the forward (maternal-to-
fetal) flow (41, 42) while others reported that it may be as high as 80% ofthe forward 
flow (41). The reason for these vast differences is unknown, however, it has been 
suggested that the differences may reflect true differences between the species that have 
been studied, or differences in the methodology that was used to assess backflux in the 
various studies (20). 
The role of the placenta will be discussed in greater detail in section I. 
D. Parathyroid Hormone (PTH} 
PTH is an 84-amino acid single-chain polypeptide (43). In humans, the PTH gene is 
located on the short arm of chromosome 11 (44), whjJe in mice it is located on 
chromosome 7 ( 45). The transcription product encodes both a "pre" signal sequence of 25 
amino acids and a "pro" sequence of 6 amino acids, in addition to the mature 84-amino 
acid peptide. As a result, the initial translational product is a 115-amino acid product 
called preproparathyroid hormone (pre-pro-PTH). The pre-pro sequence is very important 
as it ensures proper PTH intracellular transport and processing. If it is mutated or absent, 
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hypoparathyroidism may occur (43). Once the pre-pro signaling sequence has been 
cleaved, the resulting mature PTH [1-84] peptide is then packaged into secretory/storage 
granules within the parathyroid cells. The granules which store and secrete PTH can 
either contain only the full-length 84-amino acid PTH, or PTH together with the 
proteases cathepsins B and H. Granules that do not contain the proteases secrete only 
intact PTH. Granules which contain the proteases contain a mixture of amino-terminal 
and C-terminal hormone fragments of PTH ( 46). 
As previously discussed, PTH secretion is directly responsive to the ionized calcium 
concentration. In response to low blood calcium, PTH from the parathyroid glands is 
released into the circulation and returns the blood calcium to normal through its actions 
on bone and kidney. The concentration of calcium found in the blood has also been 
shown to regulate the abundance of various PTH derived peptides that are released into 
the circulation. Thus, when serum calcium is low, more intact PTH [ 1-84] is detected in 
the circulation. When the blood calcium is high, more C-terminal fragments such as PTH 
[37-84] are found (46). 
1. PTH Receptors and Signaling 
Type 1 PTHIPTHrP Receptor (PTHJR) 
The PTHlR is highly expressed in both bone and kidney where it is the target for the 
classical actions ofPTH to regulate calcium homeostasis. It is also expressed in many 
other adult tissues including the aorta, brain, breast, heart, skeletal muscle, skin and the 
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placenta (just to name a few), which are sites that are not normally thought of as being 
targets for PTH action (47). 
The PTH1R appears to be the major receptor mediating the classical actions ofPTH. 
These classical actions occur when the amino-terminal region ofPTH (PTH [1-34]) 
which has strong homology among mammalian species (43), binds to the PTH1R and 
activates several signaling pathways. More specifically, upon receptor activation, a 
cascade of events occurs which is mediated by the PTH1R coupling to different G 
proteins. Via Gas, adenylyl cyclase (AC) is stimulated. This results in the formation of 
cyclic adenosine monophosphate (cAMP) which activates protein kinase A (PKA). 
However, when PTH1R activation results in Gaq activation, phospholipase C (PLC) 
signaling occurs. Subsequently, diacylglycerol (DAG) and inositol 1, 4, 5-triphosphates 
(IP3) is formed resulting in protein kinase C (PKC) activation and the release of 
intracellular calcium. The end result of both AC and PLC pathway activation is that 
downstream biological responses are stimulated. However, whether the AC or PLC 
signaling pathway is activated, is tissue/cell specific. That is, in some tissues/cells the AC 
pathway will be activated, while in others the PLC signaling cascade will occur. This 
cell-specific receptor signaling may be explained by the sodium (Na+)- hydrogen (H+) 
exchanger regulatory factor 1 and 2 (NHERF1 and NHERF2), because it has been shown 
to be capable of changing PTH1R signaling. In the presence ofNHERFl and NHERF2 
the activated PTH1R may switch from AC signaling to PLC signaling (46, 48). 
Evidence also exists to suggest that there may be other receptors for the amino-
tenninal fragment ofPTH. These receptors however, are believed to be expressed in 
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non-classical PTH target tissues (i.e. non-kidney, non-skeletal) and have yet to be 
identified ( 49). 
PTH2 Receptor (PTH2R) 
Unlike the PTHlR, the PTH2R is expressed in relatively few tissues throughout 
the body. Some tissues shown to express the PTH2R include the placenta (50), blood 
vessels (51) , and central nervous system (50, 52). This receptor was cloned due to its 
structural similarity to the PTHlR, and although the human PTH2R is activated by 
amino-terminal PTH, this is not the case in other species that have been studied. In fact, 
the PTH2R is likely not a "true" PTH receptor at all . This is because it is believed that 
PTH is not its natural endogenous ligand. Instead, it is thought that a small peptide know 
as the hypothalamic tuberoinfundibular peptide of 39 residues (TIP 39) is the primary 
natural ligand for the PTH2R, not PTH (4, 43). Many of the biological functions 
mediated through the PTH2R are still unknown, but reports to date have shown no role 
for it in mineral homeostasis; instead, it may be important in the regulation of renal blood 
flow (4, 51), and to pain responses (43, 53). Although the PTH2R may not be relevant 
for the biological actions ofPTH, it was included here for completeness. 
Carboxy-terminal PTH Receptor (C-PTHR) 
There is evidence that a receptor exists which binds carboxy-terminal (C-
terminal) PTH fragments with high affinity. This receptor has yet to be cloned, and its 
biological role is not well understood and still requires much investigation (43, 46, 54). 
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However, studies have suggested that C-terminal PTH fragments, which do not bind to 
the PTHlR to initiate the classical effects ofPTH, actually bind to the C-PTHR to exert 
biological actions that are opposite to that ofPTH [1-34] binding to the PTHlR (43, 55, 
56). For example, unlike PTH [1-34] , C-terminal PTH fragments have been shown to 
inhibit bone resorption (57) and to decrease blood calcium concentrations (58). However, 
since a C-terminal knockout animal has yet to be made, it remains unknown how relevant 
these actions are to calcium homeostasis overall. 
E. Parathyroid Hormone Related Protein (PTHrP) 
Human PTHrP is encoded by a gene located on Chromosome 12 (59), while the 
mouse PTHrP gene is located on Chromosome 6 (60). PTHrP is widely expressed in both 
developing and adult tissues, including: cartilage, bone, mammary glands, the central 
nervous system and the placenta (61 , 62). However, unlike the endocrine hormone PTH, 
in the adult PTHrP is normally undetectable in the circulation because it functions 
principally in a paracrine/autocrine manner in many cells and tissues ( 49). Compared to 
PTH, an 84 amino acid peptide, PTHrP is much longer. In fact, in humans it has three 
isoforms: 139, 141 , and 173 amino acids in length, which result from alternative RNA 
splicing. In these isoforms, amino acids 1-139 are identical ( 49, 61 , 62). In the mouse 
however, PTHrP is a single 139 amino acid chain (49). 
Cells which secrete PTHrP cleave full-length PTHrP to produce at least 3 known 
forms of secreted peptides. These include the amino-terminal fragment, or PTHrP [1-36] ; 
the mid-region fragment, or PTHrP [38-94]; and the C-terminal fragment, or PTHrP 
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[107-139] (49, 61, 62). The biological functions of each of these fragments are unique 
and believed to function through distinct receptors. 
1. PTHrP Receptors and Signaling 
PTHJR 
Like PTH [1-34], PTHrP [1-36] also binds to the PTH1R (49, 61, 62). Both PTH 
[1-34] and PTHrP [1-36] mediate classical effects on calcium homeostasis when they 
bind and activate the PTH1R (49). As a result, it is a complex task to delineate the 
relative roles ofPTH and PTHrP in calcium and bone metabolism. In order to explore the 
role ofPTH in fetal-placental calcium and bone metabolism, PTHrP must also be taken 
into consideration. 
It has generally been believed that the anlino-terminal fragments ofPTH and 
PTHrP bind to the PTH1R with equal affinity and exert effects on mineral ion 
homeostasis with equal potency via identical mechanisms (49). More recently however it 
has become clear that PTH [1-34] and PTHrP [1-36] can differ in how they bind to the 
PTH1R. It appears that the PTH1R has the capacity to form various conformational states 
and bind the two ligands with different affinities. In one conformational state it had been 
shown that PTH binds with greater affinity and can mediate prolonged signaling (for 
hours), while PTHrP binds for only minutes. Thus, in this instance, PTH can cause 
prolonged signaling responses in bone and/or kidney PTH target cells, which can 
ultimately lead to different biological outcomes (63, 64). 
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As with PTH, previous studies have suggested that other receptors exist which 
bind the amino-terminal fragment ofPTHrP. In zebrafish a receptor (PTH3R) has been 
identified that selectively binds PTHrP [1-36] (65). Whether a homolog of this receptor 
exists in mammals remains unknown. 
Thus to review, both amino-terminal fragments ofPTH and PTHrP activate the 
PTH1R, while the PTH2R binds PTH but not PTHrP, and the PTH3R binds PTHrP but 
not PTH. 
Receptors for the mid-region and C-terminal fragments of PTHrP 
It has been reported that C-terminal regions ofPTHrP, including PTHrP [107-
139] which has been named osteostatin (62), in contrast to the actions ofPTHrP [1-36] , 
can inhibit osteoclastic bone resorption (66), while the mid-region ofPTHrP has been 
shown to stimulate placental calcium transfer ( 67 -70). It is known that both of these 
fragments do not bind to the PTH1R and have no PTH-like functions. However, even 
though there is strong evidence to suggest that both mid and C-terminal fragments of 
PTHrP have distinct receptors, they have yet to be identified ( 49). 
F. Mouse Models of PTH and/or PTHrP Deficiency 
Several knockout mouse models of PTH and/or PTHrP deficiency have been 
created, and they serve as useful models to explore the role ofPTH in fetal-placental 
calcium and bone metabolism. Each of the models vary with respect to how the function 
ofPTH and/or PTHrP is disrupted in the mouse, and as a result they offer insight into the 
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role of not only PTH, but also PTHrP and the parathyroids, in regulating fetal-placental 
calcium and bone homeostasis. 
Below, several of the relevant knockout mouse models that have previously been 
explored are listed (see Table 1 for a summary of previously published data from the 
various knockout mouse models). A model that had yet to be examined with regards to 
fetal-placental calcium and bone metabolism, the Gcm2 null, is also introduced because it 
will be utilized in the present study. Subsequent sections will discuss what has already 
been learned from these models, particularly with respect to the role ofPTH in regulating 
fetal blood calcium, skeletal development and mineralization, and placental calcium 
transfer, and what questions still remain. 
1. Homeobox A3 (Hoxa3) Null 
Deletion of the Hoxa3 gene results in a range of abnom1alities in the pharyngeal 
tissues, particularly those arising from the 3rd and 4th pharyngeal arches (71). As a result, 
Hoxa3 null mice are lacking parathyroids (aparathyroid) and circulating PTH (71, 72). 
Furthermore, they lack the thymus (athymic) and have thyroid hypoplasia. Deletion of the 
Hoxa3 gene is lethal at birth. (71). 
2. Parathyroid Hormone (Pth) Null 
Pth null mice have a normal thymus and thyroid. The parathyroid glands are 
present but enlarged: they completely lack PTH because the gene encoding PTH has been 
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deleted. Deletion of the Pth gene is not lethal prior to birth (73), but many presumably 
hypocalcemic deaths occur in subsequent weeks (Unpublished). 
Although the fetal bone phenotype has previously been evaluated in the Pth nulls 
in a C57BL/6 inbred strain background, placental calcium transfer and other parameters 
of calcium metabolism (e.g. blood ionized calcium and plasma PTHrP levels) had not yet 
been assessed. 
3. Parathyroid Hormone-related Protein (Ptltrp) Null 
Pthrp null mice have normal thymus, thyroid, and parathyroids. They completely 
lack PTHrP because the gene encoding PTHrP has been deleted. Most Pthrp null mice 
die within the first 30 minutes after birth, but occasionally pups survive several days. The 
cause of death may be from a variety of causes including hypocalcemia, restrictive lung 
disease (rigid rib cage), and acute respiratory distress syndrome due to surfactant 
deficiency (74-76). 
4. Type 1 PTHIPTHrP Receptor (Pthrl) Null 
Pthrl nuii mice have high circulating levels ofboth PTH and PTHrP. However, 
because the PTHlR, which binds the amino-terminal region of both PTH and PTHrP, is 
deleted, the biological effects of the amino-terminal ofPTH and PTHrP are absent while 
mid and C-terminal effects are retained. Depending on the genetic background that the 
Pthrlnull mice have been backcrossed into, they die between mid-gestation and 
immediately after birth (67, 75). 
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5. Glial Cells Missing 2 (Gcm2) Null 
Gcm2 encodes a transcription factor whose expression is essential for the 
development of the parathyroid glands. Thus, Gcm2 null mice Jack the parathyroid glands 
but have a normal thymus and thyroid. Despite lacking parathyroid glands and being 
hypocalcemic and hyperphosphatemic, Gcm2 null mice were reported to have normal 
circulating levels ofPTH. It was speculated by Gunther et al. (2000) that the auxiliary 
source of PTH in the Gcm2 nulls was coming from a small cluster of PTH -producing 
cells in the thymus. However, they did not attempt to find PTH-producing cells in the 
thymus of the Gcm2 null mice. Rather, they showed that there was a small cluster of 
PTH-producing cells in the thymus ofWT mice that had previously been 
thyroparathyroidectomized. In turn, they assumed that such PTH-producing cells must be 
present in Gcm2 null thymus. 
It is known that the parathyroids develop with the thymus from a bilateral 
common primordium in the third pharyngeal pouch in mouse embryos at about day 11 of 
gestation. By about day 13.5 of gestation this primordium separates into one parathyroid 
gland lobe and one thymus lobe on each side (26, 77, 78). This primordium intensively 
expresses Gcm2 (78). Several years after the Gcm2 nulls were studied by Gunther et al. 
and the start of this project, Liu et al. (2007) reported that neither PTH mRNA or PTH 
protein expression were present in the common parathyroid/thymus primordium in the 
Gcm2 null mice on embryonic day 11.5-12.5, while both were clearly present in the WT 
mice. Moreover, unpublished work from these authors has demonstrated that parathyroid 
tissue which is present in the thymus ofWT mice appears to be the result of fragments of 
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parathyroids that become detached during the developmental migration of the embryonic 
parathyroids as opposed to being PTH-producing cells that have derived de novo from the 
thymus. Thus, this work predicts that Gcm2 nulls should not have parathyroid cells in the 
thymus at all. Overall, based on this subsequent research and the fact that Gunther et al. 
(2000) failed to directly show that a small group of cells in the thymus of the Gcm2 nulls 
was responsible for producing PTH, it remains puzzling why the Gcm2 nulls had 
"normal" circulating PTH levels and where it was coming from. 
From Gcm2 HET male and female matings it was reported that 30% of the Gcm2 
null offspring die shortly after birth. The remaining nulls were viable and fertile (79). 
Unlike the previously discussed knockouts, fetal-placental calcium and bone 
metabolism in the Gcm2 null fetal mice had not yet been explored before I began this 
project. 
G. Regulation of Blood Calcium in the Fetus 
As noted previously, it is well established that fetal blood calcium is maintained at a 
level higher than in the mother. However, it is unknown exactly how early in gestation 
tllis occurs. In humans, fetal hypocalcemia has been reported as early as 15-24 weeks of 
gestation (80), while in mice it has been observed as early as day 15 of gestation which is 
the earliest time point that a sufficient blood sample can be collected for the assay 
(unpublished data, Kovacs lab). Remarkably, the ability of the fetus to maintain a blood 
calcium level higher than the mother is robust because even in the face of chronic, severe 
maternal hypocalcemia, fetal blood calcium remains unaffected (31). For example, Vdr 
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null fetal mice had nom1al ionized calcium levels, despite having Vdr null mothers that 
were severely hypocalcemic (33). The biological significance or role of the high fetal 
blood calcium is unclear. It has been suggested that it may protect against severe neonatal 
hypocalcemia (20). Under normal circumstances, in the first 12 hours after birth, the 
neonatal blood calcium level drops significantly below the maternal level before it 
eventually rises to the normal adult concentration (31). Thus, by starting at a higher than 
maternal level, the fetal blood calcium may serve to protect the fetus from dropping to a 
severely low level after birth (20). Historically, the high fetal blood calcium level has also 
been suggested to be necessary for the fetal skeleton to mineralize. Prior studies have 
suggested that to mineralize the fetal skeleton a blood calcium equal, but not above, the 
maternal level is sufficient (20, 29, 31, 34, 81 ). 
As previously discussed, in the adult it is the CaSR which directly regulates the blood 
calcium level by controlling the secretion ofPTH into the circulation. Similarly, in the 
fetus it also appears that the CaSR regulates the secretion ofPTH. This is because 
deletion ofthe CaSR leads to a stepwise increase in PTH, which suggests that the CaSR 
probably suppresses PTH in response to high fetal blood calcium. Deletion of the CaSR 
however also leads to an increase in ionized calcium. Thus indicating that the CaSR is not 
responsible for setting the high blood calcium level that is nonnally observed in the 
fetuses because in its absence, the blood calcium level becomes even high (15). 
The high fetal blood calcium level appears to be directly regulated by both PTH and 
PTHrP. This is based on the observations that in the absence ofPTHrP (Pthrp null fetal 
mice), fetal blood calcium was reduced from its nonnal high level to the maternal level 
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(67), while in the absence ofPTH and the parathyroids (Hoxa3 null fetal mice) the fetal 
blood calcium dropped significantly below the maternal level (72). Furthermore, in the 
absence ofPTH, the parathyroids and PTHrP (Hoxa3/Pthrp null fetal mice) the blood 
calcium level declined to a level that was even lower than that observed in either of the 
single mutants (29), and equal to that observed in mice lacking the PTH1R (29, 67) 
(Figure 3). Thus, both PTH (and the parathyroids) and PTHrP independently contribute 
to blood calcium in the fetus and one hormone cannot compensate for the lack of the 
other; in the absence of either the blood calcium is reduced (20, 81, 82). Although PTH 
circulates at much lower levels in the fetus as compared to PTHrP, it appears to play a 
larger role in regulating the blood calcium because absence ofPTH (and parathyroids) 
caused a greater fall in blood calcium than PTHrP alone. 
In response to hypocalcemia and lack of PTHrP, PTH increases. In Pthrp null 
fetuses, serum PTH levels were reported to be increased approximately 3-fold as 
compared to that of WT fetuses. This increase in PTH may have prevented more severe 
hypocalcemia (29), but PTH may have been be unable to compensate completely for 
absence ofPTHrP because it is restrained by the actions of the parathyroid CaSR' s which 
allow PTH to increase the blood calcium to the normal adult level, but not higher (i.e. to 
the normal fetal level). Unlike PTH however, PTHrP may not respond in the same 
manner to lack ofPTH and fetal hypocalcemia. Hoxa3 null fetuses (completely lacking 
PTH), despite having more profound hypocalcemia (below the maternal level), do not 
have an increase in plasma PTHrP (72). 
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It is uncertain how PTH and PTHrP independently and concurrently regulate blood 
calcium through the single PTHlR. It has been suggested that both ligands may actually 
not function through the PTH1R to regulate fetal blood calciun1. Instead, PTH may 
regulate blood calcium by acting on classic target tissues such as kidney and bone which 
express the PTHlR, while it may be the mid-region ofPTHrP that contributes to blood 
calcium through binding to a distinct receptor that regulates placental calcium transfer 
(20, 81' 82). 
The preceding discussion has relied heavily on data from Hoxa3 nulls which in 
addition to lacking PTH and the parathyroid glands have other problems that may 
confound their phenotype. They have abnormalities in tissues deriving from the third and 
fourth pharyngeal arches which result in the absence of the thymus (83). Thus, it is 
unclear whether the phenotype observed in the Hoxa3 null fetuses is solely the result of 
absence of PTH, whether absence of the parathyroid glands is a contributing factor, or 
even if other abnormalities in the Hoxa3 nulls contribute to the calcium and bone 
phenotype. 
See Table 1 for a sUll1illary of previously published data from the various 
knockout mouse models showing the effect ofPTH and/or PTHrP deficiency on fetal 
blood calcium. 
H. Regulation of Skeletal Development and Mineralization in the Fetus 
The fetal skeleton must undergo ample growth and significant mineralization prior to 
birth (20, 81, 82). Previous studies in fetal sheep have suggested that the fetal 
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parathyroids are necessary for these processes to occur normally because fetal 
parathyroidectomy and thyroparathyroidectomy resulted in fetal skeletons that were 
rachitic and lacking calcium (84, 85). Studies in fetal rats however, showed that the fetal 
parathyroids are not required because fetal decapitation (thought to mimic 
thyroparathyroidectomy) did not adversely affect the fetal skeleton (86). 
In the time since the surgical models above were carried out, comparative studies on 
various genetic knockout mouse models have been utilized to sort out the relative roles of 
the parathyroids, PTH and PTHrP in fetal skeletal development and mineralization. 
Studies on Pthrp nulls, which lack PTHrP, revealed that although the fetal skeletons were 
fully mineralized (29), they suffered from numerous abnormalities of endochondral bone 
formation due to premature terminal differentiation of chondrocytes in the growth plate 
(74). The absence ofPTH (and parathyroids) however, in the Hoxa3 null fetal mice, 
resulted in normal long bone and growth plate development, but the skeleton was 
significantly undermineralized (29). Removing PTH (and parathyroids) and PTHrP, as in 
the Hoxa3/Pthrp null, resulted in smaller fetuses with a more severe Pthrp null 
chondrodysplasia and undermineralized skeletons (29). Essentially, the phenotype of 
Hoxa3 nulls was superimposed on that of Pthrp nulls. Thus, it appears that for nonnal 
development of the cartilaginous skeletal scaffold which is sequentially resorbed and 
replaced with the bone matrix, PTHrP is required, while PTH or functioning fetal 
paratyhroids are required for the fetal skeleton to become mineralized before birth (20). 
More specifically, it is thought that PTHrP acts locally in the growth plate to direct the 
development of the cartilaginous skeletal scaffold (87), whereas PTH mineralizes the 
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fetal skeleton by maintaining sufficient circulating levels of minerals, such as calcium 
(29) and by direct actions on osteoblasts to stimulate bone formation. Furthermore, it is 
believed that in order for the fetal skeleton to mineralize sufficiently, the fetal blood 
calcium concentration must be maintained at a level that is at least equal, but not 
necessarily higher, to the maternal blood calcium level (20). 
Subsequent to the Hoxa3 null studies discussed above, studies involving Pth null 
mice were reported. Like the Hoxa3 null mice, Pth null mice also had undermineralized 
skeletons (73). However, unlike the Hoxa3 nulls which were reported to have no skeletal 
abnormalities beyond skeletal undermineralization, the Pth nulls showed quite a different 
phenotype with slightly shortened long bones, abnormally formed skulls, smaller 
vertebral bodies, and shorter metacarpal and metatarsal bones. Furthermore, with closer 
examination it was also found that among many other abnormalities, the long bones of 
the Pth nulls also had enlarged hypertrophic zones, increased cortical thickness, and 
decreased osteoblast number (73). With the phenotypes varying so significantly between 
the two models of absence of fetal PTH, the role of PTH in fetal skeletal development 
and mineralization became less certain. The phenotypic differences observed in the above 
studies may have resulted because both mouse models were studied in different genetic 
backgrounds. Hoxa3 null mice were studied in the background of Black Swiss (29), while 
the Pth null mice were studied in a C57BL/6 background (73), which are known to have 
a lower blood calcium level as compared to Black Swiss mice (67). The phenotypic 
differences between the two knockout mouse models are quite interesting. The Pth nulls 
lacked only one thing (i.e. PTH) but had abnormal skeletons, while the Hoxa3 nulls 
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lacked multiple things (i.e. PTH, parathyroids, thymus) but had normal skeletons (albeit 
undermineralized). This leads to the question: how could multiple abnormalities add up 
to a normal skeleton, and only one abnormality cause an abnormal skeleton? Tllis very 
puzzle made it necessary to examine the two models in the same genetic background. 
See Table 1 for a summary of previously published data from the various knockout 
mouse models showing the effect ofPTH and/or PTHrP deficiency on fetal skeletal 
development and mineralization. 
I. Placental Calcium Transport 
1. The Placenta 
The placenta assumes many functions that are carried out by separate organs in the 
adult body. It acts as the fetal lungs, disposes of fetal waste, is a site of hormone 
production, and performs many other functions. Perhaps the most fascinating aspect of 
the placenta however, is its architecture. It is comprised of cells from two genetically 
distinct organisms; the mother and the fetus ( 40). 
The structure of the placenta varies considerably among different species. They have 
various shapes, cellular organizations and different patterns with respect to how it is 
distributed over the uterine lining ( 40, 88) . Both sheep and rodent placenta have 
contributed to our knowledge of the placental unit and the factors that regulate placental 
calcium transfer. Thus, it is important to be aware ofthe various types of placenta, how 
they differ, and how they compare to the human placenta because all these factors may 
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affect our understanding of how the placenta functions, and how, or if, findings from 
animal studies can apply to humans. 
The placenta of sheep, based on gross morphology, can be classified as a 
cotyledonary placenta. This means that the placental tissue is restricted to numerous (60-
70 in a single pregnancy) individual elements know as cotyledons, which are spread over 
the entire uterine wall. Rodents and humans however have the most localized type of 
placenta, known as discoid, in which the placental tissue is confined to a single plate that 
attaches to the uterine wall ( 40, 88). 
Placentas can also be classified according to the number of cell layers that separate 
the maternal and fetal blood, which also reflects the degree to which the trophoblast layer 
of the embryo invades the maternal uterine tissue. Based on these elements, sheep 
placenta is considered to be epitheliochorial. Six layers of tissue separate the maternal 
and fetal blood because the uterine cell layer remains intact; it is not invaded by the fetal 
trophoblasts at all (Figure 4A). In contrast, humans and rodents have a haemochorial 
placenta. This type of placenta shows the greatest extent of fetal trophoblast invasion into 
the maternal uterine tissue, which results in the maternal blood being in direct contact 
with the fetal chorion layer (Figure 4B) ( 40, 88). 
Mice are great experimental models for studying placental development and function 
as the overall structure of human and rodent placenta (both discoid and haemochorial) are 
very similar. However, there are some structural differences between the rodent and 
human placenta that should be noted. First, although both have a haemochorial type 
placenta, rodents are further classified as being haemotrichorial, meaning it has three 
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layers of placental trophoblast cells (labyrinthine trophoblasts (i.e. Syncytiotrophoblasts), 
spongiotrophoblasts, and giant trophoblasts) that separate the maternal blood from the 
fetal blood. The human placenta however is haemomonochorial, as it has a single 
trophoblast cell layer separating the maternal and fetal blood (88-90). A second 
difference between the human and mouse placenta exists in the area of the placenta in 
which the fetal and maternal blood comes in closest contact with one another. In humans, 
tree-like stmctures, know as villi, protmde from the fetal side into the intervillous space, 
which is filled with maternal blood, allowing the villi to "float" in the large blood-filled 
space. In rodents however, instead ofthe large blood-filled space, there is a labyrinth. 
Thus, instead of the villi floating freely in the maternal blood, the villi are surrounded by 
a series of small channels that are filled with maternal blood (91 ). Another difference 
between the human and rodent placenta is that the rodent, but not the human placenta, 
contains a unique structure known as the intraplacental yolk sac (IPYS). The IPYS is a 
bilayered membrane that is located between the fetal blood vessels and the maternal 
blood filled channels. Overlying the fetal vessels are tall colmm1ar cells, while on the 
opposite side, small parietal (or cuboidal) cells overlie the maternal blood spaces and a 
thick basement membrane know as Reichert's membrane (Figure 5). This structure has 
been shown to highly express many calcitropic hormones, receptors, and channels, 
including calcium adenosine triphosphatase (Ca2+-ATPase), CaSR, PTHlR, VDR, 
calbindin-D9k (CaBP9k), and transient receptor potential vanilloid 6 (TRPV6). 
Furthermore, a decrease in calcitropic horn1ones in this stmcture, for example the 
decrease in CaBP9k in the Pthrp null fetuses, coincides with a decrease in placental 
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calcium transfer (92). Therefore, due to its well situated positioning and calcitropic gene 
expression it is likely that the IPYS is a site of maternal-fetal calcium exchange (20, 92, 
93). 
2. Techniques for Assessing Placental Calcium Transport 
Various techniques have been utilized to study the process of placental calcium 
transport. The techniques are quite different from one another, and each offers its own 
benefit and limitations. The placental perfusion technique has been utilized in sheep (94, 
95), rat (96, 97), and more recently, mouse (98, 99) studies. This technique involves 
removing the fetus from the uterus and attaching the placenta via the umbilical vessels to 
a semi-closed circuit. The placenta is then perfused in situ with either actual fetal blood 
or a blood substitute, while the flow rate and perfusion pressure of the system is kept 
constant (Figure 6). Depending on what is being studied, the system can then be altered 
accordingly. For example, to test the effect of a specific peptide on placental calcium 
transfer, the peptide of interest can be injected directly into the portion ofthe circuit that 
is connected to the umbilical arteries that will flow into the placenta (in-flow), while 
continuous sampling to measure changes in the calcium concentration can be taken from 
the portion of the circuit that is coming from the placenta via the umbilical vein (94). 
Similarly, to actually measure the rate of calcium transfer, both 45Calcium (Ca) and 
5 1Chromium (Cr)-Ethylenediaminetetraacetic Acid (EDTA) can be administered into the 
in-flow of the circuit, and the clearance of 45Ca relative to 51 Cr-EDTA can be monitored 
to determine the rate of calcium transfer (96). This method has also been utilized to 
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indirectly (because the fetus is removed) study the contribution of the fetal parathyroids 
to placental calcium transfer. In fetal lamb studies, this was accomplished by performing 
a fetal thyroparathyroidectomy, then supplementing the fetus with thyroid horn1one for a 
period oftime before the placental perfusion circuit was set up to assess placental 
calcium transfer (94, 95). In rat studies, to simulate a thyroparathyroidectomy, 
decapitation was performed, and a couple of days later the fetuses were removed and the 
placenta were perfused in situ to evaluate the effect oflack of parathyroids on placental 
calcium transport (96). In recent years, the placental perfusion technique, with some 
adaptations, has been utilized in mice. Due to the small nature of mice, in order to 
successfully place a catheter in the umbilical vessel it is necessary to dilate the 
vasculature with nitroglycerin. Furthermore, due to the small volume of blood in the 
mouse, unlike studies in rats and sheep, numerous maternal blood samples cannot be 
collected over the course of the experiment. Thus, the maternal radioisotope 
concentration, which is utilized in a formula to determine the rate of transfer across the 
perfused placenta, is determined from a maternal radioisotope disappearance curve that 
was created from collecting single samples from different dams at varying time points, 
rather than collecting serial maternal blood samples at various time points throughout a 
single experiment (98, 99). 
Another very different technique, which allows the fetus to remain intact, has also 
been utilized in mice to assess placental calcium transfer. This technique involves giving 
the pregnant mother an intracardiac injection containing 45Ca and 5 1Cr-EDTA. 5 minutes 
after the maternal injection, the fetuses are removed, and the amount of each isotope that 
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has accumulated within each fetus is determined. Because 51 Cr-EDTA only crosses the 
placenta by passive diffusion it serves as a control for differences in flow rate between 
the individual placentas in one litter, 45Ca however is actively transported across the 
placenta from mother to fetus as well as crossing passively. Thus, by correcting for the 
rate of diffusion (using the 51Cr-EDTA) the relative rate of placental calcium transfer in 
each fetus in the litter can then be detem1ined (67). Unlike fetal surgery or decapitation 
that was used in combination with the placental perfusion technique (discussed above) to 
assess the contribution of the fetal parathyroids on placental calcium transfer, this 
teclmique utilizes knockout mice. For example, in previous studies male and female mice 
HET for the Hoxa3 gene were mated such that litters would contain WT, HET and Hoxa3 
null fetuses, which lack the parathyroids. Pregnant mothers were then given the 
intracardiac injection of 45Ca and 5 1Cr-EDTA, and placental calcium transfer was then 
assessed to see if it differed between genotypes (72). Furthermore, using this technique to 
assess the effect of specific hormones on the rate of placental calcium transfer is quite 
different than using the placental perfusion technique. The testing of various hom1ones 
can be accomplished through performing a laparotomy and administering an 
intraabdominal injection of the test peptide to the fetus in utero, prior to giving the 
mother the radioisotope intracardiac injection to assess the rate of placental calcium 
transfer (67). 
In summary, the techniques that have been used to assess placental calcium transfer 
differ significantly. Therefore, when reviewing placental calcium transfer studies it is 
very important to differentiate between the teclmiques that have been used, and keep in 
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maintain the normal fetal blood calcium level but also having to mineralize the fetal 
skeleton. This is a great demand placed on the fetus because the mineralization occurs 
very rapidly, with 80% of the required mineral being accreted in the third trimester in 
humans (7) and 95% of the required mineral being accreted in the final 5 day of gestation 
in rats (8). In humans, it is likely that the site of active transport is the fetal-facing 
basement membrane of the syncytiotrophoblast cells, while in rodents it is likely the 
labyrinthine trophoblasts and the basal surface of the endodem1 of the IPYS (20, 31, 92). 
At these sites, it is thought that (similar to calcium transfer across the intestinal mucosa 
and kidney) (100), calcium enters through calcium channels, such as TRPV6, at the 
maternal-facing basement membrane, is then carried across the cell by calcium binding 
proteins, such as calbindin-D9k, and finally actively expelled at the fetal-facing basement 
membrane by Ca2+-ATPase (i.e. the calcium pump) (20, 81, 82, 92, 101) (Figure 7). 
Although it is clear that active placental calcium transfer is an important process 
in fetal calcium homeostasis, the components and regulating factors have not been fully 
elucidated. It is thought that both the maternal and fetal factors contribute to regulating 
this process (20). 
Matemal Regulatio11 
Maternal hormones may influence the process of fetal-placental calcium transport 
by either acting directly on the placenta or by altering (increasing or decreasing) the 
maternal blood calcium level. However, studies in animal models have suggested that 
despite maternal hypocalcemia or hormone deficiencies, the normal maternal-to-fetal 
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calcium transfer can usually be sustained (20, 31, 81, 82). For exan1ple, placental 
perfusion studies in sheep found that the rate of placental calcium transfer was unaffected 
by maternal hypocalcemia caused by either a parathyroidectomy or by a restricted 
calcium diet (94, 1 02). Likewise, in fetal mice, it was discovered that ablation of V dr did 
not adversely affect placental calcium transfer, even though the Vdr null mothers suffered 
from severe hypocalcemia (33). The fact that the rate of placental calcium transfer is not 
negatively impacted under these circumstances does not necessarily mean that the fetus is 
unaffected by maternal hypocalcemia. It is likely that because of the low maternal 
calcium concentration, the fetal-placental unit may be working much harder to pump the 
normal amount of calcium across the placenta to the fetus. Furthermore, although not 
evident in rodents, in humans, maternal hypocalcemia due to hypoparathyroidism has 
been associated with problems such as fetal parathyroid hyperplasia, skeletal 
demineralization, intrauterine fractures, and bowing of the long bones, which are all 
symptoms consistent with intrauterine fetal hyperparathyroidism (103, 104). 
F eta/ Regulation 
Several animal models have been utilized to explore the potential role of fetal 
hormones, and their receptors, in regulating placental calcium transfer. The receptor for 
1, 25(0H)2D3, VDR, has been shown to be expressed in the placenta of sheep (1 05), 
humans (106, 107), rats (108), and mice (92). Furthermore in mice, the VDR has been 
shown to be expressed highly in the IPYS as compared with trophoblasts (92). The VDR 
is also known to be involved in calcium transport in both the intestine (109, 110) and 
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kidney (11 0). Based on the above findings, it is reasonable to infer that the VDR is 
involved in calcium transport across the placenta. This idea has been supported by several 
studies. First, it was reported that in sheep, 1 ,25-(0H)2D3 partly restored reduced calcium 
transfer (as assessed by the placental perfusion technique) that resulted from a 
nephrectomy (101). Furthermore, in other placental perfusion studies in rats (111) and 
sheep (112), it was reported that pharmacological doses of 1,25-(0H)2D3 or 1a-
hydroxycholecalciferol increased calcium transfer. Contrary to these findings however, 
studies in mice have concluded that it is unlikely that the VDR or 1,25-(0H)2D3 (which 
was indirectly tested) plays a role in regulating placental calcium transfer. This 
conclusion was based on the fmdings that Vdr null fetal mice had a normal rate of 
placental calcium transfer, normal levels of many calcitropic honnones, and normal 
placental expression of CaBP9k, which is thought to play an important role in maternal-
fetal calcium transfer in late gestation (33, 92, 101). Thus, it was theorized that 
1 ,25(0H)2D3 is likely not required for the normal regulation of placental calcium transfer, 
at least in mice (20, 33), since the ablation of fetal VDR did not alter placental calcium 
transfer. However, in the above Vdr null studies, placental calcium transfer was non-
signjficantly increased in the Vdr null fetal mice. (33). This may indicate that the role of 
VDR is to actually decrease, rather than increase, placental calcium transfer. 
The role of the parathyroid glands in regulating placental calcium transfer has also 
been examined. In thyroparathyroidectorllized fetal sheep (supplemented with thyroid 
hormone) (94, 95), and in decapitated fetal rats (to approximate a 
thyroparathyroidectomy) (96), placental calcium transfer was found to be reduced as 
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assessed by the placental perfusion technique (94-96). Together, these results lead to the 
conclusion that the parathyroids play an important role in active maternal-fetal calcium 
exchange. Furthermore, in the fetal thyroparathyroidectomized sheep studies, when 
autologous blood from intact fetal sheep (i.e. which have parathyroid glands) was infused 
into the perfusion circuit, calcium transfer across the perfused placenta of the 
thyroparathyroidectomized fetal sheep was restored (95). In similar sheep studies 
however, it was discovered that PTH did not restore calcium transport (70). Therefore, it 
appeared likely that the parathyroids might be producing something other than PTH that 
regulated placental calcium transfer (70). In fact, it was thought that it may be PTHrP that 
was responsible for regulating placental calcium transfer. PTHrP [1-141], PTHrP [1-86] 
and PTHrP [67-86] all stimulated placental calcium transfer whereas PTH was without 
effect. The collective results seemed to indicate that it was the mid-molecular form of 
PTHrP, PTHrP [67-86], that was somehow active in regulating the transfer of calcium 
across the placenta, because PTHrP [1 -34], like PTH, had no effect (68-70). The overall 
results from studies on thyroparathyroidectomized fetal sheep led to the theory that 
PTHrP, which may be produced by the parathyroid glands, is a cmcial factor in 
regulating placental calcium transfer, while PTH is not. Although it was concluded that it 
was PTHrP from the parathyroids that stimulated calcium transfer, this is not certain. 
Circulating levels ofPTHrP were not measured in these studies, and thus it remains 
unknown whether the levels of PTHrP were reduced as a result of the 
thyroparathyroidectomy. 
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Studies in fetal mice further examined the role ofPTHrP in the process of placental 
calcium transfer. Similar to the studies on sheep, these studies also implicated PTHrP, 
more specifically the mid-molecular region ofPTHrP, to be responsible for stimulating 
placental calcium transfer. Furthermore, as assessed not by the placental perfusion 
technique, but rather by examining intact fetal mice, it was found that Pthrp null fetal 
mice had reduced placental transfer of calcium, but when treated with PTHrP [ 1-86) or 
PTHrP [67-86) calcium transfer increased. Treatment with PTHrP [1-34] or PTH [1-86] 
however, had no effect (67). 
One confounding piece of evidence against the role ofPTHrP in regulating 
placental calcium transfer comes from a study on Pthrp null mice. Contrary to the study 
discussed above, it was reported that placentas from Pthrp null fetuses actually showed 
an increase in the rate of calcium transfer across the placenta as compared to placentas 
from both WT and Pthrp +/-fetuses (98). In this study, calcium transfer was assessed by 
the placental perfusion technique adapted for mice. It is likely that this accounts for the 
opposite results observed between this study and that which assessed placental calcium 
transfer in intact Pthrp null fetuses . Tllis is due to the fact that PTHrP is expressed in the 
smooth muscle vasculature and exerts effects on vascular development and physiology 
(113). Thus, it is likely that the vasculature of the Pthrp null mice is different from that of 
WT mice. As a result, dilating the vasculature with nitroglycerin prior to measuring 
placental calcium transfer may have resulted in different responses between genotypes 
(e.g. the Pthrp nulls may dilate more than WT or HET fetuses), and affected the rate of 
placental calcium transfer observed in each. Furthermore, not only are the fetuses absent 
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in this method, but there is only one placenta examined per pregnancy. Thus, there are no 
in utero littermates for the null to be compared to, which would allow the affect of the 
vasodilator to be taken into account. Instead, the method assumes that the blood flow 
from mother to fetus is the same from mother to mother. This however, may not be the 
case. 
As with fetal sheep studies, studies on Pthrp nulls did not help detennine if the fetal 
parathyroids produce PTHrP, or if parathyroid derived PTHrP could be the source that is 
important for placental calcium transfer. This is because Pthrp null fetuses do not 
produce PTHrP in any tissues. Studies in other genetically altered mice however, may be 
infom1ative. As previously mentioned, Hoxa3 null fetuses completely lack PTH, and are 
aparathyroid and athymic (83). In spite of this, they had a normal rate of placental 
calcium transfer and unaltered plasma PTHrP levels (72). In addition, Pthr 1 null fetuses 
(which lack the PTHlR) had an increased rate of placental calcium transfer and elevated 
plasma PTHrP levels. It was found however, that PTHrP mRNA was upregulated in both 
the placenta and liver, but not the neck region that would contain the parathyroids (72). 
Thus, in contrast to fetal sheep studies, studies in fetal mice suggested that the fetal 
parathyroids do not produce PTHrP. This is consistent with a rat study which reported 
that PTHrP was not detectable in the fetal parathyroids, as assessed by in situ 
hybridization, immunohistochemistry, and RT-PCR (114). 
Despite the evidence in favor for a role ofPTHrP, but not PTH, in stimulating 
placental calcium transfer, there is also evidence suggesting that PTH may indeed 
stimulate placental calcium transfer. In rat decapitation studies, as discussed above, it was 
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found that PTH did stimulate placental calcium transfer (96). Furthermore, it has been 
reported that vesicles created from human syncytiotrophoblast basal membranes in vitro, 
increased calcium accumulation when treated with PTH [1-34] (115). The fact that the 
PTH1R is highly expressed in the placenta, particularly in the IPYS which is believed to 
be a site of maternal-fetal calcium exchange (67, 92), also suggests that PTH may play a 
role in regulating placental calcium transfer; especially since the PTHlR is not the 
receptor that the mid-region ofPTHrP acts on to stimulate placental calcium transfer 
(67). Furthermore, the previously discussed studies carried out by Kovacs eta/ (1996) 
showed that treating Pthrp null fetuses in utero with PTHrP [67-86] increased calcium 
transfer while treatment with PTH [1-86] did not. It was later discovered that Pthrp null 
fetuses had a significant increase in endogenous circulating PTH (29). Thus, treating the 
fetuses with exogenous PTH may have been ineffective if the fetuses were already 
maximally upregulating placental calcium transfer in response to the high endogenous 
PTH. 
As can be seen from the research reviewed above, there are discrepancies among 
various animal models and studies regarding the role of the parathyroids in placental 
calcium transfer, the source ofPTHrP that is important for stimulating placental calcium 
transfer, and the role, if any, ofPTH in regulating placental calcium transfer. These 
differences may be true species differences, or they may be due to methodological 
differences. The experimental design in the current study, which is discussed in detail in 
the next section (i.e. II. Project Description, Purpose and Hypothesis), allows some of 
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these issues to be addressed and will help clarify some of the inconsistencies that 
currently exist in the literature. 
See Table 1 for a summary of previously published data from the various knockout 
mouse models showing the effect ofPTH and/or PTHrP deficiency on placental calcium 
transfer. 
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II. Project Description, Purpose and Hypothesis 
As can be seen from the previously reviewed literature, studies on genetically 
engineered mouse models have provided great insight into the role ofPTH in fetal-
placental calcium and bone homeostasis. Despite the efforts however, the role ofPTH 
remained unclear. Therefore, the purpose of the present doctoral research was to further 
examine the role ofPTH in fetal-placenta] calcium and bone homeostasis and test the 
hypothesis that: PTH, despite its low circulating levels during fetal life, plays an 
important role in regulating not only f etal blood calcium and skeletal development, but 
also placental calcium transfer. To test this hypothesis, several remaining questions 
regarding the role ofPTH in fetal calcium homeostasis were addressed: 
1) Is the phenotype of the Pth null fetal mice in the Black Swiss background the 
same as the Pth null fetal mice in the C57BL/6 background? 
2) Does absence ofPTH have the same consequences on skeletal mineralization and 
blood calcium as absence ofPTH and parathyroids? If not, why does the 
phenotype of the Pth nulls differ from that of the Hoxa3 nulls? 
3) Does PTHrP increase in response to fetal hypocalcemia and/or absence ofPTH? 
4) Does PTH regulate placental calcium transfer? 
5) Does PTH regulate placental gene expression? 
6) Is PTH expressed locally in the placenta? 
To help answer these questions, two mouse models were utilized: the Pth 
knockout and the Gcm2 knockout. These models served as excellent tools for addressing 
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the above questions. The Gcm2 nulls served as an intermediate model between the Pth 
nulls and the Hoxa3 nulls: Hoxa3 nulls, have absence ofPTH and parathyroids; Pth nulls, 
have absence ofPTH but retention of parathyroids; Gcm2 nulls, have absence of 
parathyroids, but retention of some PTH. Thus, examining the Gcm2 nulls and re-
investigating the Pth nulls in the same genetic background (Black Swiss) as the Hoxa3 
null mice were previously evaluated, helped determine if genetic background could 
explain the differences in skeletal phenotypes observed between the Pth nulls (original 
report) and the Hoxa3 nulls. Furthermore, it helped elucidate the relative roles ofPTH, 
PTHrP, and the parathyroids in fetal calcium and addressed whether the Hoxa3 null 
phenotype is due to the absence ofPTH alone. 
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III. Materials and Methods 
A. Animal Husbandry 
1. Pth Null Mice 
The Pth11111Dgo knockout mice (i.e. Pth null mice) utilized in tllis study were 
obtained from Dr. Andrew Karaplis (McGill University, Montreal, Quebec, Canada), and 
were in a C57BL/6 background. Targeted ablation of the murine Pth gene, specifically 
replacing the coding sequence of mature PTH on exon 3 with a neomycin (NEO) resistant 
gene, was achieved by homologous recombination in embryonic stem cells as previously 
described (73). 
2. Gcm2 Null Mice 
The Gcmi11111 K'Yknockout mice (i.e. Gcm2 null mice) utilized in this study were 
obtained from Dr. Gerard Karsenty at the Baylor College of Medicine, Houston, TX, 
USA (now at Columbia University, New York, NY, USA), and were in a C57BL/6 
background. As previously described, the knockout mice were generated by using 
embryonic stem cell technology and all four exons were replaced with a NEO cassette 
(79). 
3. Colony Maintenance and Backcrossing 
Both the Pth and Gcm2 mice were back crossed into Black Swiss (Taconic Farms 
Inc., Germantown, NY), an outbred strain of mice, for at least three generations prior to 
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the start of any studies and then almost mmually so the mice were closer to 7-10 
generations in the latter experiments. Colonies were then maintained by mating 
heterozygous-deleted Pth males and females, and Gcm2 males and females to produce 
litters that contained wild-type (WT or +/+), heterozygous(+/- or HET), and (Pth or 
Gcm2) null(-/-) mice. 
4. Animal Housing 
Animals were maintained in a facility operated by Animal Care Services of 
Memorial University of Newfoundland, in accordance with the Canadian Council on 
Animal Care (CCAC). The light/dark cycle consisted of 9:00 am - 9:00pm of light, and 
9:00pm - 9:00am of darkness. Water and standard mouse chow (1% calciun1, 0.75% 
phosphorus) was give ad libitum. Male breeders were housed individually, while females 
were housed 4 per cage. All experimental procedures were approved by the Institutional 
Animal Care Committee (IACC) ofMemorial University of Newfoundland. 
5. Timed Matings 
Pth +/-males and females and Gcm2 +/-males and females were mated overnight 
twice weekly. The following morning, the females were checked manually for the 
presence of a vaginal mucous plug. The presence of a plug marked embryonic day (ED) 
0.5, where the normal gestational period in these mice is nineteen days. Non-plugged 
females were then returned to their original housing cage, until the next mating. 
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B. Genotyping of Animals 
1. Mouse Identification 
At approximately three weeks of age (the time of weaning) mice were briefly 
anaesthetized with Isoflurane TM (Baxter) and given a numbered ear tag for identification 
purposes. 
2. Tail Clipping 
At the time of weaning and when fetal samples were collected, a small portion of 
tail was clipped from each of the mice. The piece of tail was then placed in a 1.5 ml 
microcentrifuge tube (Fisher Scientific) that contained 500111 of lysis buffer (100 mM 
Tris-hydrogen chloride [HCL], pH 8.0 I 500 mM ethylenediaminetetraacetic acid 
[EDTA], pH 8.0 I 0.2% sodium dodecyl sulfate [SDS] I 200 mM sodium chloride [NaCl], 
and 100 Jlg/ml of proteinase K [Invitrogen]). The tubes were then placed in an isotherm 
oven (Fisher Scientific) at 55°C for 18-24 hours. Following this incubation period the tail 
samples were digested and ready for deoxyribonucleic acid (DNA) extraction. 
3. DNA Extraction 
Tail samples were removed from the oven, shaken by hand for 2-3 minutes and 
then centrifuge at 13, 000 rpm for 10 minutes. The supernatant was then transferred to 
fresh a microcentrifuge tube containing 0.5 ml of isopropanol, and were inverted several 
times to precipitate the DNA. Small pipette tips were then used to transfer the 
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precipitated DNA into a microcentrifuge tube containing 0.5 ml of deionized water. 
Samples were then shaken by hand for 5 minutes to dissolve the DNA, and 0.5 ml of 
phenol/chloroform/isoamyl alcohol (1 00:100:1) was added. Next, the samples were 
shaken vigorously for 1 minute and then centrifuged for 2 minutes at 13, 000 rpm. The 
aqueous layer was then transferred to a fresh microcentrifuge tube by pipetting, and 1.0 
ml of cold 0.12 M sodium acetate (NaOAc) in ethanol (EtOH) was added. Tubes were 
inverted several times and then centrifuged for 10 minutes at 13, 000 rpm to form a DNA 
pellet. The supernatant was then discarded, and 1.0 ml of70 % EtOH was added. After 
centrifuging for another 10 minutes, the EtOH was decanted, and any remaining EtOH 
was removed by pipetting. The DNA pellet was then air dried, resuspended in Tris EDTA 
buffer (TE) and stored at 4°C until samples were genotyped (by Polymerase Chain 
Reaction). 
4. Polymerase Chain Reaction (PCR) 
To genotype the mice, PCR was carried out on the DNA that was extracted from 
the mouse tails. For both the Pth and Gcm2 colonies a four primer system was utilized. 
That is, two primers were utilized to detect the normal gene (i.e. Gcm2 or Pth gene) and 
two primers were utilized to detect the presence of the NEO cassette. 
The normal WT Gcm2 gene was detected by utilizing the two sequence specific primers 
below: 
G-F (forward): 5'- CAC CCT GCC AAA TGG TGG ATA ACA (Invitrogen) 
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G-B (reverse): 5'- CCC TCG CAT AAG TCA GCA AAC ATC (Invitrogen) 
The normal WT Pth gene was detected by utilizing the two sequence specific primers 
below: 
PTHl (forward): 5'- GAG GCT TTG TAG TGG GTT TT (Invitrogen) 
PTH2 (reverse): 5'- AGA GAA GTG GAA ATG GAG AG (Invitrogen) 
The Pth null and Gcm2 null were detected by utilizing two specific primers for the 
neomycin (NEO) resistant gene: 
Nl (forward): 5'- GGA GAG GCT ATT CGG CTA TGA C (Invitrogen) 
N2 (reverse): 5'- CGC ATT CGA TCA GCC ATG ATG G (Invitrogen) 
The PCR cocktail included 1 OX PCR buffer (20 mM Tris-HCL, pH 8.4, 50 mM 
potassium chloride (KCL) [Invitrogen]), deoxynucleotide triphosphates (dNTP's) (0.2 
mM of each deoxycytidine triphosphate ( dCTP), deoxyguanosine triphosphate ( dGTP), 
deoxyadenosine triphosphate (dATP) and deoxythymidine triphosphate (dTTP) 
[Invitrogen]), the appropriate primers (PTHl , PTH2 or G-F, G-B and Nl and N2 
[Invitrogen]), 50 mM magnesium chloride (MgCh) [Invitrogen], Taq DNA polymerase 
(0.02 U/~1 [Invitrogen]) and deionized water. 49 ~1 of the cocktail was then added to 
PCR tubes (Fisher Scientific) and 1.5 ~I of the DNA sample obtained from the mouse tail 
was added. PCR tubes were then placed in the Peltier Thermal Cycler (PT-200 DNA 
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Engine Thermal Cycler- Dual Alpha Blocks) where the following PCR conditions were 
applied. 
For the Pth primers: denaturation at 94°C for 45 seconds, annealing at 59°C for 
40 seconds and then elongation at 72°C for one minute. These steps were repeated for 35 
cycles, and were followed by 7 minutes at 72°C. Samples were then held at 4°C forever. 
For the Gcm2 primers: denaturation at 94°C for 45 seconds, annealing at 62°C for 
one minute, followed by elongation for one minute at 72°C. After repeating these steps 
34 times, there was 10 minutes at 72°C. Samples were then held at 4°C. 
5. Gel Electrophoresis 
The PCR products were then electrophoresed on a 1.2 % agarose gel ( 1.2 g of 
agarose [Invitrogen] I 10 ml of lOX TAE [pH 8.0, 0.12 M EDTA, 0.40 M Tris, 11.5 % 
Glacial Acetic Acid] I 90 ml of deionized water I 0.06 % ofEthidium Bromide 
[Invitrogen] or 0.20 % of SYBR Safe™ Stain [Invitrogen]) immersed in 700 ml of lX 
T AE buffer. 2 fll of Orange G loading dye (1 0 ml of 1 OX T AE I 500 mg of Orange G 
powder I 50 ml of glycerol) was added to the PCR tube following completion of PCR. 10 
fll of each PCR sample was then loaded into the wells of the agarose gel and run for 
approximately 30 minutes at 200 volts in an EASY-CAST™ electrophoresis system. A 
picture ofthe gel was then taken using a Kodak GEL LOGIC 100 ln1aging System with 
Kodak Molecular Imaging Software. For the Pth colony, the presence of a single 520 
base pair (bp) band indicated that the mouse was WT for the Pth gene, the presence of a 
single 300 bp band indicated that the mouse was null for Pth gene, while the presence of 
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both bands indicated that the mouse was +/- for the Pth gene (Figure 8). For the Gcm2 
colony, the WT band was denoted by a single 572 bp band, the Gcm2 null was denoted 
by a single 300 bp band, while the Gcm2 +/-mice showed the presence of both bands 
(Figure 9). 
C. Blood, Amniotic Fluid and Tissue Collection 
1. Blood Collection 
On embryonic day (ED) 18.5 heterozygous maternal whole blood was collected 
from the tail vein. The fetuses were quickly removed by cesarean section (C-section) and 
the fetal whole blood was collected after carotid/jugular transection. Maternal and fetal 
whole blood was collected in 60 J..Ll heparinized capillary tubes (Bayer) and kept on ice 
until ionized calcium was measured. 
For serum collection, both the maternal and fetal whole blood san1ples were 
collected in 60 J..Ll micro-hematocrit capillary tubes (Bayer). Capillary tubes containing 
the blood were then placed in a Micro-MB microcentrifuge (Thermo Scientific) equipped 
with the capillary tube plate rotor. Samples were spun for 5-10 minutes at 14, 000 rpm. 
When samples were removed, the serum was clearly separated from the clotted blood. A 
glass cutter was then utilized to cut the capillary tube at the junction where the serum and 
clotted blood met. The serum was then decanted into 0.6 ml microcentrifuge tubes 
(Fisher Scientific) and stored at - 20 °C. 
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For plasma collection, 60 J.!l micro-hematocrit capillary tubes were flushed with 
40 TIU/ml aprotinin (Sigma) in 0.5 M EDT A and used to collect the maternal and fetal 
whole blood samples. The samples were then decanted into 0.6 ml microcentrifuge tubes 
containing 2 J.!L of 40 TIU/ml aprotinin. Fresh capillary tubes were again flushed with 
aprotinin and then used to collect the samples from the microcentrifuge tubes. To 
separate the plasma, samples were then centrifuged for 5-10 minutes at 14, 000 rpm. 
Plasma was collected from the capillary tubes, placed in 0.6 ml microcentrifuge tubes and 
stored at - 70 °C. 
Following blood collection, whole fetuses were then weighed and stored at - 20 
°C for ashing. 
2. Amniotic Fluid Collection 
On ED 17.5 or 18.5 a terminal C-section, by cervical dislocation, was carried out 
on pregnant heterozygous females and the intact uterus was removed. Each amniotic sac 
was then lanced and the fluid was collected in 60 J.!l micro-hematocrit capillary tubes. 
San1ples were transferred to 0.6 ml microcentrifuge tubes and stored at - 20 oc. 
3. Whole Fetus and Tissue Collection 
On ED 18.5 terminal C-section were carried out on heterozygous females. Whole 
fetuses and/or tissue samples were then collected and stored appropriately depending on 
the future use of the specimen. 
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Intact fetuses that were to be utilized for histology were placed in 10% buffered 
formalin (37% formaldehyde I lOX PBS [pH 7.3, 1.37 M NaCl, 0.027 M KCl, 0.43 M 
Na2HP04• 7H20, 0.015 M KHzP04, deionized water] I distilled water). From theses 
samples, fetal tibias were dissected from the whole fetus and embedded in paraffin. 51J.m 
sections were cut using a Leica RM 2135 microtome. 
Intact fetuses used for Alizarin Red S and Alcian Blue staining were genotyped 
by removing a portion of the skin, rather than the tail, and no blood samples were taken. 
Whole fetuses were then immediately placed in 95% EtOH. At that point, they were 
ready to start the staining protocol. 
At the time of terminal C-sections, whole placentas and neck samples were also 
collected from some fetuses. The neck samples were made by coronal cuts just below the 
fetal mandible and above the sternal notch in order to include the thyroid and 
parathyroids. Ribonucleic acid (RNA) was to be extracted from these samples, thus they 
were immediately snap-frozen using liquid nitrogen, and san1ples were stored at - 70 °C 
in RNase/DNase free 1.5 ml microcentrifuge tubes. 
D. Placental Calcium Transfer 
On ED 17.5 or 18.5 pregnant heterozygous females were briefly anesthetized with 
Isoflurane™ and administered a 100 )ll intracardiac injection consisting of 50 ).!Ci of 45Ca 
and 50 ).!Ci of51Cr-EDTA in 0.9% saline. Females were then placed in a plexiglass box 
coated in lead for 5 minutes, after which time a terminal C-section was carried out by 
cervical dislocation. The uterus was quickly removed and then each fetus was removed 
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from its amniotic sacs. The fetuses were placed in 12 mm x 75 mm disposable round 
bottom polystyrene culture test tubes (Fisher Scientific). Forceps were used to pith the 
brain and the tubes were then capped. The 5 1Cr-EDTA activity in each fetus was then 
detem1ined using a 1480 WIZARD™ 3" automatic gamma counter (Perkin Elmer). 1 ml 
of Scintigest™ (Fisher Scientific) was then added to each tube and vortexed until the 
fetuses began to spin. Fetuses (with the 1 ml of Scintigest™) were then transferred to a 
disposable 20 ml scintillation vial (Fisher Scientific). 9 ml of Scintigest™ was then added 
to each of the vials, which were then placed in an isotherm oven (Fisher Scientific) at 
55°C for 24 to 48 hours. The fetuses were vortexed several times during this time. When 
the fetuses were fully solubilized they were removed from the oven, and 10 ml of 
ScintiVerse® (Fisher Scientific) and 5 drops of glacial acetic acid (Fisher Scientific) was 
added to each vial. The vials were then completely covered in aluminum foil and placed 
in the dark for 24 hours to reduce bioluminescence. The activity of 45Ca present in each 
fetus was then determined using a LS 6500 Multi-Purpose Scintillation Counter 
(Beckman Coulter). After the activity of each isotope present in each fetus was 
determined, the ratio of 45Ca to 51 Cr-EDTA activity for each fetus was used to determine 
the calcium transfer. The ratios were then normalized to the mean value of the 
heterozygotes within each litter [i.e. percent of the HET mean(% of+/- Mean)]. 
Heterozygotes were chosen to be the baseline comparison because heterozygote fetuses 
account for approximately 50% of fetuses in a litter and therefore provided a more robust 
and stable value for normalization. Placental calcium transfer measurements in relevant 
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previous studies have been reported in this manner (67, 72). Normalization allowed all 
the litters to be combined for analyses. 
E. Fetal PTH Injections (in utero) 
On ED 18.5, Pth +/-dams were anesthetized by administering an intraperitoneal 
injection of Pentothal® (Abbott Laboratories, Limited). A C-section was then carried out 
on the mother and approximately half of the fetal mice were injected in utero with 1 nmol 
PTH [1-84] (Bachem) in 2f.ll of saline, while the other halfwere injected with 2 f.ll of 
saline. The intraabdorninal injections were administered to the left side of each fetus (to 
avoid puncturing the liver) using a microinjection pipette and sutures were placed over 
the gestational sacs of the PTH injected fetuses so they could be identified later. The 
mother's incision was then closed, and she was permitted to awaken. To determine the 
effect of exogenous PTH on placental calcium transfer, 85 minutes after the fetal 
injections, the placental calcium transfer procedure was performed. Thus, placental 
calcium transfer was assessed a total of90 minutes after the fetal injections. This time 
point was chosen because it was consistent with the previously discussed study which 
found that placental calcium transfer in the Pthrp null fetuses increased when assessed 90 
minutes following a fetal injection ofPTHrP [1-86] or PTHrP [67-86] (67). To determine 
the effect of the PTH in utero injections on gene expression in the placenta, a terminal C-
section (also carried out 90 minutes following the fetal injections) was carried out and the 
placentas were collected and snap-frozen in liquid nitrogen. They were stored at - 70 °C 
for later RNA extraction and microarray analysis. 
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The placental calcium transfer methodology utilized in this study requires fetuses 
from approximately 6-10 pregnant mice to compare the baseline rate of placental calcium 
transfer among WT, +/-and null fetuses . In order to compare the effect of a single 
treatment versus saline at one time point, the number of mice required more than doubles. 
Furthermore, as the procedure is terminal, measurements can only be done at a single 
time point after the in utero injection. Consequently, it was not feasible to study a time-
course ofPTH injections or determine a full dose-response curve. Thus, the 1 nmol of 
PTH was chosen because it was equimolar to the dose ofPTHrP shown in previous 
studies to be effective in increasing the rate of calcium transfer in the Pthrp null mice 
(67). However, if the 1 nmol ofPTH had not worked, before moving on to another dose, 
it would have been necessary to confirm that the PTH utilized in the study was 
biologically active. This would have been accomplished by evaluating the cAMP 
response in cultured cells to the PTH [1-84]. But since a response was seen, I did not 
think it was necessary to do this afterwards. 
F. RNA Extraction 
RNA was extracted using the RNeasy Midi Kit (Quiagen). RNA was quantified 
by UV spectrophotometry, while RNA quality was assessed by utilizing both UV 
spectrophotometry measurements and visually observing the ribosomal RNA band 
integrity by electrophoresing the samples on an agarose gel. The Agilent 2100 
BioAnalyzer (Agilent Technologies, Inc.) was used to determine the RNA quantity and 
quality of the samples utilized for rnicroarray analysis. 
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G. Complementary DNA (eDNA) Synthesis 
eDNA synthesis was performed using the SuperScript III First-Strand Synthesis 
System and carried out as per the product insert. 
H. Real-Time Quantitative Reverse Transcriptase-PCR (Real-Time Quantitative 
RT-PCR) 
TaqMan® Gene Expression Assays for S100g (i.e. CaBP9k}, VDR, PTHrP, PTH 
and TRPV6 were utilized in the present study. These assays are pre-designed and pre-
optimized primers and probes with a fluorescent reporter dye (F AM™) at the 5' end of 
the TaqMan® MGB probe and a non-fluorescent quencher at the 3' end. In addition to 
the TaqMan® Gene Expression Assays, TaqMan® Universal PCR Master Mix (Applied 
Biosystems) was used when PTHrP expression was assessed in both neck and placenta 
RNA samples. The thermal cycler protocol then consisted of a 2 minute cycle at 50 °C, a 
10 minute cycle at 95 °C, followed by 40 cycles of 15 seconds at 95 oc and 1 minute at 
60 °C. When CaBP9k, VDR, PTH and TRPV6 expression was assessed in placenta 
samples however, in addition to the TaqMan® Gene Expression Assays, the TaqMan® 
RNA-to- CT™ 1-Step Kit (Applied Biosystems) was used instead ofthe Universal PCR 
Master Mix. This eliminated the need to carry out a separate eDNA synthesis step prior to 
quantitative real-time RT-PCR. When the TaqMan® RNA-to- CT™ 1-Step Kit was used 
the thermal cycler protocol then consisted of a 15 min cycle at 48 °C, a 10 minute cycle 
at 95 °C, followed by 40 cycles of 15 seconds at 95 oc and 1 minute at 60 °C. All real-
time quantitative RT-PCR was carried out in the ABI PRISM 7000 Sequence Detection 
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System (Applied Biosystems). All samples were performed in triplicate with a reaction 
volume of20)ll. GAPDH was used as a control gene, and the gene expression ratios were 
then calculated from differences in the threshold cycle (CT ). 
I. Skeletal Morphology and Mineral Assessment 
1. Whole Blood Ionized Calcium 
Maternal whole blood which was collected from the tail vein, and fetal whole 
blood which was collected by carotid/jugular transection, were kept on ice until analyzed 
within 30 minutes using a Chiron Diagnostics 634 Calcium/pH Analyzer (Ciba Coming 
Diagnostics Limited). 
2. Serum and Amniotic Fluid Magnesium and Phosphorus 
Magnesium and phosphorous in the serum and amniotic fluid were measured 
using colorimetric assays in the Gcm2 colony (Sigma-Aldrich). These kits were 
discontinued and this necessitated that different colorimetric assays be used in the Pth 
colony (Diagnostic Chemicals Limited, Charlottetown, PEl). All assays were carried out 
as per the product insert. 
3. Alizarin Red S and Alcian Blue Staining 
The day after whole fetuses (ED 18.5) were collected and placed in a scintillation 
vial containing 95 % EtOH, the skin was carefully peeled off. Fetuses were then 
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transferred to acetone to remove the fat. Once the fat was removed, the fetuses were then 
covered in 15 ml of staining solution (0.3% alcian blue 8GS in 70% EtOH [1 volume]/ 
0.1 %alizarin redS in 95% EtOH [1 volume]/ acetic acid [1 volume]/ 70% EtOH [17 
volumes]) for 3 days at 37 °C. The staining solution was then aspirated off and the 
fetuses were washed in distilled water. Fetuses were then placed in 15 ml of a 1 % 
aqueous solution of potassium hydroxide (KOH). Fetuses were checked daily, and when 
the skeleton was clearly visible through the surrounding tissue, the fetuses were cleared 
through a series of20 %, 50% and 80 % glycerol/ 1 %aqueous KOH solutions over a 2 
to 4 week period. After the fetuses were fully cleared, they were transferred to 100 % 
glycerin and stored at room temperature. 
4. Von Kossa Staining 
Paraffin embedded fetal (ED 18.5) tibia sections were placed on a slide warmer 
(Fisher) for 30 minutes and then put through the following steps to deparafinize and 
rehydrate the samples: Xylene - 2 minutes (2x), 100% EtOH - 2 minutes (2x), 95% 
EtOH - 2 minutes, 70% EtOH- 2 minutes, 50% EtOH - 2 minutes, distilled water - 1 
minute. Sections were then placed in a 1 % aqueous silver nitrate solution and placed 
under a strong light for 60 minutes. Following exposure to the silver nitrate, the sections 
were washed in distilled water 3 times for 2 minutes each time. Sections were then 
transferred to a 2.5 % sodium thiosulphate solution for 5 minutes, and then washed three 
times (2 minutes each time) in distilled water. Sections were then counterstained with 
methyl green (Sigma) for 2 minutes. Excess dye was blotted from the slides, washed in 1-
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butanol (Fisher Scientific) twice (1 0 seconds each time) and then washed in xylene twice 
(10 seconds each time). Permount (Fisher Scientific) was then added to the slides to 
mount the coverslips. 
5. Fetal Ash Weight and Flame Atomic Absorption Spectroscopy 
Fetuses that were previously genotyped were weighed, placed in weighed 
crucibles and reduced to ash in an oven at 500 oc for 24 hours. After the fetuses were 
reduced to ash, the crucible was once again weighed to determine the amount of ash 
present. The ash weight reflects the amount of total mineral present in the fetal skeleton. 
To control for fetal size, which varies from litter to litter, ash weight data was normalized 
to the mean value of the WT fetuses within each litter [i.e. percent of the WT mean(% of 
WT Mean)]. 
All ash samples were transferred to 20 ml scintillation vials and stored at room 
temperature until the samples were prepared for Atomic Absorption Spectroscopy 
analysis to determine the amount of calcium and magnesiun1 present in the skeletal ash. 
To do this, 253 J.!l of nitric acid was added to each scintillation vial containing the fetal 
ash. Samples were left to sit for at least 5 days at room temperature for the ash to 
dissolve, and then 10 ml of deionized water was added to each vial. Appropriate dilutions 
were made for the reading to be within the proper calibration range of the 2380 Atomic 
Absorption Spectrophotometer (Perkin-Elmer). Like ash weight data, skeletal mineral 
content data was also normalized to the mean value of the WT fetuses within each litter 
(% ofWT Mean). 
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J. Hormone Assays 
1. PTH Enzyme-Linked ImmunoSorbent Assay (ELISA) 
Serum PTH levels were determined using a Rat Intact PTH [1-84] ELISA Kit 
(Immutopics). The procedure outlined in the kit was followed and the absorbance of each 
sample was determined using a Vmax Kinetic Microplate Reader (Molecular Devices). 
The detection limit of the kit was 1.6 pg/ml and samples with a concentration below this 
limit were assigned a value equal to the detection limit. 
2. PTHrP Radioimmunoassay {RIA) 
Plasma samples were sent to the St. Vincent's Institute of Medical Research, 
Melbourne, Australia, for PTHrP analysis. The RIA was designed by Dr. T. J. Martin, 
and utilized an antibody specific for the amino-terminal portion ofPTHrP. All samples 
were analyzed in duplicate. A sufficient volume of plasma was collected from each adult 
mouse to constitute one sample, while fetal samples had to be pooled to obtain the 
necessary volume. See Appendix C for a detailed protocol. 
In fetal mouse plasma, it is likely that the sensitivity of this assay is 3.8 ± 0.3 
pmol/1. This is due to the fact that previous studies reported plasma PTHrP in Pthrp null 
fetuses to be 3.8 ± 0.3 pmol/1 (72). 
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K. Affymetrix GeneChip® Analysis 
RNA samples were shipped on dry ice to The Centre for Applied Genomics, 
Microarray Facility, at the Hospital for sick Children in Toronto, ON. This facility is an 
accredited Affymetrix service provider and initially carried out RNA quality testing via 
the Agilent 2100 BioAnalyzer (Agilent Technologies, Inc.). All san1ples were deemed to 
be of good quality, with RNA Integrity Numbers (RIN) ranging from 8.4 - 9.0 (see 
Appendix D for detailed bioanalyzer results). The Mouse GeneST 1.0 Array, which 
contains numerous probes spread across the full length of every well-annotated gene, was 
then utilized to assess gene expression in the placenta of WT and Pth null fetuses that 
were injected with either saline or exogenous PTH [1-84]. In total, 12 arrays were 
completed, which included 3 samples in each of the following groups: WT injected with 
saline, Pth null injected with saline, WT injected with PTH [1-84], Pth null injected with 
PTH [1-84]. Raw data obtained from the Mouse GeneST 1.0 Arrays, which summarizes 
all probes into a single gene expression value, were then sent to the Statistical Analysis 
Core Facility, also at The Centre for Applied Genomics, for analysis. At the Facility, 
gene annotation information was obtained from Affymetrix (March, 2008 version) and 
any probesets in the normalized data without gene names/gene assignments were 
removed. As a result, the final data set consisted of22, 158 probesets. The raw data was 
initially normalized using the robust multi-array average (RAM) algorithm (116) and 
differentially expressed genes were then identified using the Local-Pooled-Error Test 
(LPE) (117). In this method, errors within genes and between replicate arrays for genes in 
which expression values are similar are pooled, and it has been shown to have an 
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advantage in identifying subtle changes in gene expression. False discovery rate (FDR) 
(118) was used to evaluate statistical significance and was controlled at 0.05, such that 
genes with adjusted p-values < 0.05 were considered to be statistically significant. 
L. Statistical Analysis 
For all experiments fetuses from several heterozygous mothers were used to avoid 
the bias of a single mother contributing to the data. All data was analyzed using SYSTAT 
5.2.1 for Macintosh (SYSTAT, Inc., Evanston, IL). Analysis of variance (ANOVA) was 
initially used to analyze the data, followed by a post hoc test to detennine significant 
differences between pairs of means. The real-time quantitative RT-PCR data was 
analyzed using the T~lt.CT method (119). All data are presented as the mean ± standard 
error (SE). Two-tailed probabilities are reported, and a probability (p) less than 0.05 (p < 
0.05) was considered to be statistically significant. p > 0.05 was considered to be not 
significant (NS) and is denoted by p = NS. 
Details of the statistical analysis for the microarray can be found in the 
prior Affymetrix GeneChip® Analysis section (Section III. I.). 
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IV. Results 
A. Serum PTH 
As expected, the serum PTH was at or below the limit of detection of the assay 
(1.6 pg/ml) in all Pth null fetuses (Figure lOA). Serum PTH was also low in Gcm2 null 
fetuses as compared to Gcm2 +/-fetuses (Figure lOB). Although PTH was at or below 
the detection limit in some samples, detectable values ranged from 2.96 - 31 .11 pg/ml. 
The low serum PTH levels in the Gcm2 null fetuses were quite surprising. The 
initial reports by Gunther et al indicated that the serum PTH levels in Gcm2 nulls were 
normal (79). The reason for the large difference in serum PTH levels between the present 
and previous study is unknown, however, there are several factors that may be 
contributing to the different findings. First, in the present study the mice were studied in a 
Black Swiss background, while in the previous study the mice were maintained in the 
C57BL/6 background. Second, measurements in the present study were taken in fetal 
mice (ED 18.5), while adult mice were the subjects of the previous study. Finally, serum 
PTH levels in both studies were measured by using different methods. In the present 
study a rat intact PTH [1-84] ELISA kit was utilized, while in the former study an 
immtmoradiometric assay specific for rat PTH [1-34] was used. 
B. Blood and Serum Chemistries 
The blood and serum chemistry of Pth nulls and Gcm2 nulls was remarkably 
similar. Pth null and Gcm2 null fetuses were equally hypocalcemic, with an ionized 
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calcium that was 25% lower than in the +/- and WT fetuses (Figure llA and 118). The 
ionized calcium in Pth nulls and Gcm2 nulls was equal to the maternal level, with Pth +/-
mothers at 1.21 ± 0.06 mmol/L (n=8) and Gcm2 +/-mothers at 1.31 ± 0.03 (n=7). Gcm2 
+/-and Pth +/-fetuses did not show any reduction in ionized calcium. In both Pth null 
and Gcm2 null fetuses serum phosphorous was significantly higher as compared to WT 
and +/- fetuses (Figure 12A and 128). Serum magnesium in both Pth nulls and Gcm2 
nulls was reduced. In Pth nulls serum magnesium was no different as compared to Pth 
+/- fetuses (p=NS) (Figure 13A), while serum magnesium was slightly, but significantly 
reduced in Gcm2 nulls (0.87 ± 0.01 mmol/L, n=11) as compared to Gcm2 +/-fetuses 
(0.92 ± 0.01 mmol/L, n=19) (p=0.004) (Figure 138). Although statistically significant, 
the decrease in serum magnesium observed in the Gcm2 null is very small and may be 
physiologically unimportant. 
Ionized calcium, serum phosphorous and serum magnesium levels between the 
Pth +/- mothers and Gcm2 +/-mothers were no different (p=NS). 
C. Amniotic Fluid Calcium and Magnesium 
The amniotic fluid is comprised mainly of fetal urine and thus can be used to 
evaluate the amount of mineral that the fetal kidneys are excreting (120). From previous 
studies (unpublished from Dr. C.S. Kovacs laboratory) it has been shown that mineral 
amniotic fluid measurements do not differ significantly from ED 17.5 or 18.5. Thus, all 
amniotic fluid data in the current study is presented collectively. It was found that in both 
Pth null and Gcm2 null fetuses amniotic fluid calcium (Figure 14A and 148) and 
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magnesium (Figure 15A and lSB) were low as compared to+/- fetuses. This is 
consistent with both Pth nulls and Gcm2 nulls having a reduced renal filtered load 
because they have lower serum levels of these minerals. 
D. Skeletal Morphology and Mineralization 
When examining whole fetal skeletons stained with alcian blue (for cartilage) and 
alizarin red (for mineralized tissue), it appeared that both Pth null (n=3) and Gcm2 null 
(n=3) fetal mice were normal in size as compared to WT (n=3). Furthermore, the 
morphology of the skeleton and the mineralization pattern of both Pth nulls and Gcm2 
nulls appeared no different than that ofWT siblings (Figure 16 and 17). That is, before 
birth, the skeletal scaffold had developed normally, with normal long bone and tibial 
diaphyseal lengths, and the appropriate areas of the fetal skeleton were mineralized. 
These findings are in contrast to the original Pth null studies which showed that Pth nulls 
were dysmorphic with (among other things) slightly shortened long bones, abnormally 
formed skulls, vertebral bodies, and shortened metacarpal and metatarsal bones (73). The 
sole difference between Pth nulls in the fom1er study and Pth nulls in the present study is 
the genetic background: C57BL/6 in the former, and Black Swiss in the present. 
When fetal tibia sections were examined in more detail, by Von Kossa staining, it 
was evident that the overall cellular morphology and growth plates were normal in both 
Pth null (n=6) and Gcm2 null (n=6) fetuses as compared to WT (n=6) siblings. In 
addition, both Pth nulls and Gcm2 nulls appeared to have no obvious changes in mineral 
deposition as represented by the black deposits due to von Kossa's stain (Figure 18 and 
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19). However, when the fetal skeletons were reduced to ash in order to assess the amount 
of total mineral present, the ash weight ofboth Pth null and Gcm2 null fetuses was 
reduced by approximately 5% and 10% respectively, as compared to WT fetuses (Figure 
20A and 20B). This is consistent with the previously published study which showed that 
skeletal mineralization in the Pth nulls was significantly less then that of WT mice (73). 
The fetal ash was examined by Atomic Absorption Spectroscopy, by which means it was 
detennined that skeletal calcium content was reduced by 15% in the Pth nulls as 
compared to WT (Figure 21A), while it was reduced by 19% in the Gcm2 null fetuses as 
compared to WT fetuses (Figure 21B). Skeletal magnesium content was also 
significantly reduced, by 18% in Pth nulls, and 14% in Gcm2 nulls as compared to their 
respective WT fetuses (Figure 22A and 22B). 
E. Placental Calcium Transfer 
The amount of calcium transferred from the mother to the fetus in a 5 min period 
was measured to determine if a decrease in PTH or absence of PTH would affect the 
normal placental calcium transfer process. Previous findings (unpublished from Dr. C. S. 
Kovacs laboratory) indicate that calcium transfer occurs rapidly on both ED 17.5 and 
18.5, and that there is no significant difference between the two days. Thus, in the present 
study, all placental calcium transfer data is presented collectively. In the Pth null fetuses, 
placental calcium transfer was no different as compared to Pth +/- fetuses (Figure 23A). 
Gcm2 nulls increased calcium transfer by approximately 20% as compared to Gcm2 +/-
fetuses (Figure 23B). Thus, although Pth null and Gcm2 null fetuses showed identical 
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biochemical phenotypes (hypocalcemia, hypomagnesemia, and hyperphosphatemia), the 
Gcm2 nulls displayed increased placental calcium transfer. The increase in placental 
calcium transfer does not obviously affect the serum biochemistry of the Gcm2 nulls. I 
speculate that the increased rate of transfer enables the Gcm2 nulls to maintain a blood 
calcium level at the maternal level. In other words, if the aparathyroid Gcm2 nulls hadn't 
increase placental calcium transfer, then the biochemical phenotype would have been 
more severe and similar to the aparathyroid Hoxa3 nulls. Further investigations were 
done to determine why placental calcium transfer was upregulated in Gcm2 nulls but not 
in the Pth nulls. 
F. Plasma PTHrP 
It has been previously reported that high plasma PTHrP levels are associated with 
an increase in calcium transfer across the placenta (67, 72). Plasma PTHrP was measured 
to determine if increased plasma PTHrP could explain the increase in placental calcium 
transfer observed in the Gcm2 null mice. The results obtained from the PTHrP RIA 
showed that plasma PTHrP in both Pth null and Gcm2 null fetuses was no different as 
compared to their respective WT and HET littermates (Figure 24A and 24B). Thus, 
circulating PTHrP may not be responsible for the increase in placental calcium transfer 
observed in the Gcm2 null fetuses, and PTHrP does not upregulate in response to 
hypocalcemia, a finding consistent with what was previously observed in Hoxa3 nulls 
(72) (Table 1). Plasma PTHrP was also not significantly different between Pth +/-
mothers (n=6) and Gcm2 +/-mothers (n=6) (p=0.97). 
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Using the same PTHrP assay utilized in the present study, in previous studies it 
was reported that Pthrp null fetuses had a plasma PTHrP value of 3.8 pmol/1. Because 
Pthrp null fetuses cannot make PTHrP, and since PTHrP does not cross the placenta, the 
value of3.8 pmol/llikely represents the sensitivity (detection limit) ofthis assay in fetal 
mice. It has also been shown that WT fetuses had plasma PTHrP levels that were 
typically 6-8 pmol/1 (same as the WT values in the present study), and that plasma PTHrP 
in Pthr 1 null fetuses was 63.5 pmol/1. Thus, the assay can clearly distinguish between 
low (3.8 pmol/1), normal (6-8 pmol/1) and markedly hjgh (63.5 pmol/1) PTHrP levels 
(72). Consequently, it is likely that the lack of change in PTHrP levels in the Gcm2 nulls 
and Pth nulls as compared to WT and HET fetuses is real and not due to failure of the 
assay to distinguish a difference . 
G. PTHrP Expression in the Neck and Placenta 
Although plasma PTHrP levels were no different between genotypes in either the 
Pth colony or the Gcm2 colony, knowing that it is controversial whether the fetal 
parathyroids express PTHrP or not we wanted to rule out the possibility that PTHrP was 
upregulated in the parathyroids. Thus, the expression ofPTHrP in the neck region (which 
would include the parathyroid glands) was assessed by quantitative real-time RT-PCR. 
As previously mentioned, PTHrP is expressed in many fetal tissues, thus it is not 
surprising that PTHrP was detected in the fetal neck sections. As can be seen in Figure 
25A and 25B, the expression ofPTHrP messenger RNA (mRNA) in the neck of both Pth 
null and Gcm2 null mice was no different than that ofWT mice. Like the plasma PTHrP 
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results, this supports the idea that PTHrP may not be responsible for the increase in the 
transfer of calcium observed in the Gcm2 null fetuses, and that PTHrP does not increase 
in response to fetal hypocalcemia. 
PTHrP not only works in an endocrine manner, but also in an autocrine/paracrine 
mrumer in certain tissues. Thus, it is possible that PTHrP may not be increased in the 
plasma, but might be increased in the placenta and working within the trophoblasts or 
IPYS to increase the transfer of calcium from the mother to fetus. To determine if high 
placental PTHrP levels could account for the increase in calcium trru1sfer observed in the 
Gcm2 null fetuses, the expression ofPTHrP in the whole placenta was assessed by 
quantitative real-time RT-PCR. As can be seen in Figure 26A and 26B, PTHrP rnRNA 
expression in the placenta was no different between WT and Pth or Gcm2 null fetuses. 
This fmiher supports the notion that PTHrP is not responsible for the increase in calcium 
transfer observed in the Gcm2 null fetal mice: it was not increased in plasma, and the 
rnRNA was not increased in placenta or neck region. Also, it reaffirms that PTHrP does 
not upregulate in response to lack ofPTH and fetal hypocalcemia. 
H. Effect of Exogenous PTH Administration on Placental Calcium Transfer 
The data obtained thus far show that plasma PTHrP and the expression of PTHrP 
rnRNA in both the placenta and the neck of Pth null and Gcm2 null fetuses is normal, 
both the Gcm2 null and Pth null fetuses experience the satne degree of hypocalcemia, but 
only the Gcm2 nulls (which produce some PTH) upregulated placental calcium transfer. 
These led to the question whether PTH may play a role in regulating placental calcium 
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transfer, and if it could be a contributing factor to the increase in calcium transfer 
observed in the Gcm2 null fetuses. Gcm2 nulls have some circulating PTH while Pth 
nulls do not. To directly test the hypothesis that PTH plays a role in regulating placental 
calcium transfer, Pth null fetuses were injected in utero with either saline or 1.0 nmol of 
PTH [1-84]. The 1 nmol ofPTH was chosen because it was equimolar to the dose of 
PTHrP that was administered and effective in increasing the rate of placental calcium 
transfer in Pthrp null mice (67), and the Pth null fetuses were utilized because they are 
the model that completely lacks PTH. Also, they do not have other abnormalities, such as 
lacking the parathyroids, thyroid or thymus. The presence of these other abnormalities 
(such as in Hoxa3 nulls) may lead to confounding results. 
As can be seen in Figure 27, Pth null fetuses did increase calcium transfer in 
response to injections ofPTH [1-84] as compared to saline injections (p<0.033). WT and 
HET fetuses showed non-significant increases as well. This further supports the theory 
that PTH can stimulate placental calcium transfer. This increase in placental calcium 
transfer cannot be attributed to an alteration in ionized calcium because the ionized 
calcium levels did not differ between Pth null fetuses injected in utero with PTH [1-84] 
and Pth null fetuses injected in utero with saline (Figure 28). 
I. Gene Expression in WT and Pth null Placenta treated in utero with either Saline 
or PTH [1-84] 
To determine potential genes that may be contributing to the upregulation of 
placental calcium transfer observed in the Pth null fetuses when treated in utero with 
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PTH [1-84], a Mouse GeneST 1.0 Array was utilized to evaluate differential gene 
expression in the placenta. As can be seen in Table 2, the expression of some genes 
known to be involved in regulating placental calcium transfer including Trpv6 (93) and 
Cabp9k (92) were significantly decreased in Pth null fetuses as compared to WT fetuses. 
More specifically, Trpv6 expression in the Pth null placenta was decreased by 60% 
(p<<O.OOl) as compared to WT placenta, while Cabp9k expression was decreased by 
40% (p<<O.OOl). The Vdr was also shown to be significantly decreased (by 20%, 
p<<O.OOl) along with several other genes that are known to be involved in vitamin D 
metabolism including the human group-specific component (Gc) (i.e. Vitamin D-binding 
protein), which is involved in vitamin D transport and storage (121). Furthermore, the 
expression of several genes which are involved in cation and solute transport were also 
significantly reduced (e.g. Slc3al, Slc22a2). 
Trpv6, Cabp9k and Vdr mRNA expression was also assessed by real-time 
quantitative RT -PCR and confirmed that the expression of all 3 genes was significantly 
lower in the Pth null placentas as compared to WT (Figure 29A, 29B, and 29C). 
Similarly, as assessed by real-time quantitative RT -PCR the Gcm2 null placentas also had 
reduced expression of both Trpv6 and Cabp9k as compared to WT placentas (Figure 30A 
and 30B). Vdr expression however, was found to be no different between the Gcm2 null 
and WT placentas (Figure 30C). 
Despite the short time interval (90 min) between the PTH fetal injections and 
the harvesting of placentas, microarray analysis also revealed that when Pth null fetuses 
were treated in utero with PTH [1 -84], Vdr expression increased 1.8 fold (p<<0.001) as 
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compared to placentas collected from Pth null fetuses injected with saline. Furthermore, 
the expression of several solute carriers (e.g. Slc39a8, Slc23a3) also increased in 
response to the in utero treatment ofPTH [1-84] (Table 3). Real-time quantitative RT-
PCR confirmed that Vdr expression increased (1.5 fold) in response to PTH [1-84] 
treatment (Figure 31). 
Because the microarray results showed that absence ofPTH as well as PTH 
treatment affected placental gene expression, we wondered if placental gene expression 
differed between the Pth nulls and Gcm2 nulls. Despite the Gcm2 null placentas also 
having significantly reduced expression of both Trpv6 and Cabp9k as compared to WT 
and normal Vdr expression, real-time quantitative RT-PCR showed that the expression of 
Trpv6, Cabp9k and Vdr was significantly higher in the Gcm2 null placenta as compared 
to placentas harvested from Pth nulls (Figure 32A, 32B, and 32C). This may explain the 
upregulation of placental calcium transfer observed in the Gcm2 null fetuses. 
It should be noted that the difference in VDR gene expression in the Pth null 
placenta as compared to the Gcm2 null placenta (Figu re 32C) may appear to be 
exaggerated when comparing it to the figures that show the difference in placental VDR 
expression in the Pth nulls versus WT (Figure 29C) and Gcm2 nulls versus WT (Figure 
30C). However, the data are not directly comparable. For the PTH colony (Figure 29C) 
all fetuses in the analysis were injected in utero with saline, while this was not the case 
for the Gcm2 colony data. Furthermore, when the direct comparison was made between 
the Pth nulls versus Gcm2 nulls (Figure 32C), neither of the nulls were treated in utero 
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with saline, and all samples were run on the same plate for real-time quantitative RT-
PCR analysis. 
J. Placental Expression of PTH 
The results have shown that absence ofPTH alters placental gene expression and 
that treatment with PTH causes opposing changes in some of these same genes. This 
prompted the consideration that ifPTH is expressed in the placenta, and acts locally, that 
might explain how Gcm2 null placentas upregulated Trpv6, Cabp9k, and Vdr expression 
and placental calcium transfer. As determined by quantitative real-time RT -PCR, Pth 
mRNA was detected in WT and Pth null and Gcm2 null placenta. Pth expression was 
significantly lower in Pth null placentas as compared to WT (Figure 33A), and did not 
appear until the 31 51 cycle. This means that Pth null placentas either lacked PTH 
completely (false positive detection) or had a small amount ofPTH due to the presence of 
maternal cells in the placenta. Conversely, Pth expression was 1.2-fold higher (p=NS) in 
Gcm2 null placentas compared to WT (Figure 33B). Furthermore, as with Trpv6, 
Cabp9k, and Vdr, it was found that the expression of Pth mRNA in the Gcm2 null 
placentas was significantly higher than that found in Pth null placentas. In fact, Pth 
expression was almost 7-fold higher in Gcm2 null placentas than in Pth null placentas 
(p<<O.OOI) (Figure 32D). 
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Table 1: Summary of previously published literature showing the effects of loss of parathyroids and PTH (Hoxa3 null), loss 
ofPTH (Pth null), loss ofPTHrP (Pthrp null), and loss ofthe amino-terminal effects ofPTH and PTHrP (Pthrl null) on fetal 
blood calcium, skeletal development and mineralization, placental calcium transfer, serum PTH and plasma PTHrP as 
assessed in late gestation 
Ionized Skeletal 
calcium Mineralization 
Hoxa3 Below 
null maternal Reduced (29) level (72) 
Pth ? Reduced (73) 
null 
At Pthrp 
maternal Normal (29) 
null level (67) 
Well 
Pthrl below Reduced (29) 
null maternal 
level (67) 
Gcm2 ? ? 
null 
Numbers in parentheses indicate citations 
? = unknown 
Skeletal Scaffold Placental Plasma Calcium Serum PTH Development Transfer PTHrP 
Normal Undetectable Normal Normal (29) (72) (72) (72) 
Modestly abnormal (i.e. Slightly shortened Undetectable long bones, shorter metacarpals and ') ') 
metatarsals) (73) (73) 
Abnormal (i.e. Smaller overall, shortened 
limbs, rounded skull, shortened and Reduced Increased (29) Low (72) disorganized growth plate, accelerated (67) 
endochondral bone development) (29) 
Abnormal (i.e. Similar to Pthrp null, but Increased Increased (29) Increased 
more severe) (29) (67) (72) 
? ? ? ? 
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Table 2. Selected list of genes showing statistically significant differential regulation 
at baseline (i.e. saline injection) between Pth null versus WT placentas. 
Gene Gene Name Fold Adjusted Chan~e p- value 
Fabp1 fatty acid binding protein 1 2.11 0.013 
Hbb-y hemoglobin Y beta-like embryonic chain 1.88 0.001 
Krt1 Keratin 1 1.54 0.049 
Atp7b ATPase, Cu++ transporting, beta polypeptide 0.96 0.014 
Osbpl6 oxysterol binding protein-like 6 0.84 0.002 
Afp alpl1a fetoprotein 0.84 <0.001 
Lrp2 low density lipoprotein receptor-related 0.83 <<0.001 
(mega! in) protein 2 
Dab2 disabled homolog 2 (Drosophila) 0.82 <<0.001 
8430408G22Rik RIKEN eDNA 8430408G22 gene 0.82 0.044 
Slc27a2 solute carrier family 27 (fatty acid transporter) 0.81 <<0.001 
Ahsg Alpha-2-HS-glycoprptein 0.81 <0.001 
* Vdr vitan1in D receptor 0.81 <<0.001 
Apoc1 apolipoprotein C-1 0.80 0.019 
He ph hephaestin 0.80 <<0.001 
Abcc2 ATP-binding cassette 0.79 <0.001 
Slc13a3 solute carrier family 13 (sodium-dependent 0.76 0.016 
dicarboxylate transporter) 
Slc7a9 solute carrier family 7 (cationic amino acid 0.76 <<0.001 
transporter 
Apoa2 apolipoprotein A-II 0.76 <<0.001 
Cubn cubilin (intrinsic factor-cobalamin receptor) 0.75 <<0.001 
2010003K11Rik RIKEN eDNA 2010003Kll gene 0.75 0.002 
Apom apolipoprotein M 0.75 <<0.001 
Trf transferrin 0.75 <<0.001 
5033414D02Rik RIKEN eDNA 5033414D02 gene 0.74 <0.001 
Slc22a2 solute carrier family 22 (organic cation 0.73 0.001 
transporter) 
Apoc2 apolipoprotein C-ll 0.72 <<0.001 
Apob apolipoprotein B 0.72 <<0.001 
Rbp2 retinol binding protein 2 0.71 <<0.001 
Ambp alpha 1 microglobulin 0.70 <0.001 
Slc6a19 solute carrier family 6 (neurotransmitter 0.69 <0.001 
transporter) 
Slc5al solute carrier family 5 (sodium/glucose 0.69 <<0.001 
co transporter) 
Apoal apolipoprotein A-I 0.68 <<0.001 
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Gc (DBP) group specific component (vitamin D binding 0.67 <<0.001 
protein) 
Sfpd surfactant associated protein D 0.65 0.003 
Slc3al solute carrier family 3 0.64 <<0.001 
Apoa4 apolipoprotein A-IV 0.64 <<0.001 
* SlOOg S100 calcium binding protein G (calbindin 0.58 <<0.001 
ICCaBP-D9K) D9k) 
Aqp8 aquaporin 8 0.46 <<0.001 
* Trpv6 transient receptor potential cation channel, 0.40 <<0.001 
subfamily V, member 6 
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Table 3. Selected list of genes showing differential regulation at 90 minutes between 
PTH 1-84-injected versus saline-injected Pth null placentas. 
Fold Adjuste Gene Gene Name Change d p- value 
2010109I03Rik RlKEN cDNA2010109103 gene 3.68 <<0.001 
Slc39a8 solute carrier family 39 (metal ion transp01ter) 2.20 <<0.001 
Sfpd surfactant associated protein D 1.90 0.067 
* Vdr vitamin D receptor 1.79 <<0.001 
Alb albumin (Alb) 1.78 <0.001 
22 10415F 13Rik RlKEN eDNA 2210415F13 gene 1.55 <0.001 
Slc23a3 solute carrier family 23 (nucleobase 1.43 0.083 
transporters) 
Gc (DBP) group specific component (vitamin D binding 1.40 <<0.001 
protein) 
Apoa4 apolipoprotein A-IV 1.26 <<0.00 1 
1300017J02Rik RlKEN eDNA 1300017102 gene 1.25 0.012 
Rbp2 retinol binding protein 2 1.20 <0.001 
Cubn cubilin (intrinsic factor-cobalamin receptor) 0.89 0.001 
* Indicates that gene expression was confitmed by real-time quantitative RT-PCR 
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Table 4: Summary of previously published literature and current findings showing the effects ofloss of parathyroids and 
PTH (Hoxa3 null), loss of PTH (Pth null), loss of parathyroids ( Gcm2 null) loss of PTHrP (Pthrp null), and loss of the amino-
terminal effects of PTH and PTHrP (Pthr I null) on fetal blood calcium, skeletal development and mineralization, placental 
calcium transfer, serum PTH and plasma PTHrP as assessed in late gestation 
Ionized Skeletal 
calcium Mineralization 
Hoxa3 Below 
null maternal Reduced (29) level (72) 
At Reduced (73) Pth 
maternal 
null level Reduced 
Pthrp At 
maternal Normal (29) 
null level (67) 
Pthrl Well below 
maternal Reduced (29) 
null level (67) 
Gcm2 At 
maternal Reduced 
null level 
Numbers in parentheses indicate citations 
Findings from current study 
Skeletal Scaffold Placental Plasma Calcium SerumPTH Development Transfer PTHrP 
Normal Undetectable Normal Normal (29) (72) (72) (72) 
Modestly abnormal in C57BL/6 
background (i.e. Slightly shortened Undetectable 
long bones, shorter metacarpals and Normal (73) Normal 
metatarsals) (73) 
Undetectable 
Normal in Black Swiss background 
Abnormal (i.e. Smaller overall, 
shortened limbs, rounded skull, Reduced 
shortened and disorganized growth Increased (29) Low (72) 
plate, accelerated endochondral bone (67) 
development) (29) 
Abnormal (i.e. similar to Pthrp null, Increased Increased Increased (29) but more severe) (29) (67) (72) 
Normal Increased Reduced Normal 
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t RANKL 
PTH1R 
• PTH 
Osteoblast 
Osteoclast 
Precursor 
~ t MCS-F 
I t Osteoclastogenesis} 
t Osteoclast Activity - t Bone Resorption 
Figure 1: Effect of PTH on the RANK/RANKL/OPG triad in bone. 
Prolonged or repeated binding of PTH to the PTHI Ron o teo blasts, 
increases the expression ofM-CSF and RANKL. As a result, the activity of 
mature osteoclasts in increased along with the formation of osteocla ts from 
precursors ( osteoclastogenesis ). Thus, osteoclastic bone resorption is 
increased. In addition, PTH decreases the expression ofOPG (a so luble 
decoy receptor that binds to RANKL to prevent it from interacting with 
RANK), which inhibits osteoclastic bone resorption by reducing 
osteoclastogene is and the activity of mature osteoclasts. 
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~ Blood Calcium 
CaSR Not Stimulated 
t PTH (1-84] Secretion 
t Calcium Reabsorption 
t 1, 25(0Hh 0 3 Synthesis 
~ t Calcium Absorption 
t Blood Calcium 
! t Resorption (Via RANKIRANKL/OPG System: See Figure 1) 
Figure 2: Adult calcium homeostasis. When blood calcium decreases the 
CaSR on the parathyroid glands is not stimulated, resulting in PTH being 
released from the parathyroid glands. PTH in the circulation then acts 
directly on the bone and kidney, and indirectly on the intestine, to return the 
blood calcium leve l to normal. 
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Normal 
Fetal 
Blood 
Calcium 
level 
Normal 
Adult 
Blood 
Calcium 
level 
+--- Pthrp null fetuses 
+- Hoxa3 null fetuses 
+--- Pthrp/Hoxa3 null fetuses 
Pthr1 null fetuses 
Figure 3: Fetal blood calcium regulation. Blood calcium levels are 
schematically represented as a continuum on an arrow, with the normal 
fetal and normal adult levels highlighted in gray. PTH has a more dominant 
effect on fetal blood calcium regulation than PTHrP as in the absence of 
PTHrP (Pthrp null fetuses), blood calcium declines to the normal adult level 
(maternal level), while in the absence of PTH and parathyroids (Hoxa3 null 
fetuses) the blood calcium declines to well below the maternal level. 
Interestingly, when both PTH and PTHrP are absent in the fetus 
(Pthrp/Hoxa3 null fetuses and Pthr 1 null fetuses), blood calcium declines to 
a level that is even lower than that observed in the absence of PTH alone. 
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Fetal Side Fetal Side 
Fetal Capillary 
H~ ~:::::i'~~:is  H 
~Chorionic Epithelial Cells~ 
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::::::::::::: Epithelial Cells 0 ~ ~~Q 
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· - : :-:-;.___ Materna~ Connective """ 
·- · = ---- tissue Maternal Blood 
Maternal ide 
A. Epitheliochorial 
Maternal Capillary 
Endothelium 
Space 
Maternal Side 
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Figure 4: Schematic representation of the tissue layers composing (A) 
epitheliochorial and (B) hemochorial type placentas. In the epitheliochorial 
placenta, all 3 fetal tissue layers (capillary endothelium, connective tissue and 
chorionic epithelial) and all 3 matemal layers oftissue (capillary endothelium, 
connective tis ue and endometrial epithelial) remain. In the hemochorial 
placenta, all the maternal tissue layers have been eroded and the maternal blood 
bathes the chorionic epithelial layer. 
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A. 
B. 
Parietal 
Yolk Sac 
Trophoblasts 
Visceral Yolk Sac 
Maternal Vessels 
Reichert's Membrane 
Sinus of Duval 
Fetal Vessels 
Figure 5: Schematic illustrating the location and anatomy of the 
intraplacental yolk sac (IPYS). (A) The IPYS is positioned between the 
maternal and fetal blood spaces in the placenta, such that the parietal layer and 
Reichert's membrane are in contact with the dome of the placenta, while the 
visceral yolk sac layer is positioned next to this layer, but separated by the yolk 
sac cavity. (B) In the IPYS, Reichert's membrane and the parietal yolk sac layer 
(cuboidal cells) overlie the maternal blood spaces and vessels, whereas the 
visceral yolk sac layer (columnar cells) overlies the fetal blood vessels. The 
sinus of Duval, which communicates with the yolk sac cavity and the uterine 
lumen, is located between the two yolk sac layers. (Reprinted from Kovacs eta!. 
Calcilropic gene expression suggests a role for the intraplacental yolk sac in 
maternal-fetal calcium exchange. Am J Physiol Endocrinol Metab. 2002 
Mar;282(3):E721-32, Copyright (2002), usedwith permissionfrom The 
American Physiological Society (Appendix A). 
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Figure 6: Placental perfusion technique. In this teclmique, the fetu i 
completely removed from the uterus. The umbilical vessels are then connected 
to a semiclosed circuit, where the reservoir contains a blood substitute or 
autologous fetal blood, and perfusion of the placenta occurs in situ. The effect 
of peptides on maternal-fetal calcium transfer can be tested by administering 
them to the circuit on the arterial side, and then sampling on the venous side of 
the circuit (Reprintedfrom Pediatric Bone, Kovacs C.S. , Chapter JJ : Fetal 
Mineral Homeo tasis, pp 271-296, opyright (2003), with permi sian from 
Elsevier (Appendix B). 
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Maternal-Facing 
Ba ement 
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Membrane 
Figure 7: Schematic illustrating the process of active placental 
calcium transport. In both humans and rodents calcium enters the ce ll 
through calcium channels (e.g. TRPV6) on the surface of the maternal-
facing basement membrane. Calcium is then shuttled across the cell by 
calcium binding proteins (e.g. CaBP9k) and finally it is actively extruded 
from the cell at the fetal-facing basement membrane surface by the active 
calcium pump (Ca2+-ATPase). 
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WT +I- Pth null 
- 520 bp 
-300 bp 
Figure 8: Genotyping of the Ptlt mou e colony by PCR and gel 
electrophoresis. A single 520 bp band indicated that the mouse wa WT (+/+), 
a single 300 bp band indicated that the mouse was null for the Pth gene ( -/-), 
whi le the presence of both bands indicated that the mouse was HET (+/-)for 
the Pth gene. 
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WT +I- Gcm2 null 
-572 bp 
-300 bp 
Figure 9: Genotyping of the Gcm2 mouse colony by PCR and gel 
electrophoresis. A single 572 bp band indicated that the mouse was WT (+/+), a 
single 300 bp band indicated that the mouse was null for the Gcm2 gene(-/-), 
while the presence of both bands indicated that the mouse wasH -T (+/-)for the 
Gcm2 gene. 
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Figure 10: Serum PTH (mean ± SE) in fetuses (ED 18.5) obtained from (A) Pth 
+I- mothers and (B) Gcm2 +1- mothers. erum PTH in the Pth nulls was lower 
(reduced to the level of detection) as compared to Pth +1- and WT fetuses. Similarly, 
serum PTH in the Gcm2 nulls was reduced as compared to Gcm2 +I- and WT fetuses. 
The numbers in parentheses indicate the number of fetuses studied. 
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Figure 11: Ionized calcium (mean± SE) in fetuses (ED 18.5) obtained from (A) 
Pth +1- mothers (B) Gcm2 +1- mothers. The mean maternal ionized calcium is 
shown by the dashed line. Both Pth null fetuses and Gcm2 null fetuses had an ionized 
calcium that was decreased, to approximately the maternal level, as compared to WT 
and +I- fetuses. The numbers in parentheses indicate the number of fetuses studied. 
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Figure 12: Serum phosphorous (mean± SE) in fetuses (ED 18.5) obtained from 
(A) Pth +1- mothers (B) Gcm2 +1- mothers. The mean maternal phosphorous is 
shown by the dashed line. Serum phosphorus was significantly increased in both Pth 
null fetuses and Gcm2 null fetuses as compared the respective WT and +I- fetuses. 
The numbers in parentheses indicate the number of fetuses studied. 
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Figure 13: Serum magnesium (mean± SE) in fetuses (ED 18.5) obtained from (A) 
Pth +1- mothers and (B) Gcm2 +I- mothers. The mean maternal magnesium is 
shown by the dashed line. Serum magnesium was slightly reduced in the Pth nulls as 
compared to both WT and Pth +1-. In the Gcm2 nulls, serum magnesium was 
significantly reduced as compared to WT and Gcm2 +I- fetuses. The numbers in 
parentheses indicate the number of fetuses studied. 
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Figure 14: Amniotic fluid total calcium (mean ± SE) in fetuses (ED 18.5 or 17.5) 
obtained from (A) Pth +I- mothers and (B) Gcm2 +/- mothers. Total calcium in the 
amniotic fluid was significantly less in both Pth null and Gcm2 null as compared to 
the respective WT and +I- fetuses. The numbers in parentheses indicate the number of 
fetuses studied. 
91 
p < 0.003 
p < 0.015 A B p < 0.005 
p < 0.001 
~ ~ ~ 1. 0 
~ 1. 0 ~ 
'-" 
WT 
(5) 
+I -
(8) 
Pth null 
(3) 
'-" 
~ 
. c;; 0. 
(!) 
~ 0. 
~ 0. 
WT 
(6) 
+ I- Gcm2 null 
(17) (6) 
Figure 15: Amniotic fluid total magnesium (mean± SE) in fetuses (ED 18.5 or 
17.5) obtained from (A) Pth +/- mothers and (B) Gcm2 +I- mothers. Total 
magnesium in the amniotic fluid was significantly less in both Pth nulls and Gcm2 
nulls as compared to the respective WT and +I- fetuses. The numbers in parentheses 
indicate the number of fetuses studied. 
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Figure 16: Representative pictures of intact Pth null and WT fetal skeletons (ED 
18.5) stained with alcian blue (for catilage) and alizarin red (for mineralized 
tissue). Fetuses obtained from Pth +/- mothers. Skeletal morphology, size and 
mineralization pattern was no different between Pth null (n=3) and WT (n=3) fetuses. 
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Figure 17: Representative pictures of intact Gcm2 null (n=3) and WT (n=3) fetal 
skeletons (ED 18.5) stained with alcian blue (for catilage) and alizarin red (for 
mineralized tissue). Fetuses obtained from Gcm2 +/- mothers. Skeletal morphology, 
size and minerali zation pattern was no different between Gcm2 null (n=3) and WT 
(n=3) fetuses. 
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Figure 18: Representative sections showing Von Kossa staining of tibias and 
growth plates that have been counter-stained with methyl green. Fetuses (ED 
18.5) obtained from Pth +/- mothers. Pth null fetuses (n=6) appeared to have a 
normal amount of mineral deposition (represented by black deposits) within the tibia, 
and have normal growth plates as compared to WT (n=6) siblings. 
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Figure 19: Representative sections showing Von Kossa staining of tibias and 
growth plates that have been counter-stained with methyl green. Fetuses (ED 
18.5) obtained from Gcm2 +!- mothers. Gcm2 null fetuses (n=6) appeared to have a 
normal amount of mineral deposition (represented by black deposits) within the tibia, 
and have normal growth plates as compared to WT (n=6) siblings. 
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Figure 20: Ash weight, normalized to the mean weight of WT fetuses within each 
litter (% WT mean ± SE) in fetuses (ED 18.5) obtained from (A) Pth +/- mothers 
and (B) Gcm2 +/- mothers. Ash weight was reduced in both Pth nulls and Gcm2 
nulls. In the Gcm2 nulls it was significantly reduced as compared to both WT and+/-
fetuses, while Pth nulls only differed significantly from Pth +/-fetuses. The numbers 
in parentheses indicate the number of fetuses studied. 
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Figure 21: Skeletal calcium content, normalized to the mean skeletal calcium 
content ofWT fetuses within each litter(% WT mean± SE) in fetuses (ED 18.5) 
obtained from (A) Ptlt +1- mothers and (B) Gcm2 +1- mothers. Skeletal calcium 
was significantly reduced in both Pth and Gcm2 nulls, as compared to the respective 
WT and +I- fetuses. The numbers in parentheses indicate the number of fetuses 
studied. 
98 
A 
WT 
(22) 
p < 0.002 
p < o.o36 I 
II 
+I - Pth null 
(42) (25) 
B 
110 
§ ~ 100 
....... ~ 90 
en Q.> ~~ 80 
~ f-; 70 
~ ~ 60 
~ 4-; 50 
...... 0 
~ ~ 40 ] e._., 30 
r/) 20 
p < 0.006 
p < 0.002 
c-1 
10 
Oi-~--~--~--~--~~~ 
WT 
(17) 
+ I - Gcm2 null 
(60) (33) 
Figure 22: Skeletal magnesium content, normalized to the mean skeletal 
magnesium content ofWT fetuses within each litter(% WT mean± SE) in 
fetuses (ED 18.5) obtained from (A) Pth +/- mothers and (B) Gcm2 +/- mothers. 
Skeletal magnesium was significantly reduced in both Pth and Gcm2 nulls, as 
compared to the respective WT and +I- fetuses. The numbers in parentheses indicate 
the number of fetuses studied. 
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Figure 23: 45Ca/51Cr activity accumulated in each fetus at 5 minutes, normalized 
to the mean value of the heterozygotes within each litter (% HET mean ± SE). 
Fetuses (ED 17.5 or 18.5) obtained from (A) Pth +/- mothers and (B) Gcm2 +/-
mothers. Placental calcium transfer was no different in Pth null fetuses as compared 
to WT and Pth +/-fetuses. In contrast, calcium transfer was significantly increased in 
Gcm2 null fetuses as compared to WT and Gcm2 +/-fetuses. The numbers in 
parentheses indicate the number of fetuses studied. 
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Figure 24: Plasma PTHrP levels (mean ± SE) in fetuses (ED 18.5) obtained from 
(A) Pth +/- mothers and (B) Gcm2 +/- mothers. The mean maternal PTHrP level is 
shown by the dashed line. Plasma PTHrP in the Pth null and the Gcm2 null was no 
different as compared to WT and +I- fetuses. The numbers in parentheses indicate the 
number of fetuses studied. 
101 
A 
WT 
(3) 
p=NS 
Pth null 
(3) 
B 
.4 
.2 
1 
.S: 
.& 
.4 
.2 
n. 
WT 
(3) 
p =NS 
T 
Gcm2 null 
(3) 
Figure 25: PTHrP mRNA expression (mean fold ± SE) in neck tissue of fetuses 
(ED 18.5) obtained from (A) Pth +/- mothers and (B) Gcm2 +/- mothers. Real-time 
quantitative RT-PCR showed that PTHrP expression in the neck of both Pth null and 
Gcm2 null fetuses was no different as compared to WT fetuses. Tests were performed 
in triplicate and normalized to a GAPDH control. The numbers in parentheses indicate 
the number of fetuses studied. 
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Figure 26: PTHrP mRNA expression (mean fold ± SE) in the placenta of fetuses 
(ED 18.5) obtained from (A) Pth +/- mothers and (B) Gcm2 +/- mothers. Real-time 
quantitative RT-PCR showed that PTHrP expression in the placenta of Pth null and 
Gcm2 null fetuses was no different as compared to WT. Tests were performed in 
triplicate and normalized to a GAPDH control. The numbers in parentheses indicate 
the number of fetuses studied. 
103 
Saline D PTH (1-84) 
p < 0.033 
140 
p=NS p=NS 
120 §' D n 
~ 
::E 
(7) (13) (24) (13) (7) (8) 
WT + I - Pth null 
Figure 27: Effect ofPTH treatment on placental calcium transfer(% HET mean 
± SE). Fetuses (ED 17.5 or 18.5) obtained from Pth +/-mothers were treated in utero 
with saline or PTH 1-84. 85 minutes later the isotope was administered and 5 min 
after that the 45Ca/51 Cr ratio was measured. Pth nulls increased placental calcium 
transfer in response to injections ofPTH (1-84) as compared to saline. The numbers in 
parentheses indicate the number of fetuses studied. 
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Figure 28: Ionized calcium (mean ± SE) in fetuses (ED 18.5) 90 min after an in 
utero injection of either saline or PTH (1-84). Ionized calcium was no different 
between Pth null fetuses that were treated in utero with either saline or PTH (1-84). 
The numbers in parentheses indicate the number of fetuses studied. 
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Figure 29: (A) TRPV6 (B) CaBP9k (C) VDR mRNA expression (mean fold± SE) 
in placenta harvested from WT and Pth null fetuses (ED 18.5) that were treated 
in utero with saline. Real-time quantitative RT-PCR showed that TRPV6, CaBP-9k, 
and VDR expression in the placenta of saline injected Pth null fetuses was 
significantly decreased as compared to placenta ofWT fetuses that were also injected 
in utero with saline. Tests were performed in triplicate and normalized to a GAPDH 
control. The numbers in parentheses indicate the number of fetuses studied. 
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Figure 30: (A) TRPV6 (B) CaBP9k (C) VDR mRNA expression (mean fold± SE) 
in placenta harvested from WT and Gcm2 null fetuses (ED 18.5). Real-time 
quantitative RT-PCR showed that TRPV6 and CaBP9k expression in the placenta of 
Gcm2 null fetuses was significantly decreased as compared to placenta of WT fetuses. 
VDR expression however was no different between WT and Gcm2 null placentas. 
Tests were performed in triplicate and normalized to a GAPDH control. The numbers 
in parentheses indicate the number of fetuses studied. 
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Figure 31: VDR mRNA expression (mean fold± SE) in placenta harvested from 
Pth null fetuses (ED 18.5) that were treated in utero with either PTH 1-84 or 
saline. Real-time quantitative RT-PCR showed that VDR expression in the placenta of 
Pth null fetuses injected with PTH 1-84 was significantly increased as compared to 
placenta of Pth null fetuses that were injected in utero with saline. Tests were 
performed in triplicate and normalized to a GAPDH control. The numbers in 
parentheses indicate the number of fetuses studied. 
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Figure 32: (A)TRPV6 (B) CaBP9k mRNA expression and (C) VDR and (D) PTH 
mRNA expression (mean fold ± SE) in placenta harvested from Gcm2 null fetuses 
(gray bars) as compared to Pth null placenta (black bars). Real-time quantitative 
RT-PCR showed that TRPV6, CaBP9k, VDR, and PTH expression in the placenta of 
Gcm2 null fetuses was significantly higher as compared to placenta of Pth null 
fetuses .. Tests were performed in triplicate and normalized to a GAPDH control. The 
numbers in parentheses indicate the number of fetuses studied. 
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Figure 33: PTH mRNA expression (mean fold± SE) in the placenta of fetuses 
(ED 18.5) obtained from (A) Pth +/- mothers and (B) Gcm2 +/- mothers. Real-time 
quantitative RT-PCR showed that as compared to WT, PTH expression in the placenta 
of Pth nulls was significantly lower. In Gcm2 null placenta however, PTH expression 
was slightly (but not significantly) increased as compared to PTH expression in 
placenta harvested from WT fetuses. Tests were performed in triplicate and 
normalized to a GAPDH control. The numbers in parentheses indicate the number of 
fetuses studied. 
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Figure 34: New findings in fetal blood calcium regulation. Blood calcium levels 
are schematically represented as a continuum on an arrow, with the normal fetal and 
normal adult levels highlighted in gray. In contrast to what was originally thought, 
PTH does not have a more dominant effect on fetal blood calcium regulation than 
PTHrP. In the absence ofPTHrP (Pthrp null fetuses), absence ofPTH (Pth null), and 
reduction ofPTH (Gcm2 null) blood calcium declines to the normal adult level 
(maternal level). 
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V. Discussion 
The present doctoral research examined the role ofPTH in fetal-placental calcium 
and bone metabolism because the role ofPTH in regulating these processes was 
uncertain. Based on the published findings in the Hoxa3 null fetal mice and other data 
reviewed in the introduction, it was hypothesized that: PTH, despite its low circulating 
levels during fetal life, plays an important role in regulating not only fetal blood calcium 
and skeletal development, but also placental calcium transfer. 
Two different gene knockout mouse models within the same Black Swiss genetic 
background were utilized: the Pth null, which served as a model of complete absence of 
PTH, and the Gcm2 null, which served as a model of severe hypoparthyroidism (i.e. 
significantly reduced PTH). The phenotypes of the two nulls were found to be quite 
similar, except that placental calcium transfer was increased in Gcm2 nulls but 
unchanged in Pth nulls. In addition, calcitropic gene expression within the placenta 
differed between the two nulls, and treating the Pth nulls with exogenous PTH elicited an 
exciting finding: placental calcium transfer increased. 
The following discussion will cover the current findings and highlight the role of 
PTH in regulating fetal blood calcium, fetal skeletal development, and in greater depth, 
placental calcium transfer and placental gene expression. 
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A. Is the Phenotype of the Pth Null Fetal Mice in the Black Swiss Background the 
Same as the Ptlt Null Fetal Mice in the CS7BL/6 Background? No 
The present study showed that the Pth null fetuses had a mild hypoparathyroid 
phenotype, with blood calcium reduced only modestly (equal to the maternal level), 
hyperphosphatemia, low amniotic fluid calcium and magnesium content, and a reduction 
in the skeletal mineral content. Similarly, Gcm2 null fetuses had reduced serum PTH 
levels and a very similar phenotype to that of the Pth null fetuses. Furthermore, other 
than being undermineralized, the skeletons of both Gcm2 null and Pth null fetuses were 
normal. That is, the skeletal scaffold of the fetuses developed normally, showing no 
severe abnormalities in endochondral bone formation, limb length, cellular morphology, 
or mineralization pattern. These results are in contrast to those previously published on 
the Pth null mice. Originally, Pth nulls were reported to have numerous skeletal 
abnormalities including slightly shortened long bones, tibial diaphysis that were 
significantly shorter than normal, enlarged hypertrophic zones and decreased osteoblast 
number (73) (For a summary of present and previous findings see Table 4). The 
discrepancy between the present and the previous study may be attributed to differences 
in genetic background. In the previous study, the Pth nulls were studied in a C57BL/6 
background, while in the present study the Black Swiss background was utilized. It has 
previously been shown that Black Swiss fetuses have a higher ionized calcium level than 
C57BL/6 mice (67), and that the Black Swiss mice have a higher bone mineral density 
than C57BL/6 mice (data from Kovacs lab, submitted). This and other genetic differences 
between the Black Swiss and C57BL/6 may impact the overall physiology of the mice 
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and result in a phenotypic difference. As a result, the skeletal development of the Pth null 
fetal mice was more severely affected in the C57BL/6 background. The idea of genetic 
background affecting phenotype is consistent with the findings from other studies. For 
example, in both Pthrl null and multiple endocrine neoplasia type 1 (Menl) null mice, 
genetic background was shown to have an affect on lethality. In the hybrid C57BL/6-
129/SvJ background, Pthrl null mice died at mid-gestation; while in the Black Swiss 
background they survived until immediately after birth (67). In Men] null mice, 
embryonic lethality was extended by two days when backcrossed into the C57BL/6 
background as compared to the 129S6/SvEv background. Genetic background has also 
been shown to have a dramatic affect on the occurrence of neural tube defects in the 
Men] null fetal mice. In fact, neural tube defects did not occur in Men] null mice when 
placed in the C57BL/6 background, but occurred exclusively when backcrossed into the 
129S6/SvEv background (122). 
The fact that two independent models ofPTH deficiency, studied in the same 
genetic background, showed reduced blood calcium levels and undermineralized 
skeletons indicates that PTH is indeed required for the fetus to maintain the normally 
high blood calcium level that is observed in the fetus (higher than the maternal level), and 
to sufficiently mineralize the fetal skeleton before birth. Furthern1ore, contrary to what 
was previously thought (20), it shows that maintaining a blood calcium at the maternal 
level is not necessarily sufficient for the fetus to mineralize the fetal skeleton before birth. 
With the decline in blood calcium to the maternal level, there was a 5-l 0% reduction in 
skeletal mineral content in both the Pth null and Gcm2 null fetuses respectively. It is 
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likely that PTH contributes to skeletal mineralization through maintaining the high blood 
calcium level that is normally observed in fetuses, which would allow sufficient calcium 
to be readily available to mineralize newly formed fetal bone before birth. This implies 
that one purpose of the fetal hypercalcemia may be to facilitate skeletal mineralization. 
B. Does Absence of PTH Have the Same Consequences on Skeletal Mineralization 
and Blood Calcium as Absence of PTH and Parathyroids? If Not, Why Does the 
Phenotype of the Pth Nulls Differ From T hat of the Hoxa3 Nulls? No 
If absence ofPTH alone explained the Hoxa3 null phenotype, then Pth nulls and 
Hoxa3 nulls should have the san1e phenotype. However, this is not the case. In previous 
studies, Hoxa3 null fetal mice (lacking PTH and parathyroids) were found to have a 
significantly reduced blood calcium level (well below the maternal level), 
hyperphosphatemia, hypomagnesemia, low mineral content in the anmiotic fluid, and a 
25% decrease in skeletal calcium content (72). The more severe phenotype (lower blood 
calcium and less calcium content of the skeleton) of the Hoxa3 null fetuses as compared 
to both Pth null and Gcm2 null fetuses, which had a blood calcium equal to the maternal 
level and a 14% and 19 % reduction in skeletal calcium content, respectively, confirms 
that the absence of parathyroids and PTH causes a more severe abnormality than absence 
ofPTH alone (for a summary of previous and present findings see Table 4). Furthermore, 
contrary to what was originally thought, PTH does not have a more dominant effect on 
fetal blood calcium regulation than PTHrP. In the absence ofPTHrP (Pthrp null fetuses) , 
absence ofPTH (Pth null), and reduced PTH (Gcm2 null) blood calcium declined to the 
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normal adult level (maternal level). In the complete absence ofPTH and parathyroids 
(Hoxa3 null fetuses) however, the blood calcium declined to a level below the maternal 
level. The lowest blood calcium occurred with absence ofPTH, PTHrP, and parathyroids 
(Pthrp/Hoxa3 null) or absence of the amino-terminal actions of both PTH and PTHrP 
(Pthlr null) (Figure 34).Thus, in the absence of one hom1one (PTH or PTHrP), blood 
calcium is moderately affected and one hormone does not make up for the lack of the 
other. When both hormones are absent or when the parathyroids are absent, blood 
calcium is more severely affected. 
Why might the absence ofPTH and parathyroids affect fetal blood calcium and 
skeletal mineralization more severely than PTH alone? The fact that the Pth null and 
Hoxa3 null mice were studied in the same genetic background rules out that the 
phenotypic differences were due to different genetic background. Rather, it may be that 
removing the parathyroids causes a greater effect because it not only removes PTH, but 
also other secretory products of the parathyroids. Among them are endothelin-1 (123), 
chromogranin A (CgA) (124) and parathyroid hypertensive factor (PHF) (125). 
In previous studies endothelin-1 has been shown to stimulate both bone formation 
and resorption (126) and act as a vasoconstrictor in fetal systemic and umbilical vascular 
beds (127). The role of CgA has previously been examined by creating a chromogranin A 
gene ( Chga) knockout mouse model. In one report, Chga nulls had elevated urinary 
catecholamine excretion, but otherwise seemed normal. They were viable, showed no 
developmental abnormalities, and locomotor and endocrine functions appeared to be 
normal including serum PTH, phosphorous, and calcium levels. It was also noted that 
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other granins were upregulated (e.g. CgB and secretogranin II) in the adrenal medulla, 
hypothalamus, pituitary and thyroid, and it was concluded that other chromogranins were 
likely compensating for the lack of CgA (128). In another study, it was reported that 
some Chga null mice died prenatally, and that those born suffered severe growth 
retardation in the first 4-5 weeks after birth. Furthermore, these mice were hypertensive 
(129). Lack of CgA may not be solely responsible for the phenotype of Chga null mice 
because secreted CgA is cleaved into numerous biologically active peptides which among 
other things, inhibit vasoconstriction and inhibit the release of certain hormones (130). 
PHF, as the name suggests, is associated with some forms of hypertension (131). It has 
also been shown to increase vascular smooth muscle calcium uptake (131, 132). 
It is possible that lacking one or more of parathyroid derived endothelin, CgA, or 
PHF could account for the more severe phenotype observed in the Hoxa3 nulls, but 
whether or not any of these factors actually play a role in fetal calcium and bone 
metabolism is unknown. Another possibility is that the parathyroids produce some as yet 
unknown factor that regulates fetal mineral homeostasis. Finally, the Hoxa3 nulls suffer 
from other abnormalities, including absence of the thymus and thyroid hypoplasia, which 
may also somehow contribute to the more severe hypoparathyroid phenotype of Hoxa3 
nulls. 
Like the Hoxa3 nulls the Gcm2 nulls are also lacking the parathyroid glands, so 
why is the phenotype in the Gcm2 nulls equivalent to the Pth nulls, and not as severe as 
the Hoxa3 nulls? The fact that the Gcm2 nulls have some PTH and/or the fact that they 
can increase placental calcium transfer, may allow them to compensate for the lack of 
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other parathyroid derived factors (e.g. CgA, PHF), whereas the Hoxa3 nulls cannot. 
Alternatively, if there is a small cluster of cells in the thymus of Gcm2 nulls that produce 
some PTH, as was suggested by Gunther et al. (2000), then perhaps those cells can also 
produce the other parathyroid derived factors. However, the work from Dr. Nancy 
Manley's lab, cited earlier, makes it unlikely that Gunthers hypothesis is correct. 
C. Does PTHrP Increase in Response to Fetal Hypocalcemia and/or Absence of 
PTH? No 
In the present study, although both the Pth nulls and Gcm2 nulls experienced the 
same degree of hypocalcemia and a similar skeletal phenotype, only the Gcm2 nulls show 
a small, but significant increase in placental calcium transfer. It was hypothesized that the 
small amount ofPTH in the Gcm2 nulls could be responsible for stimulating placental 
calcium transfer above the normal WT value. However, because PTHrP is known to 
regulate placental calcium transfer (67-70), PTHrP was assessed to determine if it could 
accotmt for the increase in placental calcium transfer seen in the Gcm2 null fetuses. It 
was found that both nulls had normal plasma PTHrP levels. 
Next, we evaluated PTHrP expression in the neck region (containing fetal 
parathyroids) ofboth nulls. Admittedly, it is controversial as to weather or not murine 
fetal parathyroids produce PTHrP in addition to PTH (20). While there is evidence that 
fetal sheep parathyroids produce PTHrP (70), a careful study of fetal rat parathyroids has 
shown no evidence ofPTHrP mRNA by RT-PCR (114). The whole neck region was used 
because the fetal parathyroids are very small and difficult to isolate. As assessed by 
118 
quantitative real-time RT-PCR, PTHrP mRNA expression in the neck region ofboth Pth 
null and Gcm2 null fetuses was not increased. It is possible that the tissue studied (neck 
section) was too large, and obscured the PTHrP signal from the parathyroids. But given 
the nom1al circulating level ofPTHrP, it seems unlikely that the parathyroids could be 
producing an increased amount of PTHrP that would have to circulate in order for it to 
act on the placenta, and that it would not have be detected in the circulation. 
In addition to working in an endocrine manner, PTHrP can also function in an 
autocrine/paracrine fashion. Thus, PTHrP may have only increased locally in the placenta 
to stimulate placental calcium transfer. In both the Gcm2 nulls and Pth nulls however, 
there was no upregulation ofPTHrP mRNA observed in the placenta. In combination, the 
lack of increase in plasma PTHrP, and lack of increase in PTHrP mRNA in the neck or 
placenta, makes it unlikely that PTHrP is responsible for the increase in placental calcium 
transfer observed in the Gcm2 null fetuses. 
The phenotype of both the Pth null and Gcm2 null fetuses (although not as severe 
as the Hoxa3 nulls) was similar to that of the Hoxa3 null fetuses, which also did not 
upregulate PTHrP despite having an even lower blood calcium level as compared to both 
Pth and Gcm2 null fetuses (72). Thus, it is evident from the previous and present study 
that PTHrP does not increase in response to fetal hypocalcemia and/or absence ofPTH. 
This is in contrast to PTH which has been shown to increase in response to fetal 
hypocalcemia caused by numerous factors including maternal hypocalcemia (31 ), 
deletion of the Pthrp gene (29), and inactivating mutations of the CaSR (15). Thus, in 
fetal life, it appears that PTH and PTHrP are regulated differently. Because PTH 
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increases in response to fetal hypocalcemia, it is likely that PTH is regulated by the CaSR 
on the parathyroids and normally kept suppressed by the high fetal blood calcium. PTHrP 
however, does not appear to be regulated by the CaSR or blood calcium. Instead, it may 
be regulated by other factors, such as the amount of calcium that is being transferred 
across the trophoblasts and the IPYS (20). Alternatively, it is possible that PTHrP is 
autonomously produced by the placenta and not subject to any regulation by calcium 
flux. 
D. Does PTH Regulate Placental Calcium Transfer? Yes 
Over the years many studies have attempted to explain the process of placental 
calciwn transfer and the influential factors that affect it. These studies have utilized 
various techniques for assessing the transfer of calcium across the placenta, namely the 
placental perfusion technique (94, 95, 98, 99) and a technique for assessing intact fetal 
mice (15, 33, 67, 72). There are inconsistencies among various studies, but strong 
experimental evidence has led to the consensus that PTHrP (the mid-molecular region) 
regulates placental calcium transfer (67-70). 
There is less consistent evidence for a role ofPTH in regulating placental calcium 
transfer. Thyroparathyrodectomized fetal sheep were reported to have reduced placental 
calcium transfer, which remained unaltered when the placenta was infused with PTH (as 
assessed by placental perfusion) (70). Similarly, reduced placental calciwn transfer in the 
Pthrp null fetal mice was also found to be unaffected by in utero treatments ofPTH (as 
assessed with the fetus intact) (67). In addition, it was reported that Hoxa3 null fetuses 
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have normal placental calcium transfer, despite the completely absence of PTH (72). On 
the other hand, studies in decapitated (to simulate a parathyroidectomy) fetal rats, showed 
that PTH [1-84] increased the rate of placental calcium transfer (96). Furthermore, PTH 
[1-34] has been shown to increase calcium transport across vesicles that were created in 
vitro from human syncytiotrophoblast basal membranes (115). 
In the present study Gcm2 nulls, which have some PTH, showed an increase in 
placental calcium transfer. Since PTHrP was not increased in the circulation, neck or 
placenta of Gcm2 nulls, we hypothesized that PTH may explain the increase in placental 
calcium transfer. We directly tested this by treating Pth null fetuses in utero with either 
saline or PTH [1-84], and then performing the placental calcium transfer experiment. A 
statistically significant increase in placental calcium transfer was observed in the Pth null 
fetuses treated with PTH [1-84], as compared to Pth null fetuses treated with saline. This 
data provides more substantial evidence to support the thesis that: PTH, despite its low 
circulating levels during fetal life, plays an important role in regulating not only fetal 
blood calcium and skeletal development, but also placental calcium transfer. 
Based on the previously discussed in vitro studies on human vesicles created from 
human placental cells, and the fact that the PTH1R is highly expressed in the placenta, 
particularly in the IPYS which is believed to be a site of maternal-fetal calcium exchange 
(92), it is likely that PTH[ 1-84] exerts its effects on placental calcium transfer by binding 
to the PTH1R. This is because the PTH1R binds PTH [1-34], but not the mid-molecular 
region ofPTHrP which is known to regulate placental calcium transfer. 
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As previously discussed, a strong piece of evidence that supported the notion that 
PTH does not regulate placental calcium transfer is that treating Pthrp null fetuses (that 
have reduced placental calcium transfer) with mid-molecular fragments ofPTHrP 
increased placental calcium transfer, while treatment with PTH [1-84] did not (67). The 
current findings however, suggest that PTH [ 1-84] can stimulate placental calcium 
transfer. In retrospect, Pthrp null fetuses were found to have a significant increase 
(approximately 3 fold versus WT) in endogenous PTH (29), and this may explain why 
Pthrp null fetuses failed to respond to PTH treatment in the earlier experiments. 
E. Does PTH Regulate Placental Gene Expression? Yes 
In light of the exciting finding that treating Pth null fetuses in utero with PTH [1-
84] increased placental calcium transfer, the next step was to explore the possible 
mechanisms by which PTH might be acting to regulate this process. Initially, gene 
expression at baseline (placenta from Pth nulls treated in utero with saline verses 
placenta from WTs treated in utero with saline) was examined. As assessed by 
microarray and real-time quantitative RT-PCR, it was found that at baseline, Pth null 
placentas had a significant decrease in Trpv6, Cabp9k, and Vdr mRNA's as compared to 
WT placenta. Furthermore, the microarray showed that the expression of several other 
genes involved in cation and solute transport were significantly decreased. The fact that 
all of these genes were significantly downregulated in the Pth null placenta as compared 
to WT suggests that PTH may regulate not only calcium, but other solute transfer. 
Furthermore, the fact that Trpv6, Cabp9k, and Vdr were all dowmegulated in the Pth null 
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placenta, at first glance it would seem to predict that placental calcium transfer would 
also be decreased in the Pth null mice. This is not the case however; placental calcium 
transfer was normal in the Pth null fetuses. This may be explained by the findings from 
previous studies. In Trpv6 null mice, placental calcium transfer was decreased (93), and 
in Pthrp nulls, which have reduced placental calcium transfer, the expression of CaBP9k 
in the IPYS was significantly reduced (67, 92). Placental calcium transfer of Vdr nulls 
however, was reported to be increased, along with the placental expression ofTRPV6 
(33), indicating that VDR may act as a break on the placental calcium transfer system, 
such that in its absence, placental calcium transfer increases. Thus, in the present study 
the relative changes in TRPV6, CaBP9k, and VDR, may have balanced each other out, 
leading to no net change in placental calcium transfer. 
Next, changes in gene expression in response to PTH treatment were examined 
between placentas from Pth nulls treated in utero with PTH [1-84] versus placentas from 
Pth nulls treated in utero with saline. It was found that the expression of Vdr and vitamin 
D binding protein increased significantly, along with several solute carriers, when fetuses 
were treated with PTH [1-84] as compared to saline. These samples were collected at the 
same time point as when placental calcium transfer was assessed; 90 min after the in 
utero saline or PTH [1-84] injections. With this short interval, it is unlikely that the 
changes observed in mRNA expression could result in protein synthesis occurring fast 
enough to account for the differences in placental calciun1 transfer that was observed. 
Rather, it is likely that PTH achieved its effect on placental calcium transfer by working 
directly on its receptor in the placenta to open channels to allow more calcium to be 
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transferred from mother to fetus. However, observing changes in mRNA expression at 90 
minutes shows that PTH can indeed regulate placental calcitropic gene, and other solute 
transporter, expression. 
Although Gcm2 null placentas had significantly lower expression of both Trpv6 
and Cabp9k as compared to WT (like Pth nulls), and Vdr expression no different from 
that ofWT, when placental gene expression between the Pth nulls and Gcm2 nulls (no 
treatment) was compared, it was revealed that the expression of Trpv6, Cabp9k, and Vdr 
were all significantly increased in the Gcm2 null placentas as compared to Pth null 
placentas. This may in part explain the difference in placental calcium transfer observed 
between the Pth nulls and Gcm2 nulls. More specifically, why placenta calcium transfer 
was increased in the Gcm2 null placentas, but not in the Pth null placentas despite having 
a similar biochemical phenotype. 
F. Is PTH Expressed Locally in the Placenta? Yes 
The finding that PTH can regulate placental gene expression prompted the 
consideration that PTH might be expressed in the placenta. As assessed by real-time 
quantitative RT-PCR, it was discovered that PTH was present in the placenta ofWT and 
both Pth null and Gcm2 null fetuses. Furthermore, PTH was found to be significantly 
higher in the Gcm2 null placenta as compared to the Pth null placenta. Thus, it is likely 
that the low circulating levels ofPTH in the Gcm2 null fetuses is coming from not only 
the thymus (if at all), but also the placenta. It may be the case that PTH acts locally in the 
placenta to regulate calcium, and other solute transfer, and that the circulating PTH may, 
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or may not be relevant. Based on these and the previously discussed findings, although it 
has not been directly tested in the present study, it is conceivable that PTH in Gcm2 null 
fetuses plays a role in regulating placental calcium transfer. 
PTH was significantly lower in Pth null placenta as compared to both WT and 
Gcm2 null placenta, but it was still detectable. This may reflect a false positive 
expression finding, or it may be that the small amount ofPTH that was detected in the 
Pth null placenta was derived from the maternally derived tissue portion of the placenta. 
To determine the source ofthe PTH production in the placenta in situ RT-PCR and/or 
immunohistochemistry could be utilized. Alternatively, it would be interesting to study 
PTH expression in placentas collected from Pth nulls from a Pth null pregnancy to 
determine ifthe signal is eliminated. 
lfPTH is expressed locally in the placenta and is contributing to the increase in 
calcium transfer observed in the Gcm2 null fetuses, the question remains why the Hoxa3 
nulls do not increase calcium transfer in response to severe hypocalcemia? They, like the 
Gcm2 nulls, lack the parathyroids, but presumably are still capable of producing PTH. 
Although it remains to be investigated, it is speculated that deleting the Hoxa3 gene not 
only affects the development of the tissues deriving from the third and fourth pharyngeal 
pouch, but for some yet unknown reason also affects placental morphology and/or 
placental gene expression which results in the Hoxa3 null placenta not being able to 
produce PTH locally and/or increase calcium transfer. 
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G. Study Pitfalls and Limitations 
An unresolved inconsistency in the present study is that although placental 
calcium transfer was not reduced in either the Gcm2 null or Pth null fetuses, both nulls 
had reduced blood calcium, reduced amniotic fluid calcium and reduced skeletal calcium 
content. One explanation is that backflux, or flow of calcium from fetus to mother may 
have been increased in order to account for the lack of mineral present in the fetuses. The 
technique used in this study to assess placental calcium transfer does not measure 
backflux. However, the short 5 minute interval used between administering the isotopes 
and the removal of the fetus makes it less likely that the placental calcium transfer 
measurement is not confounded by backflux of the isotope. This is evident from previous 
studies on Pthrp knockout mice, which reported that extending the time between isotope 
administration and removal of the fetuses increased the relative difference in placental 
calcium transfer between the genotypes, which likely indicates that the longer the 
interval, the more the results are confounded by backflux. Thus, with only the 5 minute 
interval there is less time for the isotope to be transferred from the mother to the fetus, 
become diluted in the circulation ofthe fetus, and return in substantial amow1ts across the 
placenta to the mother (67). Alternatively, the fact that placental calcium transfer was not 
reduced in either the Gcm2 null or Pth null fetuses, but that both nulls had reduced blood 
calcium, reduced amniotic fluid calcium and reduced skeletal calciwn content, may 
indicate that the "normal" (i.e. WT) rate of calcium transfer is only adequate if the 
parathyroids and normal PTH levels are present. Thus, without normal PTH levels and/or 
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parathyroids the "normal" rate of calcium transfer is not sufficient to meet the demands 
of the developing fetus. 
Another pitfall in the present study is that neither Pth null nor Gcm2 null placenta 
morphology was assessed as compared to WT. Thus, it remains possible that placental 
calcium transfer in either the Pth nulls and/or Gcm2 nulls was affected by morphological 
changes in the placenta. 
Animal research is important in order to uncover the complexity of living 
systems, and understand bodily processes, diseases and possible treatments. However, as 
with any research, there are limitations. The present work showed that deficiency ofPTH 
in fetal life, results in hypocalcemia and an undermineralization skeleton, and that PTH 
plays a role in regulating placental calcium transfer and can affect placental gene 
expression. Although insightful, the limitations of extrapolating these findings and 
applying them to humans must be addressed. 
Mice are great experimental models to use when studying placental function, 
because the overall structure of human and rodent placenta are similar, with both being 
discoid and haemochorial. However, several structural differences exist between the 
rodent and human placenta. First, rodents have a haemotrichorial placenta, while humans 
have a haemomonochorial placenta (89). Second, rodents have an intricate labyrinth 
where the maternal and fetal blood comes in close contact with one another, whereas in 
humans villi from the fetal side protrude into the intervillous maternal blood-filled space 
and float freely (91). Finally, unlike humans, the rodent placenta contains an IPYS which 
is believed to be a site of maternal-fetal calcium exchange (20, 92, 93). As a result of 
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these structural differences, it is possible that the human and rodent placenta do not 
function similarly. However, whether these structural differences result in functional 
differences or not remains unknown. It may also be the case that differences exist simply 
due to difference between species. Thus, our findings in mice may not necessarily be 
applicable to humans. 
In the present study, knockout mouse models allowed us to explore the role ofPTH in 
fetal-placental calcium and bone homeostasis, in a way that would obviously not be 
suitable if dealing with humans. Although useful, there are limitations when using such 
models. One notable challenge is that of compensatory effects. That is, when knocking 
out a gene of interest it is possible that the effect observed, or lack thereof, may be the 
result of another hormone or mechanism being triggered that compensates for the lack of 
the gene of interest. Also, when knocking out a gene, it is possible that the phenotype 
observed may not be directly due to the gene knocked out, but rather due to effects on 
another gene. Consequently, it is clear that one must be cautious in drawing conclusions 
from studies of single knockout mouse models. In the area of fetal calcium and bone 
metabolism, much of what we do understand has been drawn from comparing phenotypes 
of various knockout mouse models. This approach is very useful, but if utilized, the 
limitations must be acknowledged. That way, studies can be designed in the best possible 
way to help minimize being led astray. For example, it is necessary to consider genetic 
background. When making comparisons between knockouts, the genetic background 
should be the same because phenotypic differences may simply result from the variability 
in the fetal milieu caused by genetic background. 
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H. Clinical Implications 
The fetal period is known to be a time of rapid skeletal development and 
mineralization, with 80% of the mineral required before birth being accumulated in the 
last trimester of pregnancy in humans (7). Elucidating the mechanisms by which the fetus 
accomplishes this may ultimately lead to novel approaches to treat such conditions as 
osteoporosis and other metabolic bone diseases. 
In humans, fetal hypoparathyroidism may occur for numerous reasons including 
lack of parathyroid development, as in DiGeorge syndrome (133), or impaired 
parathyroid development from mutations in the Gcm2 gene (134-13 7). The effect that this 
has on fetal blood calcium, and skeletal development and mineralization however, to my 
knowledge, is unknown. From these studies it is predicted that PTH deficiency in the 
fetus will result in hypocalcemia and impaired skeletal mineralization. Knowing this 
could affect how infants born with hypoparathyroidism are assessed and treated after 
birth, and how they will be monitored as they age. Furthermore, knowing that such 
complications could result if PTH deficiency is present in utero, could possibly lead to in 
utero treatments to diminish, or avoid, adverse outcomes. 
I. Overall Summary and Conclusions 
The purpose of the present PhD dissertation was to determine whether PTH is 
required for regulating fetal-placental mineral homeostasis and skeletal development. It 
was hypothesized that: PTH, despite its low circulating levels during f etal life, plays an 
important role in regulating not only f etal blood calcium and skeletal development, but 
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also placental calcium transfer. To address this, two different genetic mouse models 
were utilized; the Pth null mice, which served as a model of complete absence ofPTH, 
and the Gcm2 null mice which served as a model of severe hypoparathyroidism. The 
hypothesis was supported as it was determined that in the absence, or deficiency, ofPTH 
a fetal hypoparathyroid phenotype resulted. The fetuses experienced hypocalcemia, 
hypomagnesemia, hyperphosphatemia, low amniotic fluid mineral content, and reduced 
skeletal mineral content. Furthermore, PTH was found to be expressed in the placenta, 
regulated placental expression of genes involved in calcium transfer, including TRPV6 
and CaBP9k, and directly stimulated placental calcium transfer. It is though that PTH 
may contribute to placental gene expression and function, via two different pathways. 
That is, the endocrine/systemic pathway, which would utilize parathyroid-derived PTH, 
and the paracrine/autocrine pathway, which would utilize placental-derived PTH. 
Whether these current findings are applicable to human fetuses that are deficient in (or 
completely lacking) PTH remains unknown. 
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VI. Future Directions 
The current study presents some very interesting findings regarding the role of 
PTH in fetal-placental calcium and bone homeostasis. However, many questions still 
need to be addressed if the importance ofPTH in fetal skeletal development and placental 
function, and how it absence (or deficiency) affects the fetal milieu, is to be completely 
understood. 
First, as the present study suggests that PTH plays a role in regulating placental 
calcium transfer, it would be of great value to determine which region of PTH is 
responsible for this process. It is likely that it is the amino-terminal fragment. This is 
based on the fact that it is the amino-terminal region ofPTH that binds to the PTH1R, 
which is highly expressed in the placenta (and IPYS), and not the receptor that the mid-
molecular region ofPTHrP functions to regulate placental calcium transfer. Furthermore, 
in previous studies it was reported that PTH [1-34], the amino-terminal region, increased 
calcium transport in vesicles that were created from human syncytiotrophoblast basal 
membranes (115). However, although likely, it remains possible that some other region 
ofPTH, other than the amino-tem1inal region, is responsible for stimulating placental 
calcium transfer in mice, and that its actions are mediated via a receptor other than the 
PTHlR. Thus, this question must be directly addressed. Similar to previous studies in 
Pthrp null mice which showed that it was the mid-molecular region ofPTHrP that was 
responsible for stimulating placental calcium transfer (67), various fragments ofPTH 
could be tested to determine which region ofPTH is responsible for stimulating placental 
calcium transfer. 
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Second, another very interesting finding in the present study is that PTH was 
expressed in the placenta. In fact, PTH was not only expressed in the WT placenta, but 
also (at significantly lower levels) in the placenta of Pth nulls. Because the Pth nulls 
cannot produce PTH, it is likely that the PTH detected in the placenta harvested from Pth 
null fetuses was coming from the maternally derived tissue portion of the placenta, which 
makes up very little of the total placenta (unpublished). In the WT placenta however, it is 
likely that PTH is expressed in the whole placenta (i.e. placental tissue derived from both 
maternal and fetal sources) because the expression ofPTH is significantly higher in WT 
placenta as compared to that of Pth null placenta. Thus from the current findings it is 
evident that PTH is locally produced in the placenta, however, where it is produced 
remains unknown. This is necessary to determine if the role ofPTH in fetal-placental 
calcium and bone homeostasis is to be completely understood. Due to the relatively low 
expression levels ofPTH in the placenta, it was unknown whether PTH in the placenta 
would be detectable by traditional reverse-transcriptase PCR (RT-PCR). Preliminary 
studies were carried out, and PTH was found to be detectable in both WT and Pth null 
placenta by RT-PCR, and like quantitative real-time RT-PCR, PTH expression in the Pth-
null placenta was lower, yet still detectable, as compared to WT placenta (unpublished 
data). Therefore, although the expression is relatively low, in situ RT-PCR could be 
utilized to localize PTH expression in the placenta. 
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APPENDIXC 
N- Terminal PTHrP Radioimmunoassay (RIA) Protocol 
Reagents 
Standard: 
Antibody: 
Tracer: 
Assay Buffer: 
Antigoat Sac Cel: 
Aprotinin: 
Plasma samples: 
Pooled normal plasma: 
Controls Cl, C2 and C3: 
Recombinant PTHrP (1-84), reconstitute 2 ~-tgllO~-tl aliquot 
in 1 ml assay buffer which gives a concentration of 200,000 
pmol/L. Several dilutions ranging from 0.8 to 400 pmol!L 
concentrations are then made. They included the following 
standard concentrations: 0, 0.8, 2, 4, 8, 15, 20, 30, 40, 80, 
200, 400 pmol/L. 
INCSRAR antihuman PTHrP (1-40) goat number 906. 
Dilute 11100 stock solution to 1110, 000 and use 100 
~-tlltube. Final dilution 1/40,000. 
125! Tyr0PTHrP (1-34), 10,000 cpm in 100 ~-tl. 
0.05 M Barbitone pH 8.6 with 0.5% BSA, 0.02% Tween, 
0.05% Sodium Azide, 0.5 ml (20TTIJ) Aprotinin 
(Trasylol)/1 00 ml assay buffer. 
SAC-CEL Anti-sheep/goat code: AA-SAC2 (Science Made 
Simple [IDS]). 
Protease inhibitor from bovine lung (Sigma A-1153), 
reconstitute 100 mg with 10 ml 0.05M barbital buffer, pH 
8.6. 
Collect in 0.5 M EDTA 100 ~-tl (or EDTA coated tube) and 
Aprotinin 100 ~-tl (4TIU)/10 ml of 
blood. 
EDTA plasma with Aprotinin from haemochromatosis 
patients are pooled and used as control for binding changes 
observed in the presence of plasma. 1 00 ~-tl is added to each 
standard tube. 
Low, medium and high levels (C1, C2 and C3) of 
recombinant hun1an PTHrP (1-84) are added to normal 
human plasma. 
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Assay Procedure 
Day 1: 
Incubate the following: Standard or sample (50 J.!l) 
Antibody (50 J.!l) 
Assay buffer/pooled normal plasma (50 J.!l) 
Non-specific binding tube, incubate the following: Assay buffer (100 J.!l) 
Normal plasma (50 J.!l) 
At room temperature for 4 hours 
Add tracer, 5000 cpm (50 J.!l) and incubate overnight at room temperature. 
Final incubation volume is 200 J.!l per tube. 
Day2: 
Add anti-goat Sac-Cel (50J.!l) and incubate for 30 minutes at room temperature. 
Add 0.5 ml distilled water to each tube. 
Centrifuge and aspirate supernatant. 
Count pellet using multigammer counter (Cobra 5005, Packard, Downer Grover, IL) 
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Electropherogram Summary Continued ... 
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ABSTRACT 
Parathyroid hormone (PTH) plays an essential role in regulating calcium and bone homeostasis in the adult, but whether PTH is required 
at all for regulating fetal-placental mineral homeostasis and skeletal development is uncertain. We hypothesized that despite its low 
circulating levels during fetal life, PTH plays a critical role in regulating these processes. To address this, we examined two different 
genetic models of PTH deficiency. Pth null mice have enlarged parathyroids that are incapable of making PTH, whereas Gcm2 null mice 
lack parathyroids but have PTH that arises from the thymus. Pth nulls served as a model of complete absence of PTH, whereas Gcm2 nulls 
were a model of severe hypoparathyroidism. We determined that PTH contributes importantly to fetal mineral homeostasis because in its 
absence a fetal hypoparathyroid phenotype results with hypocalcemia, hypomagnesemia, hyperphosphatemia, low amniotic fluid 
mineral content, and reduced skeletal mineral content. We also determined that PTH is expressed in the placenta, regulates the placental 
expression of genes involved in calcium and other solute transfer, and may directly stimulate placental calcium transfer. Although 
parathyroid hormone- related protein (PTHrP) acts in concert with PTH to regulate fetal mineral homeostasis and placental calcium 
transfer, unlike PTH, it does not upregulate in response to fetal hypocalcemia.© 2010 American Society for Bone and Mineral Research. 
KEY WORDS: FETUS; PTH/PTHRP; BONE MINERALIZATION; ION TRANSPORT/ PLACENTA; KNOCKOUT; ANIMAL MODELS/RODENT; GROWTH AND 
DEVELOPMENT 
Introduction 
Parathyroid hormone (PTH) plays an essential role in regulating calcium and bone homeostasis in the adult. 
Absence or peripheral resistance to its actions causes hypo-
calcemia, hyperphosphatemia, reduced bone turnover, and 
calcifications of soft tissues and basal ganglia.n> 
In contrast, whether PTH is required at all for regulating fetal-
placental mineral homeostasis and skeletal development is 
uncertain. The fetal biochemical milieu differs from the adult and 
is characterized by elevations of ionized calcium, magnesium, 
and phosphate above the maternal values and active transfer of 
calcium, magnesium, and phosphate across the placenta.(2) The 
skeleton rapidly mineralizes during the third trimester in humans 
and the last 4 to 5 days of gestation in rodents.(2J Circulating 
levels of PTH and 1 ,25-dihydroxyvitamin D (calcitriol) are low 
compared with adult values, whereas parathyroid hormone-
related protein (PTHrP) is increased in the fetal circulation during 
late gestation.(3J These and other observations prompted the 
hypothesis that PTHrP might assume the actions of PTH during 
fetal life, and our previous studies of feta l mineral homeostasis in 
Pthrp null fetuses examined this possibility. 
We found that Pthrp null fetuses had hypocalcemia (equal to 
maternal blood level). hypomagnesemia, hyperphosphatemia, 
reduced fetal-placental calcium transfer, normal amniotic fluid 
calcium content, and normal skeletal mineral content.(4·5> Serum 
PTH was increased threefold in Pthrp null fetuses compared with 
wild-type (WT) fetuses and may have prevented more severe 
hypocalcemia.(SJ However, the biochemical abnormalities in 
Pthrp null fetuses indicate either that PTH could not fully 
compensate for the absence of PTHrP or that it was restrained by 
the actions of the parathyroid calcium-sensing receptor (CaSR) to 
maintain the lower, adult-normal value of serum calcium.(6J 
These observations reaffirmed the hypothesis that PTHrP is an 
important regulator of fetal mineral homeostasis, but further 
study of the role of fetal PTH was warranted. 
We next examined Hoxa3 null fetuses as a model for 
aparathyroidism; these mice also lack the thymus and are 
completely devoid of PTH.m We found more profound hypocal-
cemia than in Pthrp null fetuses such that the blood calcium level 
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was reduced well below the ambient maternal calcium concen-
tration.<s.a) Hoxa3 nulls also had hypomagnesemia, hyperpho-
sphatemia, a normal rate of placental calcium transfer, low 
amniotic fluid mineral content, and reduced skeletal calcium and 
magnesium content. We also created and studied Hoxa3/Pthrp 
double mutants that lacked both PTH and PTHrP. These double-
mutant fetuses had much lower blood calcium and skeletal mineral 
content than either of the single mutants; their phenotype was 
similar to what we observed in mice lacking the PTH/PTHrP 
receptor.<4'5l 
Thus our previous investigations showed that absence of 
parathyroids caused a more substantial reduction in serum 
calcium and skeletal mineral content than absence of PTHrP 
despite the fact that PTH normally circulates at low levels in the 
fetus. Removing both parathyroids and PTHrP (or the PTH/PTHrP 
receptor) caused even more severe abnormalities, suggesting 
that PTH can partly compensate for the absence of PTHrP or that 
both PTH and PTHrP normally contribute to the regulation of 
fetal blood calcium and skeletal mineralization. However, Hoxa3 
null mice have other abnormalities in tissues derived from the 
third pharyngeal arch that contribute to their mortality after birth 
and which may affect their biochemical and skeletal phenotype. 
Thus the specific role of PTH in fetal calcium homeostasis 
required further investigation. 
In this study, we hypothesized that despite its low circulating 
levels, PTH plays a critical role in regulating fetal calcium 
homeostasis and skeletal mineralization. To address this- and 
to avoid being led astray by possibly confounding features of one 
mutant model-we examined two different genetic models of 
PTH deficiency. Pth null mice have enlarged parathyroids that are 
incapable of making PTH; the adults display hypocalcemia and 
hyperphosphatemia.<9l Gcm2 null mice lack parathyroids but have 
PTH that arises from the thymus; the adults also have 
hypocalcemia and hyperphosphatemia.<lol Pth nulls served as a 
model of complete absence of PTH, whereas Gcm2 nulls were a 
model of severe hypoparathyroidism. In both colonies, the pups 
are born in the expected Mendelian ratios, but survival of null mice 
is reduced after birth. We have observed that this is due, in part, to 
the mother, who selectively tosses these otherwise healthy-
appearing pups from the nest (even if the investigator puts them 
back in); there also may be postnatal hypocalcemia-related deaths. 
In both colonies, the null mice that survive are fertile and grossly 
indistinguishable from their WT and heterozygous littermates. 
Materials and Methods 
Animal husbandry 
The creation of Pth null and Gcm2 null mice has been described 
previously.<9' 10l The original strains were back-crossed into Black 
Swiss (Taconic, Germantown, NY, USA) for three generations 
prior to beginning any studies and at least annually thereafter 
such that the mice are about 10 generations into Black Swiss. The 
colonies were maintained by breeding heterozygous-deleted 
mice together. Genotyping was done by PCR on DNA extracted 
from tail clips of weaned pups. Mice were mated overnight; the 
presence of a vaginal mucus plug on the morning after mating 
marked embryonic day (ED) 0.5. Normal gestation in these mice 
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is 19 days. All mice were given a standard chow (1% calcium, 
0.75% phosphorus) diet and water ad libitum. All studies were 
performed with the prior approval of the Institutional Animal 
Care Committee of Memorial University of Newfoundland. 
Chemical and hormone assays 
Whole blood, plasma, serum, and amniotic fluid were collected 
using methods described previously.<Bl Ionized calcium was 
measured on whole blood using a Chi ron Diagnostics 634 Ca2+ 1 
pH Analyzer (Chiron Diagnostics, East Walpole, MA). Total 
calcium, phosphate, and magnesium were measured using 
colorimetric assays in the Gcm2 colony (Sigma-Aldrich, Oakville, 
Ontario, Canada); discontinuation of these kits necessitated that 
different colorimetric assays had to be used in the Pth colony 
(Diagnostic Chemicals Limited, Charlottetown, Prince Edward 
Island, Canada). PTH was measured with a rodent PTH 1-34 
Elisa kit that has a detection limit of 1.6 pg/ml (lmmutopics, 
San Clemente, CA, USA). Plasma PTHrP was measured using a 
sensitive RIA with an antibody directed to an amino-terminal 
epitope on samples that had been collected in a cocktail 
of aprotinin and EDTA.(lll WT fetuses typically have values 
of 6 to 8 pmoi/L, whereas Pthrp null fetuses had values of 
3.8 ± 0.3 pmoi/L; this likely represents the detection limit of the 
assay in fetal mouse plasma<Bl (and unpublished data). 
Placental calcium transfer 
This procedure has been described in detail elsewhere.<4 l Briefly, 
pregnant dams on ED 18.5 were given an intracardiac injection of 
SO j..LCi 4sCa and 50 j..LCi of 51 Cr-EDTA. Five minutes later, the dams 
were sacrificed, and each fetus was removed from its placenta. 
The ratio of 45Ca to 5 1Cr radioactivity within each fetus was 
measured using a gamma counter and a liquid scintillation 
counter, respectively. The mean 4 5Cal1Cr activity ratio of the 
heterozygous fetuses in each litter was set at 100% in order that 
the results from different litters could be pooled for analysis. 
Fetal PTH treatment 
On ED 18.5, we exposed the uteri of Pth heterozygous dams and 
gave half the fetuses an intraabdominal injection of 1 nmol rat 
PTH 1-84 (Bachem, Torrance, CA) in 2 iJ.L saline, whereas the 
remaining fetuses received 2 iJ.L saline. Sutures were placed over 
the gestational sacs of the PTH-injected fetuses so that they 
could be identified later. The mother's incision was closed, and 
she was permitted to awaken and move about normally. Eighty-
five minutes after the fetal injections, the placental calcium 
transfer procedure described earlier was carried out (ending 
90 minutes from the time of PTH or saline injection). In separate 
experiments (no radioactivity) to determine the effect of PTH 
treatment on placental gene expression, at 90 minutes after 
the fetal injections, the placentas were removed, snap frozen 
with liquid nitrogen, and stored at - 70°C for subsequent RNA 
extraction, microarray, and real-time quantitative RT-PCR. 
Fetal ash and skeletal mineral assay 
As described previously,<sl intact fetuses (ED 18.5) were reduced 
to ash in a furnace (500°C x 24 hours). A Perkin Elmer 2380 
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Atomic Absorption Flame Spectrophotometer (Norwalk, en 
determined the calcium and magnesium content of the ash. 
Alizarin red S and alcian blue preparations 
As described in detail previously,!Sl fresh fetuses were fixed in 
95% EtOH followed by clearing with acetone, stained with alcian 
blue 8GS and alizarin red S, and then immersed in 1% aqueous 
KOH until the fetal skeleton was clearly visible through the 
surrounding tissue. They were transferred into 100% glycerine 
for permanent storage. 
Histology 
Undecalcified fetal tibiae were fixed in paraformaldehyde, 
dehydrated in graded alcohol series, and embedded in paraffin. 
Then 5 f..lm sections were deparaffinized, rehydrated, and 
transferred to distilled water. For von Kossa staining, the 
sections were transferred to 1% aqueous silver nitrate solution 
and exposed for 45 minutes under a strong light. They then were 
washed thrice in distilled water, placed in 2.5% sodium 
thiosulfate (5 minutes), and washed thrice again in distilled 
water. Finally, they were counterstained with methyl green, 
dehydrated in 1-butanol and xylene, and mounted. 
RNA extraction 
RNA was extracted from snap-frozen placentas and anterior neck 
sections using an RNeasy Midi Kit (Qiagen, Valencia, CA). The 
placental samples were representative ofthe entire placenta and 
included the three trophoblast cell types and intraplacental yolk 
sac; the maternal contribution is limited to endothelial cells that 
line maternal blood vessels. Quality of the RNA samples used 
for microarray analysis was assessed with the Agilent 2100 
BioAnalyzer (Agilent Technologies, Palo Alto, CA), whereas the 
quality of other RNA samples was assessed using ultraviolet (UV) 
spectrophotometry and inspection of ribosomal RNA integrity on 
the electrophoresced gel. 
Microarray 
Placental RNA from PTH- or saline-treated fetuses was analyzed at 
the Centre for Applied Genomics, Microarray Facility, Hospital for 
Sick Children (Toronto, Ontario, Canada). The Mouse Gene ST 1.0 
Array (Affymetrix, Santa Clara, CA) was completed on 12 samples 
(one sample per chip), representing three samples for each of 
the four groups: WT and Pth null, each treated with either saline or 
PTH (1 -84). 
Primary data analysis at the Statistical Analysis Core Facility of 
the Centre for Applied Genomics used the March 2008 gene 
annotation information from Affymetrix. Probesets without gene 
names/gene assignments were removed, leaving 22,158 pro-
besets. Raw data were normalized using the robust multiarray 
average (RMA) algorithm,!12l and differentially expressed genes 
then were identified using the local-pooled-error test (LPE).P3l 
False discovery rate (FDR)(14l was set at 0.05 such that genes 
with adjusted p values of less than .05 were considered to be 
statistically significant. The data discussed in this publication 
have been deposited in NCBI's Gene Expression Omnibus and 
are accessible through GEO Series accession number GSE16983 
(www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSE16983). 
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Real-time quantitative RT-PCR 
We used TaqMan Gene Expression Assays, which are predesigned 
primers and probes for optimal amplification, to determine 
expression of S100g (CaBP-9K), VDR, PTHrP, PTH, and TRPV6. In 
addition to the TaqMan Gene Expression Assays, TaqMan Universal 
PCR Master Mix (Applied Biosystems, Foster City, CA) was used 
when PTHrP expression was assessed in both neck and placental 
RNA samples. Details of conditions and cycle times have been 
reported previously.Psl To assess S100g (CaBP-9K), VDR, PTH, and 
TRPV6 expression in placental samples, we used the TaqMan RNA-
to-Cr 1-Step Kit (Applied Biosystems) in addition to the TaqMan 
Gene Expression Assays. This eliminated the need to carry out a 
separate eDNA synthesis step prior to real-time quantitative RT-
PCR. With use of the TaqMan RNA-to-Cr 1-Step Kit, the thermal 
cycler protocol then consisted of a 15 minute cycle at 48°(, a 
1 0 minute cycle at 95°C, followed by 40 cycles of 15 seconds 
at 95 oc and 1 minute at 60°C. We performed all real-time 
quantitative RT-PCR using the ABI PRISM 7000 Sequence Detection 
System (Applied Biosystems), as described previously.!16l All 
samples were analyzed in triplicate. Relative expression ratios 
were representative of the threshold cycle (the PCR cycle at which 
an increase in reporter fluorescence is above a baseline signal) 
normalized to GAPDH and compared with WT animals. 
Statistical analysis 
Data were analyzed using SYSTAT 5.2.1 for Macintosh (SYSTAT, 
Inc., Evanston, IL, USA). ANOVA was used for the initial analysis; a 
post hoc test was used to determine which pairs of means 
differed significantly from each other. Real-time PCR results were 
analyzed by the rll.t>CT method, where the target and reference 
are amplified in separate wells0 7l Two-tailed probabilities 
are reported, and all data are presented as mean ± SE. 
Results 
Serum chemistries 
As expected, serum PTH was undetectable in all Pth null fetuses 
(Fig. 1A). In Gcm2 null fetuses, the PTH level ranged from low to 
undetectable, indicating that some fetuses had circulating PTH 
likely arising from the thymus (see Fig. 1 8). Both Pth null and Gcm2 
null fetuses shared identical phenotypes of hypocalcemia, 
hypomagnesemia, and hyperphosphatemia (Table 1); this pattern 
is very similar to the phenotype of Pthrp null fetuses in the same 
genetic background. The ionized calcium was reduced to the 
maternal level, equal to the level of Pthrp null fetuses but well 
above the level observed in aparathyroid Hoxa3 null fetuses within 
the same genetic background (see Fig. 1 C, 0). Amniotic fluid 
calcium and magnesium were low in both Pth null and Gcm2 null 
fetuses (see Table 1 ), which is consistent with reduced renal filtered 
load from the lower serum levels of these minerals. 
Response of PTHrP 
We had observed previously that PTH upregulates in the absence 
of PTHrP (i.e., in Pthrp null fetuses); we now examined whether 
PTHrP upregulates in response to hypocalcemia and absence of 
PTH. Circulating plasma PTHrP levels were no different from 
respective WT and heterozygous littermates (see Fig. 1£, F) . The 
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Fig. 1. Lack ofPTH causes hypocalcemia but no compensatory increase in PTHrP in either Pth null or Gcm2 null fetuses. Serum PTH was undetectable(< 1.6 pg/ml) in 
all Pth nulls (A) and low but detectable (5.0 pg/mL) in Gcm2 nulls (8). Both null genotypes had hypocalcemia (equal to the mate mal calcium concentration) (C, 0) but no 
alteration in plasma PTHrP (E, F) and no upregulation of PTHrP mRNA (as detected by real-time quantitative RT-PCR) in the neck region that contains the parathyroids 
(G, H). Fetuses from the Pth colony are shown in black; those from the Gcm2 colony are shown in gray. Numbers in parentheses indicate the numbers of pups studied. 
Dashed lines indicate the mean maternal concentrations for each parameter, which were collected and measured simultaneously with the fetal samples. 
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Table 1. Biochemical Weight and Skeletal Mineral Measurements from Pth and Gcm2 Null Fetuses Versus Respective Siblings and 
Mothers 
Pth Colony Gcm2 Colony 
WT ± Null Maternal WT ± Null Maternal 
Ca2+ (mM) 1.75 ± 0.05 1.74 ± 0.03 1.31 ± 0.04* 1.21 ± 0.06 1.77 ± 0.02 1.82 ± 0.02 1.34 ± 0.03* 1.31 ± 0.03 
Mg(mM) 1.17 ± 0.13 1.32 ± 0.07 1.11 ± 0.10 ... 0.80 ± 0.09 0.90 ± 0.01 0.92 ± 0.01 0.87 ± 0.01 .. 0.88 ± 0.02 
P04 (mM) 2.97 ± 0.17 3.03 ± 0.11 3.54 ± 0.11 .. 2.45 ± 0.20 3.23 ± 0.26 3.32 ± 0.16 4.57 ± 0.15* 3.18 ± 0.17 
Amniotic total 2.19 ± 0.14 2.14 ± 0.10 1.50 ± 0.15 .. 2.35 ± 0.17 2.23 ± 0.10 1.75 ± 0.13 .. 
Ca (Mm) 
Amniotic Mg (mM) 1.44± 0.09 1.35 ± 0.07 0.88 ± 0.12 .. 1.15 ± 0.07 1.20 ± 0.04 0.90 ± 0.07 .. 
Weight (g) 1.03 ± 0.03 1.02 ± 0.02 1.03 ± 0.03 1.03 ± 0.03 1.05 ± 0.02 1.03 ± 0.02 
Ash (mg) 19.1 ± 0.5 19.7 ± 0.4 18.1 ± o.5· 20.1 ± 0.5 21 .1 ± 0.3 18.0 ± 0.4* 
Calcium 69.5 ± 2.5 69.4 ± 1.7 59.6 ± 2.3* 58.9 ± 2.2 64.9 ± 1.2 47.8 ± 1.6* 
(mg/g ash) 
Magnesium 24.3 ± 1.0 22.4 ± 0.7 19.8 ± 0.9* 21 .0 ± 0.7 20.5 ± 0.4 18.5 ± 0.5* 
(mg/g ash) 
Note that the kits used to measure total Ca, Mg, and P04 in the Pth colony were not the same as the kits used for the Gcm2 colony because the 
manufacturer discontinued the original kits; thus the results for total Ca, Mg, and P04 are not directly comparable between the two colonies. 
•p < .001; .. p < .01; ... p < .08 versus respective heterozygous siblings. 
lack of a difference is likely real because this assay previously 
distinguished Pthrp null fetuses from WT fetuses and also found 
very high (63.5 pmoi/L) PTHrP levels in PTH/PTHrP receptor 
(Pthr1) null fetuses.<a> However, in order to rule out a local 
increase in PTHrP within fetal parathyroids, we extracted RNA 
from anterior neck sections that included the parathyroids and 
found no elevation in PTHrP mRNA by quantitative real-time RT-
PCR (see Fig. 1 G, H). 
wr Pth null 
wr Pth null 
Skeletal phenotype 
Both Pth null and Gcm2 null fetuses showed a grossly normal 
skeletal phenotype, as shown by alizarin red S- and alcian blue-
stained intact specimens in Fig. 2(A, 8). In an earlier report, the 
tibial diaphysis was significantly shortened in Pth nulls from an 
inbred C57BU6 background,<9> but we observed that long bone 
and tibial diaphyseal lengths of both Pth null and Gcm2 null 
B 
\ 
WT Gcm2null 
wr Gcm2null 
Fig. 2. Gross and microscopic skeletal morphology of ED 18.5 WT, Pth null, and Gcm2 null fetuses. Skeletal preparations stained with alizarin red S (for 
mineral) and alcian blue (for cartilage) show that both Pth null fetuses (A) and Gcm2 null fetuses (8) had normal axial and appendicular skeletons, including 
lengths of long bones and mineralization pattern. Panels C and D display von Kossa- stained tibial sections that were counterstained with methyl green. 
Pth null and Gcm2 null tibiae showed apparently normal endochondral development with no alteration in the lengths or cellular morphology of the 
cartilaginous or bony compartments, although less mineral (detected by von Kossa) appeared to be present in both null genotypes. 
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fetuses (in an outbred Black Swiss background) were normal at 
gross and microscopic levels (see Fig. 2A- 0). Body weights of the 
Pth null and Gcm2 null fetuses were no different from those of 
their respective WT siblings (see Table 1 ). Histologic sections 
demonstrated normal endochondral bone development with 
no alteration in the length or morphology of the cartilaginous 
zones and the growth plate (see Fig. 2(, 0). Von Kassa staining 
suggested a modest reduction in skeletal mineral content that 
was confirmed by ash weight and mineral content measure-
ments in both phenotypes (see Fig. 2C, 0 and Table 1 ). These 
reduct ions in skeletal calcium and magnesium content were 
about half of what we had observed previously in Hoxa3 null 
fetuses.<sl 
Placental calcium transfer 
Fetal hypocalcemia might be caused by a reduction in maternal-
fetal calcium flux; conversely, fetal hypocalcemia might induce 
a compensatory increase in maternal-fetal calcium transport. 
However, in Pth null fetuses, no alteration in placental 
•sea transfer was noted (Fig. 3A). In Gcm2 null fetuses, a modest 
but statistically significant increase in •sea transfer was detected 
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(see Fig. 38). To test whether PTHrP might explain this increase in 
placental calcium transfer, we assayed placental PTHrP mRNA by 
quantitative real-time RT-PCR and found no increase in PTHrP in 
either Pth null or Gcm2 null fetuses (see Fig. 3(, 0). As noted 
earlier, circulating PTHrP levels were not increased in Gcm2 nulls 
either. 
Role of PTH in placental calcium transfer 
Whether PTH contributes to the regulation of placental calcium 
transfer has been unclear, whereas midmolecular fragments of 
PTHrP have been shown to stimulate this process in fetal lambs 
and mice.14•18·19l Our previous studies in Pthrp null fetuses had 
shown no effect of PTH treatment, but those fetuses already had 
threefold upregulation of endogenous PTH and therefore might 
have been unable to respond to administration of exogenous 
PTH.14•5l We used Pth null fetuses as a model to test the ability of 
PTH treatment to increase the rate of maternal-fetal calcium 
transfer. We treated all fetuses in utero with injections of either 
saline or a dose of PTH 1-84 that was equimolar to the dose of 
PTHrP 1-86 that had proved effective in Pthrp null fetuses. 
We then assayed placental calcium transfer 90 minutes after 
p < 0.0094 
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Fig. 3. Placental calcium transfer and placental PTHrP mRNA. After administration of •sea and s1Cr-EDTA to the mother, Pth null fetuses showed no 
alteration in the relative transfer of 45Ca compared w ith WT and Pth+l- littermates (A). Conversely, Gcm2 null fetuses showed a significant upregulatlon In 
•sea accumulation (8) . This increase In placental calcium transfer was not due to a compensatory increase in PTHrP. Placental PTHrP mRNA was unaltered 
in Pth null (Q and Gcm2 null (0 ) fetuses, as assessed by real-time quantitative RT-PCR. Figure 1 (£,F) showed that plasma PTHrP also was unaltered in either 
genotype. Fetuses from the Pth colony are shown in black; those from the Gcm2 colony are shown in gray. Numbers in parentheses indicate the numbers 
of pups stud ied. 
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treatment. A statistically significant increase in placental calcium 
transfer occurred in Pth null fetuses (Fig. 4). This increase in 
45Ca accumulation was not secondary to altered systemic 
calcium homeostasis because PTH treatment did not alter the 
fetal ionized calcium (1 .29 ± 0.09 mM in PTH-treated versus 
1.31 ± 0.10 mM in saline-treated Pth null fetuses, p = NS). 
To identify possible mechanisms through which PTH might be 
acting on the placenta, we extracted RNA from placentas of PTH-
or saline-injected WT and Pth null fetuses and performed a 
genome-wide microarray. At baseline, Pth null placentas had a 
60% reduction in TRPV6 mRNA, a 40% reduction in calbindin D-
9K mRNA, and a 20% reduction in VDR mRNA versus WT 
placentas; the expression of other genes involved in cation and 
solute transport also was significantly reduced (Table 2). The 
expression of TRPV6, calbindin D-9K, and VDR mRNAs was 
assessed independently by quantitative real-time RT-PCR, and 
each was reduced by 60% to 80% in the Pth null versus WT 
placentas (Fig. SA- C). In response to PTH administration, Pth null 
placentas had a 1 .8-fold increase in VDR mRNA, and the 
expression of several solute carriers also increased (Table 3). 
Quantitative real-time RT-PCR confirmed that the VDR mRNA had 
increased 1 .5-fold over baseline in response to PTH 1-84 
treatment (see Fig. 50). 
Comparison of Pth and Gcm2 null placentas and 
detection of placental PTH 
We examined the expression TRPV6, calbindin D-9K, and VDR 
mRNAs in Gcm2 null placentas and found that TRPV6 and 
calbindin D-9K were reduced by 80% and 55%, respectively, 
compared with their WT siblings (p < .001), whereas VDR mRNA 
was unchanged from the WT value (p = NS; data not shown). The 
real-time RT-PCR then was repeated using RNA from Gcm2 and 
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Fig. 4. PTH 1-84 stimulates placental calcium transfer in Pth null fetuses. 
Treatment in utero with 1 nmol PTH 1-84 versus saline resulted in a 
significant increase in the transfer of 45Ca to Pth null fetuses. Saline-
injected fetuses are shown in black bars; PTH 1-84-injected fetuses are 
~hown in hatched bars. Numbers in parentheses indicate the numbers of 
pups studied. 
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Pth null placentas compared side by side. The relative 
expressions of TRPV6, calbindin D-9K, and VDR all were 
significantly higher in Gcm2 null placentas than in Pth nulls 
(Fig. 6A- C). 
Our findings prompted the consideration that PTH m ight be 
expressed in the placenta; if so, it should be absent in Pth nulls 
but present in Gcm2 nulls. By real-time quantitative RT-PCR, PTH 
mRNA was detected in WT placentas obtained from both 
colonies; furthermore, PTH expression was 1.2-fold higher in 
Gcm2 null placentas than in WT placentas (p = NS). Direct 
comparison of RNA from Gcm2 and Pth null placentas studied 
side by side by real-time PCR showed PTH expression to be 
almost sevenfold higher in Gcm2 null placentas than in Pth null 
placentas (p < .001) (see Fig. 60). Expression in Pth nulls did not 
appear until the thirty-first cycle and may indicate a false-positive 
detection or the presence of maternal sources of PTH mRNA. 
Discussion 
The PTH/PTHrP receptor is well known to mediate many of the 
N-terminal actions of PTH and PTHrP. An unresolved paradox is 
how these two ligands can both be present in the fetal 
circulation but still carry out distinct roles. We undertook the 
current studies to further clarify the role of PTH, expecting to see 
a phenotype identical to aparathyroid Hoxa3 null fetuses-that 
is, marked hypocalcemia (well below the maternal calcium level), 
hypomagnesemia, hyperphosphatemia, low amniotic fluid mineral 
content, and a 25% reduction in skeletal calcium content. 
Instead, we found a milder hypoparathyroid phenotype with 
modestly reduced blood calcium concentration (equal to the 
maternal level), hyperphosphatemia, low amniotic fluid mineral 
content, and a 10% reduction in skeletal calcium content. 
The modestly reduced skeletal mineral content of Pth null and 
Gcm2 null fetuses confirms that PTH is required to achieve 
normal mineralization of the skeleton prior to term. The role of 
PTH may be to directly drive skeletal mineralization by 
stimulating osteoblast function or to maintain the normally 
high feta l blood calcium concentration and thereby facilitate 
mineralization of newly formed bone. Absence of PTH did not 
alter endochondral bone development or limb lengths in either 
genetic model, which suggests that the role of PTH to facilitate 
mineralization may be through its role to maintain the serum 
calcium concentration and not through any effect on chon-
drocyte or osteoblast physiology. The original report of Pth null 
fetuses had indicated significant shortening of the tibial 
diaphysis, whereas we observed no such shortening in Pth or 
Gcm2 null fetuses(9>; the difference between that report and this 
one may be the respective genetic backgrounds of the mice 
(C57BU6 versus Black Swiss). The fact that two distinct models of 
PTH deficiency shared the same skeletal phenotype suggests 
that it was caused directly by PTH deficiency and not 
confounded by unknown factors. 
In our prior studies, the phenotype of lower blood calcium and 
reduced skeletal mineral content was progressively more severe 
in aparathyroid Hoxa3 fetuses and PTH/PTHrP receptor (Pthr1) 
null fetuses.(S) In this study, two different models of PTH 
deficiency in animals of the same genetic background had 
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Table 2. Selected List of Genes Showing Statistically Significant Differential Regulation at Baseline (i.e., Saline Injection) Between Pth 
Null Versus WT Placentas 
Gene Gene name Fold change Adjusted p value 
Fabp7 Fatty acid binding protein 1 2.11 .013 
Hbb-y Hemoglobin Y, beta-like embryonic chain 1.88 .001 
Krt7 Keratin 1 1.54 .049 
Atplb ATPase, Cu2 1 transporting, beta-polypeptide 0.96 .014 
Osbp/6 Oxysterol binding protein-like 6 0.84 .002 
Afp Alpha-fetoprotein 0.84 < .001 
Lrp2 (megalin) Low-density lipoprotein receptor- related protein 2 0.83 <<.001 
Dab2 Disabled homologue 2 (Drosophila) 0.82 <<.001 
8430408G22Rik RIKEN eDNA 8430408G22 gene 0.82 .044 
Slc27a2 Solute carrier family 27 (fatty acid transporter) 0.81 <<.001 
Ahsg a-2-HS-glycoprotein 0.81 < .001 
Vdr Vitamin D receptor 0.81 <<.001 
Apoc7 Apolipoprotein C-1 0.80 .019 
He ph Hephaestin 0.80 <<.001 
Abcc2 AlP-binding cassette 0.79 < .001 
Slc73a3 Solute carrier family 13 (sodium-dependent 0.76 .016 
dicarboxylate transporter) 
Slcla9 Solute carrier family 7 (cationic amino acid transporter 0.76 <<.001 
Apoa2 Apolipoprotein A-ll 0.76 <<.001 
Cubn Cubilin (intrinsic factor-cobalamin receptor) 0.75 <<.001 
20 7 0003K7 7 Rik RIKEN eDNA 201 0003K11 gene 0.75 .002 
Apom Apolipoprotein M 0.75 <<.001 
Trf Transferrin 0.75 <<.001 
50334 7 4D02Rik RIKEN eDNA 5033414D02 gene 0.74 < .001 
Slc22a2 Solute carrier family 22 (organic cation transporter) 0.73 .001 
Apoc2 Apolipoprotein C-11 0.72 <<.001 
Apob Apolipoprotein B 0.72 <<.001 
Rbp2 Retinol-binding protein 2 0.71 <<.001 
Ambp a 1-Microglobulin 0.70 <.001 
Slc6a79 Solute carrier family 6 (neurotransmitter transporter) 0.69 < .001 
Slc5a7 Solute carrier family 5 (sodium/glucose cotransporter) 0.69 <<.001 
Apoa7 Apolipoprotein A-1 0.68 <<.001 
Gc (DBP) Group specific component (vitamin D- binding protein) 0.67 <<.001 
7 30007 7J02Rik RIKEN eDNA 1300017J02 gene 0.66 <<.001 
Ttr Transthyretin 0.66 <<.001 
Sfpd Surfactant-associated protein D 0.65 .003 
Slc3a7 Solute carrier family 3 0.64 <<.001 
Apoa4 Apolipoprotein A-IV 0.64 <<.001 
Alb Albumin 0.63 <<.001 
Mco/n3 Mucolipin 3 0.62 .041 
5700g (Ca8P-D9K) S 100 calcium- binding protein G (calbindin D9k) 0.58 <<.001 
AqpB Aquaporin 8 0.46 <<.001 
Trpv6 Transient receptor potential cation channel, 0.40 <<.001 
subfamily V, member 6 
modestly reduced blood calcium and skeletal mineral content. 
The more modest phenotype of the PTH-deficiency models may 
indicate that parathyroid tissue participates in regulating fetal 
mineral homeostasis through the release of other as yet 
unidentified factors. Further comparative study of other 
parathyroid-deleted mutants (Pax7 and others) and double 
mutants of Pth and Hoxa3 may reveal why genetic deletion of 
parathyroids in Hoxa3 nulls or absence of the PTH/PTHrP 
receptor in Pthr7 nulls caused more severe hypocalcemia and 
skeletal undermineralization than in Pth null and Gcm2 null 
fetuses. 
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In both Pth null and Gcm2 null fetuses there was no increase in 
PTHrP mRNA expression in the neck or placenta, no increase in 
plasma PTHrP, and no reduction in placental calcium transfer. 
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Fig. 5. Placental expression of TRPV6, calbindin D-9k, and VDR. Placentas were harvested from PTH 1-84- and saline-treated fetuses and analyzed by 
genome-wide microarray. Saline-treated Pth null placentas showed significant downregulation versus WT placentas in the expression of mRNAs for TRPV6 
(A), calbindin D-9k (8), and VDR (Q. Conversely, following PTH 1-84 treatment, Pth null placentas showed significant upregulat ion of VDR mRNA versus 
saline-treated Pth null placentas (0). Numbers in parentheses indicate the number of placentas studied. 
Table 3. Selected List of Genes Showing Differential Regulation at 90 Minutes Between PTH 1-84- lnjected and Saline-Injected Pth Null 
Placentas 
Gene 
2010109/03Rik 
5/c39a8 
Sfpd 
Vdr 
Alb 
2210415F13Rik 
Slc23a3 
Gc (DBP) 
Apoa4 
7300017 J02Rik 
Rbp2 
Cubn 
Gene name 
RIKEN eDNA 2010109103 gene 
Solute carrier family 39 (metal ion transporter) 
Surfactant-associated protein D 
Vitamin D receptor 
Albumin (Alb) 
RIKEN eDNA 2210415F13 gene 
Solute carrier family 23 (nucleobase transporters) 
Group-specific component (vitamin D- binding protein) 
Apolipoprotein A-IV 
RIKEN eDNA 1300017 J02 gene 
Retinol-binding protein 2 
Cubilin (intrinsic factor-cobalamin receptor) 
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Fold change Adjusted p value 
3.68 <<.001 
2.20 <<.001 
1.90 .067 
1.79 <<.001 
1.78 < .001 
1.55 < .001 
1.43 .083 
1.40 <<.001 
1.26 <<.001 
1.25 .012 
1.20 < .001 
0.89 .001 
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Fig. 6. Placental expression of TRPV6, calbindin D-9k, VDR, and PTH in Gcm2 versus Pth null placentas. Compared with their respective WT counterparts, 
Gcm2 nulls had reduced expression ofTRPV6 and calbindin D-9k but normal expression ofVDR (not shown). When compared simultaneously with Pth null 
placentas, Gcm2 null placentas had significantly higher expression ofTRPV6 (A), calbindin D-9k (8), and VDR (Q. WT and Gcm2 nul l placentas expressed PTH 
(not shown), and direct comparison of Gcm2 null with Pth null placentas revealed a sevenfold higher expression of PTH mRNA in Gcm2 null placentas (0). 
Numbers in parentheses indicate the numbers of placentas studied. 
Similarly, we reported earlier that despite more profound 
hypocalcemia, Hoxa3 null fetuses had no upregulation of 
placental PTHrP mRNA, no increase in plasma PTHrP, and no 
alteration in placental calcium transfer. These findings indicate 
that PTHrP must be regulated differently from PTH during fetal 
life. PTH is regulated by the CaSR on parathyroids, increasing in 
response to fetal hypocalcemia (such as in Pthrp null fetusesls> 
and maternal hypocalcemial20>) and increasing in response to 
inactivating mutations of the CaSR.l6> In contrast, fetal PTHrP 
does not respond to any of these stimuli; the only situation in 
which we have found PTHrP to be increased is in Pthr1 null 
fetuses, which lack the PTH/PTHrP receptor.la> PTHrP may be 
produced autonomously by the placenta or regulated by other 
factors, such as the sensing of the calcium content exchanged 
across the trophoblasts and intraplacental yolk sac.l3•21> 
We observed that Pth null placentas had reduced mRNAs for 
TRPV6, calbindin D-9K, VDR. vitamin D- binding protein, and 
other solute or cation transporters. The independent effect of 
some of these alterations can be predicted from our previous 
studies. First, in collaboration with the Hediger Laboratory, we 
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found that ablation of TRPV6 in mice significantly lowered 
placental calcium transfer.(22> Second, we noted reduced 
expression of calbindin D-9K in the intraplacental yolk sac in 
Pthrp nulls, which have reduced placental calcium transfer.l4•2 1> 
Third, ablation of VDR (Vdr null fetuses) was associated with 
normocalcemia but an increased rate of placental calcium 
transfer and increased placental expression of TRPV6.(16> The 
studies in Vdr null fetuses may indicate that calcitriol and the VDR 
act as a brake on the rate of placental calcium transfer; in the 
absence ofVDR, TRPV6 expression and placental calcium transfer 
increase. Taken together, these previous studies predict that 
some of the altered gene expression in Pth null placentas should 
increase net placental calcium transfer, whereas other alterations 
should decrease it. The decreased expression ofTRPV6, calbindin 
D-9K, and VDR (and other factors) may have offset each other to 
lead to no net change in placental calcium transfer, exactly as we 
observed in Pth null fetuses. 
Although placental calcium transfer was not reduced in the 
absence of PTH in either Pth null or Gcm2 null fetuses, the 
blood calcium, amniotic fluid calcium, and skeletal mineral 
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content all were reduced. This suggests that the rate of 
backflux or reverse flow of calcium from fetus to mother must 
have been increased in order to account for where the mineral 
went. The short 5 minute interval between administration of 
the isotopes and removal of each fetus from its placenta in this 
technique means that largely forward flow from mother to 
fetus is measured, whereas backflux is not. Within this time 
frame, the transferred isotopes become diluted in the total 
blood volume of each fetus; consequently, only a small amount 
of isotope can be expected to return via the umbilical artery 
and across the placenta to the mother within 5 minutes. The 
effect of backflux became apparent in our previous studies of 
Pthrp knockout mice, where we observed that the relative 
difference in placental calcium transfer among WT, Pthrp+1- , 
and Pthrp null fetuses increased from 5 to 1 5 to 30 minutes, 
likely indicating the progressive effect of backflux on the 
observed net fetal accumulation of isotopes. Consequently, we 
have since used the 5 minute time point in the placental 
calcium transfer experiment because this is unlikely to be 
confounded by backflux of isotope. 
The placental calcium-transfer methodology used in our 
studies has the advantage of studying intact fetuses with very 
minimal intervention: an intracardiac injection of isotopes given 
to a pregnant mouse that is anesthetized for less than 
30 seconds. Typically, fetuses from 6 to 10 pregnant mice are 
required to compare the baseline rate of placental calcium 
transfer among WT, heterozygous, and null fetuses. The number 
of mice required more than doubles in order to compare the 
effect of a single active treatment versus saline at one time point, 
and measurements can be done only at a single time point after 
injection (it is a terminal experiment). Consequently, it was not 
feasible to study a time course of PTH injections or determine a 
full dose-response curve. Thus we chose the dose of PTH and 
time point based on our earlier studies in which an equimolar 
dose of PTHrP 1-86 or 67-86 increased placental calcium transfer 
in Pthrp null fetuses.(4 > We demonstrated an increase in placental 
calcium transfer with PTH treatment of Pth null fetuses, which 
suggests that PTH may contribute to the normal regulation of 
placental calcium transfer. Our finding is consistent with earlier 
data that found that PTH 1-34 treatment could increase calcium 
transport in vesicles created from human syncytiotrophoblast 
basement membranes(23> and with the intense expression of the 
PTH/PTHrP receptor in the intraplacental yolk sac.(2 1> 
PTH 1-84 increased placental calcium transfer within 90 minutes 
of administration. At this early time point, it is likely that PTH acted 
directly through its receptor to open channels within the calcium-
transporting cells of the placenta. Nevertheless, even at 90 
minutes, we observed changes in the expression of mRNAs for 
VDR, vitamin D- binding protein, and several solute transporters. 
These changes in mRNA expression are unlikely to cause rapid 
enough changes in protein expression to account for the increased 
placental calcium transfer observed by 90 minutes, but the 
observed changes in these mRNAs indicate that PTH can regulate 
the expression of calciotropic genes and other solute transporters 
within the placenta. Moreover, the reduced placental expression of 
TRPV6, calbindin D-9K, VDR. and other solute transporters at 
baseline in Pth null fetuses is another indication that PTH may play 
a role in regulating placental function. 
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Although Pth null and Gcm2 null fetuses were biochemically 
indistinguishable, the latter did have a low level of circulating 
PTH and a small increase in the apparent rate of placental 
calcium transfer. TRPV6, calbindin D-9K, and VDR each had 
significantly higher expression in Gcm2 null compared with Pth 
null placentas, and this may in part explain why the rate of 
placental calcium transfer also differed between the two null 
genotypes. Moreover, PTH expression was detected in the 
placentas of WT and Gcm2 null mice. Since the PTH/PTHrP 
receptor is intensely expressed in the placenta}21> it is possible 
that PTH acts in a paracrine fashion to regulate placental genes 
and calcium transport. It is also conceivable that the small 
amount of plasma PTH in Gcm2 nulls is derived from both thymic 
and placental sources. 
In conclusion, we have determined that PTH contributes 
importantly to fetal calcium homeostasis because in its absence a 
fetal hypoparathyroid phenotype results with hypocalcemia, 
hypomagnesemia, hyperphosphatemia, low amniotic fluid 
mineral content, and reduced skeletal mineral content. PTH 
regulates the placental expression of genes involved calcium and 
other solute transfer and may contribute to the regulation of 
placental calcium transfer. PTH may contribute to placental gene 
expression and function both through both endocrine/systemic 
(parathyroid-derived) and paracrine (placental-derived) path-
ways. To our knowledge, no fetal or cord blood calcium 
measurements have been reported from human fetuses that lack 
parathyroids, such as owing to DiGeorge syndrome. Our results 
predict that DiGeorge syndrome will cause hypocalcemia in 
utero and impaired skeletal mineralization. 
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